Substituted heterocyclic compound, preparation method therefor, insecticidal composition, and use thereof

Abstract

The present invention belongs to the technical field of pesticides, and specifically relates to a substituted heterocyclic compound, a preparation method therefor, an insecticidal composition, and a use thereof. The compound is represented by general formula I, Q representing formula II; X represents alkyl, halogenated alkyl, or the like; Y represents O or N-Y1; R4 and R 5 each independently represent hydrogen, halogen, alkyl, or the like; and R6 represents hydrogen, alkyl, halogenated alkyl, or the like. The compound exhibits excellent control effects against Spodoptera frugiperda, Spodoptera litura, Mythimna separata, Nilaparvata lugens, and the like.

Description

Technical Field The present invention belongs to the technical field of pesticides, particularly relating to a substituted heterocyclic compound, a preparation method therefor, a pesticidal composition and an application thereof. Background Art In recent years, owing to the long-term use of pest control agents such as pesticides or fungicides, diseases and pests have acquired drug resistance and become difficult to control by currently used pesticides or fungicides. In addition, some of the known pest control agents are highly toxic, or some of which damage the ecosystem by their long-term residue. In this context, although a large number of pesticides are known, it is still necessary to develop new pest control agents with low toxicity and low residue. Summary of the Invention The present invention provides a substituted heterocyclic compound, a preparation method therefor, a pesticidal composition and an application thereof. The compound has excellent pesticidal activity against Spodoptera frugiperda, Spodoptera litura, Mythimna separata, Nilaparvata lugens and the like. The technical solution adopted in the present invention is as follows: A substituted heterocyclic compound is as shown in Formula I, or a salt or N-oxide thereof: R3 wherein, Q represents Q-1 Qi represents S, NR33 or O; Q2 represents N, CH, or C-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, alkyl, alkenyl, alkynyl, cyano, nitro, cycloalkyl, aryl, heterocyclyl, cycloalkenyl, SF5, -OR51, O -O-alkylene-ORsi, -SR51, -O-alkylene-SRsi, -SOR51, -(SO2)Rsi, -O(SO2)Rsi, NR51 H        0 . ^51 S— R51 Ss- 0 N M CN ,            R51, -N(R51)2, -O(CO)R51, -O(CS)OR51, -O(CS)SR5i, -N(R5i)(COR5i), -N(R5i)(COOR5i), -N(R5i)(SO2R5i), -N(SO2R5i)2, -(C0)0R5i, -0(C0)0R5i, -(C0)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O- or-CH2OCH2-; the alkyl, alkenyl, or alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, cycloalkyl, aryl, heterocyclyl, trialkylsilyl, -OR51, -SR51, -SOR51, -(SC^Rsi, -N(R5i)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5, and -(CO)N(R5i)2; X represents alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, -N(R5i)2, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl; or -N(R5i)2 together forms heterocyclyl that is unsubstituted or substituted with a nitrogen atom at 1-position; Y represents O or N-Y1; Y1, Re, and R33 each independently represent hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cyano, -N(Rsi)2, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl; R51 independently represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl; the aforementioned cycloalkyl, heterocyclyl, aryl, or cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R; R independently represents hydrogen, alkyl, alkenyl, alkynyl; alkyl, alkenyl, or alkynyl that are substituted by at least one group selected from halogen, hydroxy, alkoxy, cyano, and alkoxycarbonyl; cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycyloalkenylalkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, alkyl, haloalkyl, alkoxycarbonyl, alkylsulfanyl, alkylsulfonyl, alkoxy, and haloalkoxy. In a specific embodiment, Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, cyano, nitro, C3-C8 cycloalkyl, aryl, heterocyclyl, C3-C8 cycloalkenyl, SF5, -OR51, -O-(C1-C8 alkylene)-OR5i, -SR51, -O-(C1-C8 alkylene)-SR5i, 0 -fs-R51 -SOR51, -(SO2)R5i, -O(SO2)R5i, NR51 w       _  p II           O . K51 2— ^51 Sc O N A N^< CN ,           R51 -N(R5i)2, -O(CO)R5i, -O(CS)OR5i, -O(CS)SR5i, -N(R5i)(COR5i), -N(R5i)(COOR5i), -N(R5i)(SO2R5i), -N(SO2R5i)2, -(CO)OR5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-or -CH2OCH2-; the C1-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C8 cycloalkyl, aryl, heterocyclyl, tri C1-C8 alkylsilyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(R5i)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, and -(CO)N(R5i)2; X represents C1-C8 alkyl, halo C1-C8 alkyl, C2-C8 alkenyl, halo C2-C8 alkenyl, C2-C8 alkynyl, halo C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, -N(R5i)2, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl; or -N(R5i)2 wherein, the “ unsubstituted or substituted by at least one group selected from oxo, C1-C8 alkyl, and C1-C8 alkoxycarbonyl; Y1, Re, and R33 each independently represent hydrogen, C1-C8 alkyl, halo C1-C8 alkyl, C2-C8 alkenyl, halo C2-C8 alkenyl, C2-C8 alkynyl, halo C2-C8 alkynyl, cyano, -N(Rei)2, C1-C8 alkoxy C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl; R51 independently represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo C1-C8 alkyl, halo C2-C8 alkenyl, halo C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl; the aforementioned C3-C8 cycloalkyl, heterocyclyl, aryl, or C3-C8 cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo C1-C8 alkyl, halo C2-C8 3 alkenyl, halo C2-C8 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R; R each independently represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl; C1-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C8 alkoxy, cyano, and C1-C8 alkoxycarbonyl; C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl C1-C8 alkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxycarbonyl, C1-C8 alkylsulfanyl, C1-C8 alkylsulfonyl, C1-C8 alkoxy, and halo C1-C8 alkoxy. In another specific embodiment, Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, C3-C6 cycloalkenyl, SF5, -OR51, -O-(C1-C6 alkylene)-ORsi, -SR51, -O-(C1-C6 alkylene)-SR5i, 0 fS-R,, -SORs,. -(SOaJRs,. O(S02)Rsi. NRsi w       _ p '1            O . K51 -rS-Rb1 S O          p Tn                          51 CN ,            k51 ,        0 -N(R5i)2, -O(CO)R5i, -O(CS)OR5i, -O(CS)SR5i, -N(R5i)(COR5i), -N(R5i)(COOR5i), -N(R5i)(SO2R5i), -N(SO2R5i)2, -(CO)OR5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-or -CH2OCH2-; the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, tri C1-C6 alkylsilyl, -OR51, -SR51, -SOR51, -(SO2)Rsi, -N(R5i)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, and -(CO)N(R5i)2; X represents C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, -N(R5i)2, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; or -N(R5i)2 together forms v wherein, the “ unsubstituted or substituted by at least one group selected from oxo, C1-C6 alkyl, and C1-C6 alkoxycarbonyl; Yi, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, cyano, -N(Rei)2, C1-C6 alkoxy C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; R51 independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; the aforementioned C3-C6 cycloalkyl, heterocyclyl, aryl, or C3-C6 cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R; R each independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C6 alkoxy, cyano, and C1-C6 alkoxycarbonyl; C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl C1-C6 alkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfanyl, C1-C6 alkylsulfonyl, C1-C6 alkoxy, and halo C1-C6 alkoxy. In another specific embodiment, Qi represents NR33 or O; Q2 represents N, CH, or C-halogen; and when Qi represents O, Q2 represents CH or C-halogen. In another specific embodiment, X represents ethyl; Y represents O. In another specific embodiment, X represents ethyl; Y represents O; Qi represents NR33 or O; Q2 represents N, CH, or C-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(R5i)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2; or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(R5i)2, -O(CO)R5i,-O(CO)OR5i, -(CO)R5i, and -(CO)N(R5i)2; Re represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; R51 independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; the aforementioned “C3-C6 cycloalkyl”, “heterocyclyl”, or “aryl” are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R; R each independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C6 alkoxy, cyano, and C1-C6 alkoxycarbonyl; C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl C1-C6 alkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfanyl, C1-C6 alkylsulfonyl, C1-C6 alkoxy, and halo C1-C6 alkoxy. In another specific embodiment, Qi represents NR33 or O; Q2 represents N, CH, or C-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, O fS-R51 -SR51, -SOR51, -(SO2)R5i, nrsi , -N(R5i)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2; or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-or -CH2OCH2-; the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(R5i)2, -O(CO)Rsi, -O(CO)ORsi, -(CO)R5i, and -(CO)N(R5i)2; X represents C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, -N(R5i)2, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; Y represents O or N-Y1; Y1 and Re each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, cyano, -N(R5i)2, C1-C6 alkoxy C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; R51 independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; the aforementioned “C3-C6 cycloalkyl”, “heterocyclyl”, or “aryl” are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R; R each independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C6 alkoxy, cyano, and C1-C6 alkoxycarbonyl; C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl C1-C6 alkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfanyl, C1-C6 alkylsulfonyl, C1-C6 alkoxy, and halo C1-C6 alkoxy. In another specific embodiment, Qi represents S, NR33 or O; Q2 represents N, CH, or C-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, C3-C6 cycloalkenyl, n        c "       0. Rsi 0 fS-R51 S_.   0 fS-R51 N M SF5, -OR51, -SR51, -SOR51, -(SO2)R5i, -O(SO2)R5i, NR51 , CN ,              ? ,R5i if R51 o , -N(R51)2, -N(R5i)(COOR5i), -N(R51)(SO2R51), -(C0)0R5i, or -(C0)R5i, or Ri and R2 together form unsubstituted or halogen-substituted -0CH20-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51; X represents C1-C6 alkyl, C3-C6 cycloalkyl C1-C6 alkyl, or-N(R5i)2; Y represents O or N-Y1; Y1, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, cyano, or C3-C6 cycloalkyl; R51 independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl; the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR; R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen. In another specific embodiment, Qi represents NR33 or O; Q2 represents N, CH, or C-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, 0 -(SO2)Rsi, nrsi , -N(R5i)2, or -(CO)Rsi, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51; X represents C1-C6 alkyl, C3-C6 cycloalkyl C1-C6 alkyl, or -N(R5i)2; Y represents O or N-Y1; Y1, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, cyano, or C3-C6 cycloalkyl; Rsi independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl; the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR; R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen. In another specific embodiment, X represents ethyl; Y represents O; Qi represents NR33 or O; Q2 represents N, CH, orC-halogen; Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, -(SO2)Rsi, -N(R5i)2, or -(C0)R5i, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51; Re and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, or C3-C6 cycloalkyl; R51 independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl; the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR; R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen. In the definitions of the compounds represented by the above-mentioned general formula(s) and all of the structural formulas hereinafter, the technical terms used, whether used alone or used in compound words, represent the following substituent groups: an alkyl group which has more than two carbon atoms and may be linear or branched. For example, the alkyl in the compound word “cycloalkylalkyl” may be -CH2-, -CH2CH2-, -CH(CH3)-, -C(CH3)2-, etc. An alkyl group is, for example, C1 alkyl: methyl; C2 alkyl: ethyl; C3 alkyl: propyl such as n-propyl or isopropyl; C4 alkyl: butyl such as n-butyl, isobutyl, tert-butyl, or 2-butyl; C5 alkyl: pentyl such as n-pentyl; C6 alkyl: hexyl such as n-hexyl, isohexyl, or 1,3-dimethylbutyl. Similarly, alkenyl is, for example, vinyl, allyl, 9 1-methylprop-2-en-1-yl,     2-methyl prop-2-en-1-yl,     but-2-en-1-yl, but-3-en-1-yl, 1-methylbut-3-en-1-yl, or 1-methylbut-2-en-1-yl. Alkynyl is, for example, ethynyl, propargyl, but-2-yn-1-yl, but-3-yn-1-yl, or 1-methylbut-3-yn-1-yl. A multiple bond may be at any position of each unsaturated group. Cycloalkyl is a saturated carbocyclic ring system having for example three to six carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. Similarly, cycloalkenyl is monocyclic alkenyl having for example three to six carbon ring members such as cyclopropenyl, cyclobutenyl, cyclopentenyl, or cyclohexenyl, wherein a double bond can be at any position. A halogen is fluorine, chlorine, bromine, or iodine. Unless otherwise specified, the “aryl” of the present invention includes, but is not limited to, phenyl, naphthyl, the “heterocyclyl” not only , etc., but also includes, but is not limited to, heteroaryl, that is an aromatic cyclic group having, for example, 3 to 6 ring atoms and also a benzo ring optionally fused with. One to four (for example, 1,2,3, or 4) heteroatoms of the ring atoms are selected from oxygen, nitrogen, and sulfur, for example, The terms “optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, the term “optionally substituted” means that a specified atom or group is unsubstituted or substituted by one or more substituents. If one group is substituted by a group, this should be understood to mean that the group is substituted by one or more groups, which may be the same or different, selected from the mentioned groups. In addition, the same or different substitution characters contained in the same or different substituent groups are independently selected, which may be the same or different. This is also applicable to a ring system formed by different atoms and units. Meanwhile, the scope of the claims will exclude those compounds chemically unstable under standard conditions which are known to a person skilled in the art. In addition, unless specifically defined, the term "substituted by at least one group" herein refers to being substituted by, for example, 1, 2, 3, 4, or 5 groups; a group (including heterocyclyl, aryl, etc.) without being specified a linking site may be linked at any position, including a site connected to C or N; if it is substituted, the substituent group may also substitute at any position as long as the valence bond theory is complied with. <5              aS For example, the heteroaryl substituted by a methyl may represent , The present invention also includes any keto-enol tautomeric form, a mixture and salt thereof, if various functional groups are present. A method for preparing the substituted heterocyclic compound, or its salt or N-oxide, comprises the following steps: (1) when Q represents Q-1, the compound represented by Formula 1-1 is prepared from the compound represented by Formula 11-1, and the reaction equation is as follows: 11-1 1-1 wherein, Hal represents halogen; W represents C1-C3 alkyl; the definitions of Ri, R2, R3, R4, R5, Re, R7, Re, R13, R14, R15, Rw, R17, Rie, R20, R21, R22, R23, R24, R25, R26, R27, R28, R30, R31, R32, R39, R40, R41, R42, R43, R44, R45, R49, R50, Qi, Q2, Q4, Qs, Qe, Q7, Q9, Qu, Q12, Q13, X, and Y are as defined as above. In a specific embodiment, the reaction (1) is carried out in the presence of an acid. In another specific embodiment, the reaction (1) is carried out in the presence of a solvent. In another specific embodiment, the acid is selected from at least one of inorganic acids (e.g., HCI, HBr, HI, H2SO4, H2SO3, H2CO3, HNO3, H3PO4, H3PO3, H2S, etc.) and organic acids (e.g., formic acid, acetic acid, propionic acid, benzoic acid, p-toluenesulfonic acid, etc.). In another specific embodiment, the solvent is selected from at least one of aromatic hydrocarbons (e.g., toluene, xylene), DMF, DMA, THF, acetonitrile, dichloroethane, DMSO, dioxane, dichloromethane, and ethyl acetate. In a specific embodiment, (2) the compound represented by Formula 11-1 is prepared by reaction between the compound represented by Formula 111-1 and the compound represented by Formula IV-1, and the reaction equation is as follows: wherein, M represents OH or halogen. In a specific embodiment, the reaction (2) is carried out in the presence of a solvent. In another specific embodiment, a condensing agent and / or a base is added during the reaction. In another specific embodiment, the base is selected from at least one of inorganic bases (e.g., K2CO3, Na2CO3, Cs2CO3, NaHCO3, KF, CsF, KI, Nai, NaOH, KOH, K3PO4, NaH, KH, etc.) and organic bases (e.g., DMAP, pyrazole, triethylamine, DIEA, KOAc, AcONa, t-BuONa, NaOMe, EtONa, etc.). In another specific embodiment, the condensing agent is selected from at least one of Py-BOP, Py-AOP, EDCI, HOBT, DCC, HBTU, and HATU. In another specific embodiment, the solvent is selected from at least one of aromatic hydrocarbons (e.g., toluene, xylene), DMF, DMA, THF, acetonitrile, dichloroethane, DMSO, dioxane, dichloromethane, and ethyl acetate. The present invention also provides an intermediate compound, as shown in Formula 11-1, 111-1, or IV-1. The present invention also provides a pesticidal composition that comprises a pesticidally effective amount of at least one of the substituted heterocyclic compound, or its salt or N-oxide; preferably, also comprises a formulation auxiliary; more preferably, further comprises an additional active ingredient. The present invention also provides a method for controlling a pest which comprises exposing the pest or its environment to a biologically effective amount of the substituted heterocyclic compound, or its salt or N-oxide, or the composition. The present invention also provides use of the substituted heterocyclic compound, or its salt or N-oxide, or the composition in pest control. Salts of the compounds of the present invention suitable according to the present invention, for example, salts with bases or acid addition salts, are all conventional non-toxic salts. Preferable are agriculturally and / or physiologically acceptable salts. Preferable are salts with inorganic bases such as alkali metal salts (e.g., sodium, potassium, or cesium salts), alkaline earth metal salts (e.g., calcium or magnesium salts), ammonium salts; or salts with organic bases, particularly with organic amines, such as triethylammonium salts, dicyclohexylammonium salts, N,N’-dibenzylethylene diammonium salts, pyridine salts, methylpyridine salts, or ethanolammonium salts; salts with inorganic acids (e.g., hydrochlorides, hydrobromides, dihydrogen sulfates, trihydrogen sulfates, or phosphates); salts with organic carboxylic acids or organic sulfonic acids (e.g., formates, acetates, trifluoroacetates, maleates, tartrates, methanesulfonates, benzenesulfonate, or 4-toluenesulfonates). It is well known that tertiary amines can form N-oxides with some of the compounds of the present invention, which are also the salts of the present invention. Depending on the nature of the substituent, the compound of Formula I may exist in the form of geometric and / or optically active isomer(s) or mixtures of corresponding isomers with various compositions. These stereoisomers are, e.g., enantiomers, diastereomers, atropisomers, or geometric isomers. Therefore, the present invention includes pure stereoisomers and any mixtures of theses isomers. The present invention further relates to a method for control of an animal pest, wherein the compound of Formula I can be used on the animal pest and / or its living environment. The control of an animal pest is preferably implemented in agriculture, forestry, and material protection. Preferably excluded from this method are methods for surgical and therapeutic treatment of human or animal bodies, as well as diagnostic methods performed on human or animal bodies. The present invention further relates to use of the compound of Formula I as a pesticide, particularly to use as a crop protectant. In the context of the present application, the term “pesticide” usually includes the term “crop protectant”. The compounds of Formula I which have good plant tolerance, favorable homeotherm toxicity, and satisfactory environment compatibility are suitable for the following use: protection of plants and plant organs against biotic and abiotic stress factors, increase of harvest yield, improvement of the quality of the harvested material, and control of animal pests, particularly insects, arachnids, helminths, nematodes and molluscs, which are encountered in agriculture, horticulture, animal husbandry, aquaculture, forestry, gardens and leisure facilities, in the protection of stored products and materials as well as in the hygiene sector. These compounds can preferably be used as pesticides. They are effective against normally sensitive and resistant species and against all or some stages of development. The abovementioned pests include but are not limited to: pests from the phylum Arthropoda, especially pests from the class Arachnida, pests from the class Chilopoda, pests from the order Collembola or the class Collembola, pests from the class Diplopoda, pests from the class Insecta, pests from the order Coleoptera, pests from the order Diptera, pests from the order Heteroptera, pests from the order Homoptera, pests from the order Hymenoptera, pests from the order Isopoda, pests from the order Isoptera, pests from the order Lepidoptera, pests from the order Orthoptera or Saltatoria, pests from the order Phthiraptera, pests from the order Psocoptera, pests from the order Siphonaptera, pests from the order Thysanoptera, pests from the order Zygentoma (=Thysanura), pests from the class Symphyla, pests from the phylum Mollusca, and pests from the class Gastropoda. The compounds of Formula I can optionally, at certain concentrations and application rates, also be used as pesticides, safeners, growth regulators or agents to improve plant properties, as microbicides or gametocides, for example as fungicides, antimycotics, bactericides, virucides (including agents against viroids) or as agents against MLO (mycoplasma-like organisms) and RLO (rickettsia-like organisms). If appropriate, they can also be used as intermediates or precursors for the synthesis of other active ingredients. The present invention further relates to formulations and use forms prepared therefrom as pesticides, for example drench, drip and spray liquors, comprising at least one compound of Formula I. In some cases, the use forms comprise additional pesticides and / or adjuvants which improve action, such as penetrants, for example vegetable oils (e.g., rapeseed oil, sunflower oil), mineral oils (e.g., paraffin oils), alkyl esters of vegetable fatty acids (e.g., rapeseed oil methyl ester or soya oil methyl ester), or alkanol alkoxylates; and / or spreaders, for example alkylsiloxanes and / or salts (e.g., organic or inorganic ammonium or phosphorous salts, for example ammonium sulfate or diammonium hydrogenphosphate); and / or retention promoters, for example dioctyl sulfosuccinate or hydroxypropyl guar polymers; and / or humectants, for example glycerol; and / or fertilizers, for example ammonium-, potassium- or phosphorus-containing fertilizers. Customary formulations are, for example, water-soluble liquids (SL), emulsion concentrates (EC), emulsions in water (EW), suspension concentrates (SC, SE, FS, OD), water-dispersible granules (WG), granules (GR) and capsule concentrates (CS); these and further possible formulation types are described, for example, by Crop Life International and in Pesticide Specifications, Manual on development and use of FAO and WHO specifications for pesticides, FAO Plant Production and Protection Papers—173, prepared by the FAO / WHO Joint Meeting on Pesticide Specifications, 2004, ISBN: 9251048576. The formulations, in addition to one or more compounds of Formula I, optionally comprise additional agrochemically active ingredients. These are preferably formulations or use forms which comprise auxiliaries, for example extenders, solvents, spontaneity promoters, carriers, emulsifiers, dispersants, antifreezing agents, biocides, thickeners; and / or further auxiliaries, for example adjuvants. An adjuvant in this context is a component which enhances the biological effect of the formulation, without the component itself having any biological effect. Examples of adjuvants are agents which promote retention, spreading, attachment to the leaf surface or penetration. These formulations are produced in a known manner, for example by mixing the compounds of Formula I with auxiliaries, for example extenders, solvents and / or solid carriers and / or other auxiliaries, for example surfactants. The formulations are produced either in suitable facilities or else before or during application. Auxiliaries used may be substances suitable for imparting special properties, such as particular physical, technical and / or biological properties, to the formulation of the compounds of Formula I, or to the use forms prepared from these formulations (for example ready-to-use pesticides such as spray liquors or seed dressing products). Suitable extenders are, for example, water, polar and non-polar organic chemical liquids, for example selected from aromatic and nonaromatic hydrocarbons (such as paraffins, alkylbenzenes, alkylnaphthalenes, chlorobenzenes), alcohols and polyols (which may optionally also be substituted, etherified and / or esterified), ketones (such as acetone, cyclohexanone), esters (including fats and oils) and (poly)ethers, unsubstituted and substituted amines, amides, lactams (such as N-alkylpyrrolidones) and lactones, sulfones and sulfoxides (such as dimethyl sulfoxide). If the extender utilized is water, it is also possible to use, for example, organic solvents as solubilizers. Useful liquid solvents are essentially: aromatics such as xylene, toluene, or alkylnaphthalenes; chlorinated aromatic hydrocarbons and chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes, or methylene chloride; aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils; alcohols such as butanol or ethylene glycol and their ethers and esters; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone; strongly polar solvents such as dimethylformamide, dimethylacetamide and dimethyl sulfoxide, and also water. In principle, it is possible to use all suitable solvents. Examples of suitable solvents are aromatic hydrocarbons such as xylene, toluene, or alkylnaphthalenes; chlorinated aromatic hydrocarbons or chlorinated aliphatic hydrocarbons such as chlorobenzene, chloroethylene, or methylene chloride; aliphatic hydrocarbons such as cyclohexane, paraffins, mineral oil fractions, mineral and vegetable oils; alcohols such as methanol, ethanol, isopropanol, butanol, or ethylene glycol and their ethers and esters; ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone, or cyclohexanone; strongly polar solvents such as dimethyl sulfoxide and water. In principle, it is possible to use all suitable carriers. Useful carriers especially include, for example, ammonium salts and ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite, or diatomaceous earth; and ground synthetic materials such as finely divided silica, alumina, and natural or synthetic silicates, resins, waxes and / or solid fertilizers. Mixtures of such carriers can likewise be used. Useful carriers for granules include, for example, crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite, dolomite; and synthetic granules of inorganic and organic meals; and also granules of organic material such as sawdust, paper, coconut shells, corn cobs, and tobacco stalks. Liquefied gaseous extenders or solvents can also be used. Particularly suitable extenders or carriers are those which are gaseous at ambient temperature and under atmospheric pressure, for example, aerosol propellant gases, such as halohydrocarbons, and also butane, propane, nitrogen, and carbon dioxide. Examples of emulsifiers and / or foaming agents, dispersants, or wetting agents having ionic or nonionic properties, or mixtures of these surfactants, are salts of polyacrylic acid; salts of lignosulfonic acid; salts of phenolsulfonic acid or naphthalenesulphonic acid; polycondensates of ethylene oxide with fatty alcohols or with fatty acids or with fatty amines or with substituted phenols (preferably alkylphenols or arylphenols); salts of sulfosuccinic esters; taurine derivatives (preferably alkyl taurates); phosphoric esters of polyethoxylated alcohols or phenols; fatty acid esters of polyols; and derivatives of the compounds comprising sulfates, sulfonates and phosphates, e.g., alkylaryl polyglycol ethers, alkyl sulfonates, alkyl sulfates, aryl sulfonates, protein hydrolysates, lignosulfite waste liquors, and methyl cellulose. The presence of a surfactant is advantageous if one of the compounds of Formula I and / or one of the inert carriers is insoluble in water and when the application takes place in water. Further auxiliaries which may be present in the formulations and the use forms derived therefrom include colorants such as inorganic pigments, for example, iron oxide, titanium oxide, and Prussian Blue; and organic dyes such as alizarin dyes, azo dyes, and metal phthalocyanine dyes; and nutrients and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum, and zinc. Additional components may be stabilizers, such as cold stabilizers, preservatives, antioxidants, light stabilizers, or other agents which improve chemical and / or physical stability. Foaming agents and defoaming agents may also be present. In addition, the formulations and the use forms derived therefrom may also comprise, as additional auxiliaries, stickers such as carboxymethyl cellulose; and natural and synthetic polymers in the form of powders, granules, or latices, such as gum arabic, polyvinyl alcohol, and polyvinyl acetate; or else natural phospholipids such as cephalins, lecithins, and synthetic phospholipids. Further possible auxiliaries are mineral and vegetable oils. Optionally, further auxiliaries may be present in the formulations and the use forms derived therefrom. Examples of such additives include fragrances, protective colloids, 17 binders, adhesives, thickeners, thixotropic agents, penetrants, retention promoters, stabilizers, sequestrants, complexing agents, humectants, and spreaders. In general, the compounds of Formula I can be combined with any solid or liquid additive commonly used for formulation purposes. Useful retention promoters include all those substances which reduce the dynamic surface tension, for example, dioctyl sulfosuccinate, or increase the viscoelasticity, for example hydroxypropylguar polymers. Useful penetrants in the present context include all those substances which are typically used to improve the penetration of active agrochemical ingredients into plants. Penetrants are defined herein by their ability to penetrate from the (generally aqueous) application liquor and / or from the spray coating into the cuticle of the plant and thereby increase the mobility of active ingredients in the cuticle. Examples include alcohol alkoxylates such as coconut fatty ethoxylate (10) or isotridecyl ethoxylate (12); fatty acid esters, for example rapeseed oil methyl ester or soya oil methyl ester; fatty amine alkoxylates, for example tallowamine ethoxylate (15); or ammonium and / or phosphorous salts, for example ammonium sulfate or diammonium hydrogenphosphate. The formulations preferably contain between 0.00000001 % and 98% by weight of the compound of Formula I, more preferably between 0.01% and 95% by weight of the compound of Formula I, most preferably between 0.5% and 90% by weight of the compound of Formula I, based on the weight of the formulation. The content of the compound of Formula I in the use forms prepared from the formulations (especially pesticides) may vary within wide ranges. The concentration of the compound of Formula I in the use forms may typically be between 0.00000001% and 95% by weight of the compound of Formula I, preferably between 0.00001% and 1% by weight, based on the weight of the use form. Application is accomplished in a customary manner appropriate for the use forms. The compounds of Formula I can also be used in a mixture with one or more suitable fungicides, bactericides, acaricides, molluscicides, nematicides, insecticides, microbicides, beneficial organisms, pesticides, fertilizers, bird repellents, phytotonics, sterilants, safeners, semiochemicals and / or plant growth regulators, in order thus, for example, to broaden the spectrum of action, to prolong the duration of action, to increase the rate of action, to prevent repulsion or prevent evolution of resistance. In addition, active ingredient combinations of this kind can improve plant growth and / or tolerance to abiotic factors (for example high or low temperatures), to drought or to elevated water content or soil salinity. It is also possible to improve flowering and fruiting performance, optimize germination capacity and root development, facilitate harvesting and improve yields, influence maturation, improve the quality and / or the nutritional value of the harvested products, prolong storage life and / or improve the processability of the harvested products. In addition, the compounds of Formula I may be present in a mixture with other active ingredients or semiochemicals such as attractants and / or bird repellents and / or plant activators and / or growth regulators and / or fertilizers. Likewise, the compounds of Formula I can be used in mixtures with agents which are useful in improvement of plant properties, for example growth, yield, and quality of the harvested material. In a particular embodiment of the present invention, the compounds of Formula I are in the form of formulations or the use forms prepared from these formulations in a mixture with additional compounds, preferably those as described below. If one of the compounds mentioned below can occur in various tautomeric forms, these forms are also included even if not explicitly mentioned in each case. Insecticides / Acaricides / Nematicides The active ingredients specified herein with their “common names” are known and are described for example in The Pesticide Manual, 16th ed., British Crop Protection Council 2012, or can be searched for on the Internet (e.g., http: / / www.alanwood.net / pesticides). (1) Acetylcholinesterase (AChE) inhibitors, for example, carbamates, e.g., alanycarb, aldicarb, bendiocarb, benfuracarb, butocarboxim, butoxycarboxim, carbaryl, carbofuran, carbosulfan, ethiofencarb, fenobucarb, formetanate, furathiocarb, isoprocarb, methiocarb, methomyl, metolcarb, oxamyl, pirimicarb, propoxur, thiodicarb, thiofanox, triazamate, trimethacarb, XMC and xylylcarb; or organophosphates, for example, azamethiphos, azinphos-ethyl, azinphos-methyl, cadusafos, chlorethoxyfos, chlorfenvinphos, chlormephos, chloropyrifos, chloropyrifos-methyl, coumaphos, cyanophos, demeton-S-methyl, diazinon, dichlorvos / DDVP, dicrotophos, dimethoate, dimethylvinphos, disulfoton, EPN, ethion, ethoprophos, famphur, fenamiphos, fenitrothion, fenthion, fosthiazate, heptenophos, imicyafos, isofenphos, isopropyl O-(methoxyaminothio-phosphoryl) salicylate, isoxathion, malathion, mecarbam, methamidophos, methidathion, mevinphos, monocrotophos, naled, omethoate, oxydemeton-methyl, parathion, parathion-methyl, phenthoate, phorate, phosalone, phosmet, phosphamidon, phoxim, pirimiphos-methyl, profenofos, propetamphos, prothiofos, pyraclofos, pyridaphenthion, quinalphos, sulfotep, tebupirimfos, temephos, terbufos, tetrachlorvinphos, thiometon, triazophos, trichlorfon, and vamidothion. (2) GABA-gated chloride channel antagonists, for example, cyclodiene-organochlorines, e.g., chlordane and endosulfan; or fiproles, e.g., ethiprole and fipronil. (3) Sodium channel modulators / Voltage-dependent sodium channel blockers, for example, pyrethroids, e.g., acrinathrin, allethrin, d-c / s,trans-allethrin, d-trans-allethrin, bifenthrin, bioallethrin, bioallethrin S-cyclopentenyl isomer, bioresmethrin, cycloprothrin, cyfluthrin, beta-cyfluthrin, cyhalothrin, lambda-cyhalothrin, gamma-cyhalothrin, cypermethrin, alpha-cypermethrin, beta-cypermethrin, theta-cypermethrin, zeta-cypermethrin, cyphenothrin[(1R)-trans isomers], deltamethrin, empenthrin[(EZ)-(1R) isomers], esfenvalerate, etofenprox, fenpropathrin, fenvalerate, flucythrinate, flumethrin, tau-fluvalinate, halfenprox, imiprothrin, kadethrin, permethrin, phenothrin[(1R)-trans isomer], prallethrin, pyrethrine, pyrethrum, resmethrin, silafluofen, tefluthrin, tetramethrin, tetramethrin[(1R) isomers], tralomethrin, and transfluthrin; or DDT; or methoxychlor. (4) Nicotinic acetylcholine receptor (nAChR) agonists, for example, neonicotinoids such as acetamiprid, clothianidin, dinotefuran, imidacloprid, nitenpyram, thiacloprid, and thiamethoxam or nicotine or sulfoxaflor. (5) Nicotinic acetylcholine receptor (nAChR) allosteric activators, for example, spinosyns such as spinetoram and spinosad. (6) Chloride channel activators, for example, avermectins / milbemycins such as abamectin, emamectin benzoate, lepimectin, and milbemectin. (7) Juvenile hormone mimics, for example, juvenile hormone analogues such as hydroprene, kinoprene, methoprene or fenoxycarb or pyriproxyfen. (8) Active ingredients having unknown or non-specific modes of action, for example, alkyl halides such as methyl bromides and other alkyl halides; or chloropicrin or sulfuryl fluoride or borax or tartar emetic. (9) Selective antifeedants, for example, pymetrozine or flonicamid. (10) Mite growth inhibitors, for example, clofentezine, hexythiazox, and diflovidazin, or etoxazole. (11) Microbial disruptors of insect midgut membranes, for example, Bacillus thuringiensis subspecies israelensis, Bacillus sphaericus, Bacillus thuringiensis subspecies aizawai, Bacillus thuringiensis subspecies kurstaki, Bacillus thuringiensis subspecies tenebrionis, and Bt plant proteins: CrylAb, CrylAc, CrylFa, Cry2Ab, mCry3A, Cry3Ab, Cry3Bb, Cry34 / 35Ab1. (12) Inhibitors of oxidative phosphorylation, inhibitors of mitochondrial ATP synthase, for example, diafenthiuron or organo-tin compounds such as azocyclotin, cyhexatin, and fenbutatin oxide or propargite or tetradifon. (13) Uncouplers of oxidative phosphorylation via disruption of the proton gradient, for example, chlorfenapyr, DNOC, and sulfluramid. (14) Nicotinic acetylcholine receptor antagonists, for example, bensultap, cartap hydrochloride, thiocyclam, and thiosultap-sodium. (15) Inhibitors of chitin biosynthesis, type 0, for example, bistrifluron, chlofluazuron, diflubenzuron, flucycloxuron, flufenoxuron, hexaflumuron, lufenuron, novaluron, noviflumuron, teflubenzuron, and triflumuron. (16) Inhibitors ofchitin biosynthesis, type 1, for example, buprofezin. (17) Moulting disruptors (in particular for Diptera, i.e., dipterans), for example, cyromazine. (18) Ecdysterone receptor agonists, for example, chromafenozide, halofenozid, methoxyfenozide, and tebufenozide. (19) Octapaminergic agonsits, for example, amitraz. (20) Complex-Ill electron transport inhibitors, for example, hydramethylnon, or acequinocyl, orfluacrypyrim. (21) Complex-I electron transport inhibitors, for example, selected from METI acaricides such as fenazaquin, fenpyroximate, pyrimidifen, pyridaben, tebufenpyrad, and tolfenpyrad; or rotenone (Derris). (22) Voltage-gated sodium channel blockers, for example, indoxacarb or metaflumizone. (23) Inhibitors of acetyl CoA carboxylase, for example, tetronic and tetramic acid derivatives such as spirodiclofen, spiromesifen, and spirotetramat. (24) Complex-IV electron transport inhibitors, for example, phosphine such as aluminium phosphide, calcium phosphide, hydrogen phosphide, and zinc phosphide; or cyanide. (25) Complex-ll electron transport inhibitors, for example, cyenopyrafen and cyflumetofen. (28) Ryanodine receptor effectors, for example, diamides such as chlorantraniliprole, cyantraniliprole, and flubendiamide. Additional active ingredients, for example afidopyropen, azadirachtin, benclothiaz, benzoximate, bifenazate, bromopropylate, chinomethionat, cryolite, dicofol, diflovidazin, fluensulfone, flometoquin, flufenerim, flufenoxystrobin, flufiprole, fluopyram, flupyradifurone, fufenozide, heptafluthrin, imidaclothiz, iprodione, meperfluthrin, paichongding, pyflubumide, pyrifluquinazon, pyriminostrobin, tetramethylfluthrin and iodomethane; and also preparations based on Bacillus firmus (1-1582, BioNeem, Votivo), and             also             the             following             compounds: 3-bromo-N-{2-bromo-4-chloro-6-[(1-cyclopropylethyl)carbamoyl]phenyl}-1-(3-chloropyridi n-2-yl)-1H-pyrazole-5-carboxamide (known from WO2005 / 077934) and 1-{2-fluoro-4-methyl-5-[(2,2,2-trifluoroethyl)sulfinyl]phenyl}-3-(trifluoromethyl)-1H-1,2,4-tri azole-5-amine             (known             from             WO2006 / 043635), {1'-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]-5-fluorospiro[indole-3,4'-piperidin]-1(2H)-yl}(2-chloropyridin-4-yl)methanone         (known         from         WO2003 / 106457), 2-chloro-N-[2-{1-[(2E)-3-(4-chlorophenyl)prop-2-en-1-yl]piperidin-4-yl}-4-(trifluoromethyl)p henyl]isonicotinamide           (known           from           WO2006 / 003494), 3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1,8-diazaspiro[4.5]dec-3-en-2-one (known from                                                       WO2009 / 049851), 3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1,8-diazaspiro[4.5]dec-3-en-4-yl-ethylcarbonate (known                        from                        WO2009 / 049851), 4-(but-2-yn-1-yloxy)-6-(3,5-dimethylpiperidin-1-yl)-5-fluoropyrimidine (known from WO2004 / 099160), 4-(but-2-yn-1-yloxy)-6-(3-chlorophenyl)pyrimidine (known from WO2003 / 076415),      PF1364 (CAS Reg. No. 1204776-60-2), 4-(5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-{2-ox 0-2-((2,2,2-trifluoroethyl)amino]ethyl}benzamide   (known from WO2005 / 085216), 4-{5-[3-chloro-5-(trifluoromethyl)phenyl]-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl}-N-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}-1-naphthamide (known from WO2009 / 002809), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-chloro-3-meth ylbenzoyl]-2-methylhydrazinecarboxylate (known from WO2005 / 085216), methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methy lbenzoyl]-2-ethylhydrazinecarboxylate   (known   from   WO2005 / 085216),   methyl 2-[2-({[3-bromo-1-(3-chloropyridin-2-yl)-1H-pyrazol-5-yl]carbonyl}amino)-5-cyano-3-methy lbenzoyl]-2-methylhydrazinecarboxylate   (known  from   WO2005 / 085216),   methyl 2-(3,5-dibromo-2-({[3-bromo-1-(3-chloropyridin-2-yl )-1 H-pyrazol-5-yl]carbonyl}amino)benz oyl]-2-ethylhydrazinecarboxylate (known from WO2005 / 085216), 1-(3-chloropyridin-2-yl)-N-[4-cyano-2-methyl-6-(methylcarbamoyl)phenyl]-3-{[5-(trifluorom ethyl)-2H-tetrazol-2-yl]methyl}-1 H-pyrazole-5-carboxamide (known from WO2010 / 069502), N-[2-(5-amino-1,3,4-thiadiazol-2-yl)-4-chloro-6-methylphenyl]-3-bromo-1-(3-chloropyridin-2-yl)-1 H-pyrazole-5-carboxamide (known from CN102057925), 3-chloro-N-(2-cyanopropan-2-yl)-N-[4-(1,1,1,2,3,3,3-heptafluoropropan-2-yl)-2-methylphe nyl]phthalamide             (known             from             WO2012 / 034472), 8-chloro-N-[(2-chloro-5-methoxyphenyl)sulfonyl]-6-(trifluoromethyl)imidazo[1,2-a]pyridine-2-carboxamide            (known            from            WO2010 / 129500), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-(1-ox idothietan-3-yl)benzamide          (known          from          WO2009 / 080250), 4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-N-(1-ox idothietan-3-yl)benzamide          (known          from          WO2012 / 029672), 1-[(2-chloro-1,3-thiazol-5-yl)methyl]-4-oxo-3-phenyl-4H-pyrido[1,2-a]pyrimidin-1-ium-2-ola te                (known                from                WO2009 / 099929), 1-[(6-chloropyridin-3-yl)methyl]-4-oxo-3-phenyl-4H-pyrido[1,2-a]pyrimidin-1-ium-2-olate (known                        from                        WO2009 / 099929), (5S,8R)-1-[(6-chloropyridin-3-yl)methyl]-9-nitro-2,3,5,6,7,8-hexahydro-1H-5,8-epoxyimida zo[1,2-a]azepine            (known            from            WO2010 / 069266), (2E)-1-[(6-chloropyridin-3-yl)methyl]-N'-nitro-2-pentylidenehydrazinecarboximidamide (known                         from                         WO2010 / 060231), 4-(3-{2,6-dichloro-4-[(3,3-dichloroprop-2-en-1-yl)oxy]phenoxy}propoxy)-2-methoxy-6-(trifl uoromethyl)pyrimidine            (known           from            CN101337940), N-[2-(tert-butylcarbamoyl)-4-chloro-6-methylphenyl]-1-(3-chloropyridin-2-yl)-3-(fluorometh oxy)-1H-pyrazole-5-carboxamide (known from WO2008 / 134969). Fungicides The active ingredients specified herein by their common names are known and described, for example, in the “Pesticide Manual” or on the Internet (for example: http: / / www.alanwood.net / pesticides). (1) Ergosterol biosynthesis inhibitors, for example, (1.1) aldimorph, (1.2) azaconazole, (1.3) bitertanol, (1.4) bromuconazole, (1.5) cyproconazole, (1.6) diclobutrazol, (1.7) difenoconazole, (1.8) diniconazole, (1.9) diniconazole-M, (1.10) dodemorph, (1.11) dodemorph acetate, (1.12) epoxiconazole, (1.13) etaconazole, (1.14) fenarimol, (1.15) fenbuconazole, (1.16) fenhexamid, (1.17) fenpropidin, (1.18) fenpropimorph, (1.19) fluquinconazole, (1.20) flurprimidol, (1.21) flusilazole, (1.22) flutriafol, (1.23) furconazole, (1.24) furconazole-c / s, (1.25) hexaconazole, (1.26) imazalil, (1.27) imazalil sulphate, (1.28) imibenconazole, (1.29) ipconazole, (1.30) metconazole, (1.31) myclobutanil, (1.32) naftifine, (1.33) nuarimol, (1.34) oxpoconazole, (1.35) paclobutrazol, (1.36) pefurazoate, (1.37) penconazole, (1.38) piperalin, (1.39) prochloraz, (1.40) propiconazole, (1.41) prothioconazole, (1.42) pyributicarb, (1.43) pyrifenox, (1.44) quinconazole, (1.45) simeconazole, (1.46) spiroxamine, (1.47) tebuconazole, (1.48) terbinafine, (1.49) tetraconazole, (1.50) triadimefon, (1.51) triadimenol, (1.52) tridemorph, (1.53) triflumizole, (1.54) triforine, (1.55) triticonazole, (1.56) uniconazole, (1.57) uniconazole-P, (1.58) viniconazole,                 (1.59)                 voriconazole,                 (1.60) 1 -(4-chlorophenyl)-2-(1 H-1,2,4-triazol-1 -yl)cycloheptanol,           (1 -61)          methyl 1-(2,2-dimethyl-2,3-dihydro-1H-inden-1-yl)-1H-imidazole-5-carboxylate,            (1-62) / \ / '-{5-(difluoromethyl)-2-methyl-4-[3-(trimethylsilyl)propoxy]phenyl}-A / -ethyl- / \ / -methylimido formamide,                                                                     (1.63) A / -ethyl-A / -methyl- / \ / '-{2-methyl-5-(trifluoromethyl)-4-[3-(trimethylsilyl)propoxy]phenyl}imido formamide,                                                                     (1-64) O-[1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl]-1 H-imidazole-1-carbothioate, and (1.65) pyrisoxazole. (2) Respiration inhibitors (respiratory-chain inhibitors), for example, (2.1) bixafen, (2.2) boscalid, (2.3) carboxin, (2.4) diflumetorim, (2.5) fenfuram, (2.6) fluopyram, (2.7) flutolanil, (2.8) fluxapyroxad, (2.9) furametpyr, (2.10) furmecyclox, (2.11) isopyrazam mixture of the syn-epimeric racemate 1RS, 4SR, 9RS and of the anti-epimeric racemate 1RS, 4SR, 9SR, (2.12) isopyrazam (anti-epimeric racemate), (2.13) isopyrazam (anti-epimeric racemate 1R, 4S, 9S), (2.14) isopyrazam (anti-epimeric racemate 1S, 4R, 9R), (2.15) isopyrazam (syn-epimeric racemate 1RS, 4SR, 9RS), (2.16) isopyrazam (syn-epimeric racemate 1R, 4S, 9R), (2.17) isopyrazam (syn-epimeric racemate 1S, 4R, 9S), (2.18) mepronil, (2.19) oxycarboxin, (2.20) penflufen, (2.21) penthiopyrad, (2.22) sedaxane, (2.23) thifluzamide, (2.24) 1-methyl- / \ / -[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-3-(trifluoromethyl)-1 H-pyrazole-4-carbox amide,                                                                         (2.25) 3-(difluoromethyl)-1-methyl-N-[2-(1,1,2,2-tetrafluoroethoxy)phenyl]-1 H-pyrazole-4-carbox amide,                                                                         (2.26) 3-(difluoromethyl)-N-[4-fluoro-2-(1,1,2,3,3,3-hexafluoropropoxy)phenyl]-1-methyl-1 H-pyra zole-4-carboxamide,                                                            (2.27) N-[1 -(2,4-dichlorophenyl )-1 -methoxypropan-2-yl]-3-(difluoromethyl )-1 -methyl-1 H-pyrazole -4-carboxamide,                                                                (2.28) 5,8-difluoro-N-[2-(2-fluoro-4-{[4-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)ethyl]quinazolin-4-amine,                  (2.29)                  benzovindiflupyr,                  (2.30) N-[(1S,4R)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(diflu oromethyl)-1 -methyl-1 H-pyrazole-4-carboxamide,                                (2.31) N-[(1 R,4S)-9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(diflu oromethyl)-1 -methyl-1 H-pyrazole-4-carboxamide,                                (2.32) 3-(difluromethyl-1-methyl-N-(1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl)-1 H-pyrazole-4-car boxamide,                                                                      (2.33) 1,3,5-trimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-carboxamide, (2.34) 1-methyl-3-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1H-pyrazole-4-c arboxamide,                                                                    (2.35) 1-methyl-3-(trifluoromethyl)-N-[(1R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazol e-4-carboxamide,                                                               (2.36) 1-methyl-3-(trifluoromethyl)-N-[(1 S)-1 J ,3-trimethyl-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazol e-4-carboxamide,                                                               (2.37) 3-(difluoromethyl)-1-methyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazol e-4-carboxamide,                                                               (2.38) 3-(difluoromethyl)-1-methyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazol e-4-carboxamide,                                                               (2.39) 1,3,5-trimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxa mide,                                                                               (2.40) 1,3,5-trimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazole-4-carboxa mide,                     (2.41)                    benodanil,                     (2.42) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyrazole-3-carboxamide, (2.43) isofetamid. (3) Respiration inhibitors (respiratory-chain inhibitors) on the complex III of the respiratory chain, for example, (3.1) ametoctradin, (3.2) amisulbrom, (3.3) azoxystrobin, (3.4) cyazofamid, (3.5) coumethoxystrobin, (3.6) coumoxystrobin, (3.7) dimoxystrobin, (3.8) enestroburin, (3.9) famoxadone, (3.10) fenamidone, (3.11) flufenoxystrobin, (3.12) fluoxastrobin, (3.13) kresoxim-methyl, (3.14) metominostrobin, (3.15) orysastrobin, (3.16) picoxystrobin, (3.17) pyraclostrobin, (3.18) pyrametostrobin, (3.19) pyraoxystrobin, (3.20) pyribencarb, (3.21) triclopyricarb, (3.22) trifloxystrobin, (3.23) (2E)-2-(2-{[6-(3-chloro-2-methylphenoxy)-5-fluoropyrimidin-4-yl]oxy}phenyl)-2-(methoxyi mino)-N-methylethanamide,                                                  (3.24) (2E)-2-(methoxyimino)-N-methyl-2-(2-{[({(1E)-1-[3-(trifluoromethyl)phenyl]-ethylidene}ami no)oxy]methyl}phenyl)ethanamide,                                               (3.25) (2E)-2-(methoxyimino)-N-methyl-2-{2-[(E)-({1-[3-(trifluoromethyl)phenyl]ethoxy}imino)met hyl]phenyl}ethanamide,                                                         (3.26) (2E)-2-{2-[({[(1E)-1-(3-{[(E)-1-fluoro-2-phenylethenyl]oxy}phenyl)ethylidene]amino}oxy)m ethyl]phenyl}-2-(methoxyimino)-N-methylethanamide,                             (3.27) (2E)-2-{2-[({[(2E,3E)-4-(2,6-dichlorophenyl)but-3-yn-2-ylidene]amino}-oxy)methyl]phenyl}-2-(methoxyimino)-N-methylethanamide,                                        (3.28) 2-chloro-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)pyridine-3-carboxamide,     (3.29) 5-methoxy-2-methyl-4-(2-{[({(1 E)-1-[3-(trifluoromethyl)phenyl]ethylidene}amino)oxy]methy l}phenyl)-2,4-dihydro-3H-1,2,4-triazol-3-one,                (3.30)                methyl (2E)-2-{2-[({cyclopropyl[(4-methoxyphenyl)imino]methyl}sulphanyl)methyl]phenyl}-3-meth oxyprop-2-enoate,                                                              (3.31) N-(3-ethyl-3,5,5-trimethylcyclohexyl)-3-(aminoformyl)-2-hydroxybenzamide,        (3.32) 2-{2-[(2,5-dimethylphenoxy)methyl]phenyl}-2-methoxy-N-methylacetamide. (4) Mitosis and cell division inhibitors, for example, (4.1) benomyl, (4.2) carbendazim, (4.3) chlorfenazole, (4.4) diethofencarb, (4.5) ethaboxam, (4.6) fluopicolide, (4.7) fuberidazole, (4.8) pencycuron, (4.9) thiabendazole, (4.10) thiophanate-methyl, (4.11) thiophanate,                 (4.12)                 zoxamide,                 (4.13) 5-chloro-7-(4-methylpiperidin-1-yl)-6-(2,4,6-trifluorophenyl)-[1,2,4]triazolo[1,5-a]pyrimidine, and (4.14) 3-chloro-5-(6-chloropyridin-3-yl)-6-methyl-4-(2,4,6-trifluorophenyl)pyridazine. (5) Compounds with multi-site activity, for example, (5.1) Bordeaux mixture, (5.2) captafol, (5.3) captan, (5.4) chlorothalonil, (5.5) copper hydroxide, (5.6) copper naphthenate, (5.7) copper oxide, (5.8) copper oxychloride, (5.9) copper sulphate, (5.10) dichlofluanid, (5.11) dithianon, (5.12) dodine, (5.13) dodine free base, (5.14) ferbam, (5.15) fluorofolpet, (5.16) folpet, (5.17) guazatine, (5.18) guazatine acetate, (5.19) iminoctadine, (5.20) iminoctadine albesilate, (5.21) iminoctadine triacetate, (5.22) mancopper, (5.23) mancozeb, (5.24) maneb, (5.25) metiram, (5.26) metiram-zinc, (5.27) oxine-copper, (5.28) propamidine, (5.29) propineb, (5.30) sulphur and sulphur preparations such as calcium polysulfide, (5.31) thiram, (5.32) tolylfluanid, (5.33) zineb, (5.34) ziram, and (5.35) anilazine. (6) Resistance inductors, for example, (6.1) acibenzolar-S-methyl, (6.2) isotianil, (6.3) probenazole, (6.4) tiadinil, and (6.5) laminarin. (7) Amino acid and protein biosynthesis inhibitors, for example, (7.1) blasticidin-S, (7.2) cyprodinil, (7.3) kasugamycin, (7.4) kasugamycin hydrochloride hydrate, (7.5) mepanipyrim,                  (7.6)                  pyrimethanil,                  (7.7) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinol-1-yl)quinoline, (7.8) oxytetracycline, and (7.9) streptomycin. (8) ATP production inhibitors, for example, (8.1) fentin acetate, (8.2) fentin chloride, (8.3) fentin hydroxide, and (8.4) silthiofam. (9) Cell wall synthesis inhibitors, for example, (9.1) benthiavalicarb, (9.2) dimethomorph, (9.3) flumorph, (9.4) iprovalicarb, (9.5) mandipropamid, (9.6) polyoxins, (9.7) polyoxorim, (9.8) validamycin A, (9.9) valifenalate, and (9.10) polyoxin B. (10) Lipid and membrane synthesis inhibitors, for example, (10.1) biphenyl, (10.2) chloroneb, (10.3) dicloran, (10.4) edifenphos, (10.5) etridiazole, (10.6) iodocarb, (10.7) iprobenfos, (10.8) isoprothiolane, (10.9) propamocarb, (10.10) propamocarb hydrochloride, (10.11) prothiocarb, (10.12) pyrazophos, (10.13) quintozene, (10.14) tecnazene, and (10.15) tolclofos-methyl. (11) Melanin biosynthesis inhibitors, for example, (11.1) carpropamid, (11.2) diclocymet, (11.3) fenoxanil, (11.4) fthalide, (11.5) pyroquilon, (11.6) tricyclazole, (11.7) 2,2,2-trifluoroethyl{3-methyl-1-[(4-methylbenzoyl)amino]butan-2-yl}carbamate. (12) Nucleic acid synthesis inhibitors, for example, (12.1) benalaxyl, (12.2) benalaxyl-M (kiralaxyl), (12.3) bupirimate, (12.4) clozylacon, (12.5) dimethirimol, (12.6) ethirimol, (12.7) furalaxyl, (12.8) hymexazol, (12.9) metalaxyl, (12.10) metalaxyl-M (mefenoxam), (12.11) ofurace, (12.12) oxadixyl, (12.13) oxolinic acid, and (12.14) octhilinone. (13) Signal transduction inhibitors, for example, (13.1) chlozolinate, (13.2) fenpiclonil, (13.3) fludioxonil, (13.4) iprodione, (13.5) procymidone, (13.6) quinoxyfen, (13.7) vinclozolin, and (13.8) proquinazid. (14) Decouplers, for example, (14.1) binapacryl, (14.2) dinocap, (14.3) ferimzone, (14.4) fluazinam, and (14.5) meptyldinocap. (15) Further compounds, for example, (15.1) benthiazole, (15.2) bethoxazin, (15.3) capsimycin, (15.4) carvone, (15.5) chinomethionat, (15.6) pyriofenone (chlazafenone), (15.7) cufraneb, (15.8) cyflufenamid, (15.9) cymoxanil, (15.10) cyprosulfamide, (15.11) dazomet, (15.12) debacarb, (15.13) dichlorophen, (15.14) diclomezine, (15.15) difenzoquat, (15.16) difenzoquat methylsulphate, (15.17) diphenylamine, (15.18) ecomate, (15.19) fenpyrazamine, (15.20) flumetover, (15.21) fluoromide, (15.22) flusulfamide, (15.23) flutianil, (15.24) fosetyl-aluminium, (15.25) fosetyl-calcium, (15.26) fosetyl-sodium, (15.27) hexachlorobenzene, (15.28) irumamycin, (15.29) methasulphocarb, (15.30) methyl isothiocyanate, (15.31) metrafenone, (15.32) mildiomycin, (15.33) natamycin, (15.34) nickel dimethyldithiocarbamate, (15.35) nitrothal-isopropyl, (15.36) octhilinone, (15.37) oxamocarb, (15.38) oxyfenthiin, (15.39) pentachlorophenol and its salts, (15.40) phenothrin, (15.41) phosphoric acid and its salts, (15.42) propamocarb-fosetylate, (15.43) propanosine-sodium,              (15.44)             pyrimorph,              (15.45) (2E)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl)prop-2-en-1-one, (15.46)               (2Z)-3-(4-tert-butylphenyl)-3-(2-chloropyridin-4-yl)-1-(morpholin-4-yl) prop-2-en-1-one, (15.47) pyrrolnitrin, (15.48) tebufloquin, (15.49) tecloftalam, (15.50) tolnifanide, (15.51) triazoxide, (15.52) trichlamide, (15.53) zarilamid, (15.54) (3S,6S,7R,8R)-8-benzyl-3-[({3-[(isobutyryloxy)methoxy]-4-methoxypyridin-2-yl}carbonyl)a mino]-6-methyl-4,9-dioxo-1,5-dioxonan-7-yl 2-methylpropanoate, (15.55) 1-(4-{4-[(5R)-5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone,                     (15.56) 1-(4-{4-[(5S)-5-(2,6-difluorophenyl )-4,5-dihydro-1,2-oxazol-3-yl]-1,3-th iazol-2-yl}piperidin-1-yl)-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone,                     (15.57) 1-(4-{4-[5-(2,6-difluorophenyl)-4,5-dihydro-1,2-oxazol-3-yl]-1,3-thiazol-2-yl}pi peridin-1 -yl )-2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]ethanone,                          (15.58) 1-(4-methoxyphenoxy)-3,3-dimethylbutan-2-yl 1H-imidazole-1 -carboxylate, (15.59) 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine,                                       (15.60) 2,3-dibutyl-6-chlorothieno[2,3-d]pyrimidin-4(3H)-one,                              (15.61) 2,6-dimethyl-1H,5H-[1,4]dithiino[2,3-c:5,6-c']dipyrrole-1,3,5,7(2H,6H)-tetrone,     (15.62) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5R)-5-phenyl-4,5-dihydro-1,2-ox azol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone,                                   (15.63) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-(4-{4-[(5S)-5-phenyl-4,5-dihydro-1,2-ox azol-3-yl]-1,3-thiazol-2-yl}piperidin-1-yl)ethanone,                                   (15.64) 2-[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]-1-{4-[4-(5-phenyl-4,5-dihydro-1,2-oxazol-3 -yl)-1,3-thiazol-2-yl]piperidin-1 -yl}ethanone,                                          (15.65) 2-butoxy-6-iodo-3-propyl-4H-benzopyr-4-one,                                   (15.66) 2-chloro-5-[2-chloro-1-(2,6-difluoro-4-methoxyphenyl)-4-methyl-1H-imidazol-5-yl]pyridine, (15.67) 2-phenylphenol         and         its salts,          (15.68) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1 -yl )q u i nol ine,                (15.69) 3,4,5-trichloropyridine-2,6-dicarbonitrile,                                             (15.70) 3-chloro-5-(4-chlorophenyl)-4-(2,6-difluorophenyl)-6-methylpyridazine,            (15.71) 4-(4-chlorophenyl)-5-(2,6-difluorophenyl)-3,6-dimethylpyridazine,                  (15.72) 5-amino-1,3,4-thiadiazole-2-thiol,                                                  (15.73) 5-chloro-N'-phenyl-N'-(prop-2-yn-1-yl)thiophene-2-sulfonohydrazide,              (15.74) 5-fluoro-2-[(4-fluorobenzyl)oxy]pyrimidin-4-amine,                                 (15.75) 5-fluoro-2-[(4-methylbenzyl)oxy]pyrimidin-4-amine,                                (15.76) 5-methyl-6-octyl[1,2,4]triazolo[1,5-a]pyrimidin-7-amine,            (15.77)            ethyl (2Z)-3-amino-2-cyano-3-phenylpropenoate,                                     (15.78) N'-(4-{[3-(4-chlorobenzyl)-1,2,4-thiadiazol-5-yl]oxy}-2,5-dimethylphenyl)-N-ethyl-N-methyli midoformamide,                                                            (15.79) N-(4-chlorobenzyl)-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamide,      (15.80) N-[(4-chlorophenyl)(cyano)methyl]-3-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]propanamid e, (15.81) N-[(5-bromo-3-chloropyridin-2-yl)methyl]-2,4-dichloropyridine-3-carboxamide, (15.82) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2,4-dichloropyridine-3-carboxamide, (15.83) N-[1-(5-bromo-3-chloropyridin-2-yl)ethyl]-2-fluoro-4-iodopyridine-3-carboxamide, (15.84) N-{(E)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phe nylacetamide,                                                                 (15.85) N-{(Z)-[(cyclopropylmethoxy)imino][6-(difluoromethoxy)-2,3-difluorophenyl]methyl}-2-phe nylacetamide,                                                                 (15.86) N'-{4-[(3-tert-butyl-4-cyano-1,2-thiazol-5-yl)oxy]-2-chloro-5-methylphenyl}-N-ethyl-N-meth ylimidoformamide,                                                             (15.87) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-(1,2,3 ,4-tetrahydronaphthalen-1-yl)-1,3-thiazole-4-carboxamide,                        (15.88) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1R)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide,                   (15.89) N-methyl-2-(1-{[5-methyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]acetyl}piperidin-4-yl)-N-[(1S)-1,2,3,4-tetrahydronaphthalen-1-yl]-1,3-thiazole-4-carboxamide, (15.90) pentyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylidene]amino}oxy)methyl]pyridin-2-yl}carba mate, (15.91) phenazine-1-carboxylic acid, (15.92) quinolin-8-ol, (15.93) quinolin-8-ol sulfate                       (2:1),                       (15.94)                       tert-butyl {6-[({[(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}carbam ate,                                                                                    (15.95) 1-methyl-3-(trifluoromethyl)-N-[2'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxami de,                                                                                (15.96) N-(4'-chlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.97) N-(2’,4'-dichlorobiphenyl-2-yl)-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide, (15.98) 3-(difluoromethyl)-1-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1H-pyrazole-4-carboxami de,                                                                                (15.99) N-(2',5'-difluorobiphenyl-2-yl)-1-methyl-3-(trifluoromethyl)-1H-pyrazole-4-carboxamide, (15.100) 3-(difluoromethyl)-1 -methyl-N-[4 '-(prop-1 -yn-1-yl)biphenyl-2-yl]-1H-pyrazole-4-carboxami de,                                                                               (15.101) 5-fluoro-1,3-dimethyl-N-[4 '-(prop-1 -yn-1 -yl)biphenyl-2-yl]-1 H-pyrazole-4-carboxamide, (15.102) 2-chloro-N-[4 '-(prop-1 -yn-1 -yl)biphenyl-2-yl]pyridine-3-carboxamide, (15.103) 3-(difluoromethyl)-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyrazole-4-carboxamide,                                                             (15.104) N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carbox amide,                                                                       (15.105) 3-(difluoromethyl)-N-(4'-ethynylbiphenyl-2-yl)-1-methyl-1H-pyrazole-4-carboxamide, (15.106) N-(4'-ethynylbiphenyl-2-yl)-5-fluoro-1,3-dimethyl-1H-pyrazole-4-carboxamide, (15.107) 2-chloro-N-(4'-ethynylbiphenyl-2-yl)pyridine-3-carboxamide, (15.108) 2-chloro-N-[4'-(3,3-dimethylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide,  (15.109) 4-(difluoromethyl)-2-methyl-N-[4'-(trifluoromethyl)biphenyl-2-yl]-1,3-thiazole-5-carboxamid e,                                                                                (15.110) 5-fluoro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4 -carboxamide,                                                                (15.111) 2-chloro-N-[4'-(3-hydroxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide, (15.112) 3-(difluoromethyl)-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]-1-methyl-1H-pyr azole-4-carboxamide,            (15.113)            5-fluoro-N-[4'-(3-methoxy-3-methyl but-1 -yn-1 -yl)biphenyl-2-yl]-1,3-dimethyl-1H-pyrazole-4-carboxamide,            (15.114) 2-chloro-N-[4'-(3-methoxy-3-methylbut-1-yn-1-yl)biphenyl-2-yl]pyridine-3-carboxamide, (15.115) (5-bromo-2-methoxy-4-methylpyridin-3-yl)(2,3,4-trimethoxy-6-methylphenyl)methanone, (15.116) N-[2-(4-{[3-(4-chlorophenyl)prop-2-yn-1-yl]oxy}-3-methoxyphenyl)ethyl]-N2-(methylsulfon yl)valinamide, (15.117) 4-oxo-4-[(2-phenylethyl)amino]butanoic acid, (15.118) but-3-yn-1-yl {6-[({[(Z)-(1-methyl-1H-tetrazol-5-yl)(phenyl)methylene]amino}oxy)methyl]pyridin-2-yl}car bamate, (15.119) 4-amino-5-fluorpyrimidin-2-ol (mesomeric form: 4-amino-5-fluorpyrimidin-2(1H)-one), (15.120) propyl 3,4,5-trihydroxybenzoate, (15.121) 1,3-dimethyl-N-(1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl)-1 H-pyrazole-4-carboxamide, (15.122) 1,3-dimethyl-N-[(3R)-1,1,3-trimethyl-2,3-dihydro-1 H-inden-4-yl]-1 H-pyrazole-4-carboxami de,                                                                               (15.123) 1,3-dimethyl-N-[(3S)-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1H-pyrazole-4-carboxami de,                                                                               (15.124) [3-(4-chloro-2-fluorophenyl )-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)methanol, (15.125) (S)-[3-(4-chloro-2-fluorophenyl)-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)metha nol,                                                                              (15.126) (R)-[3-(4-chloro-2-fluorophenyl )-5-(2,4-difluorophenyl)-1,2-oxazol-4-yl](pyridin-3-yl)metha nol,                                                                              (15.127) 2-{[3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H-1,2,4-triaz ole-3-thione,                                                                     (15.128) 1 -{[3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazol-5-yl thiocyanate,                                                                     (15.129) 5-(allylsulphanyl)-1-{[3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2, 4-triazole,                                                                            (15.130) 2-[1 -(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3H-1,2,4-triaz ole-3-thione,                                                                     (15.131) 2-{[rel(2R,3S)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3H -1,2,4-triazole-3-thione,                                                              (15.132) 2-{[rel(2R,3R)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.133) 1-{[rel(2R,3S)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triazo l-5-yl                                  thiocyanate,                                  (15.134) 1-{[rel(2R,3R)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]methyl}-1H-1,2,4-triaz ol-5-yl                               thiocyanate,                               (15.135) 5-(allylsulphanyl )-1 -{[rel(2R,3S)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]meth yl}-1H-,2,4-triazole,                                                                  (15.136) 5-(allylsulphanyl)-1-{[rel(2R,3R)-3-(2-chlorophenyl )-2-(2,4-difluorophenyl)oxiran-2-yl]meth yl}-1H-1,2,4-triazole,                                                                 (15.137) 2-[(2S,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.138) 2-[(2R,4S,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.139) 2-[(2R,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.140) 2-[(2S,4R,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.141) 2-[(2S,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.142) 2-[(2R,4S,5R)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.143) 2-[(2R,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.144) 2-[(2S,4R,5S)-1-(2,4-dichlorophenyl)-5-hydroxy-2,6,6-trimethylheptan-4-yl]-2,4-dihydro-3 H-1,2,4-triazole-3-thione,                                                            (15.145) 2-fluoro-6-(trifluoromethyl)-N-(1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)benzamide, (15.146)                  2-(6-benzylpyridin-2-yl)quinazoline,                   (15.147) 2-[6-(3-fluoro-4-methoxyphenyl)-5-methylpyridin-2-yl]quinazoline,                (15.148) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (15.149) abscisic acid, (15.150) 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]-1H-pyraz ole-4-carboxamide,                                                           (15.151) N'-[5-bromo-6-(2,3-dihydro-1H-inden-2-yloxy)-2-methylpyridin-3-yl]-N-ethyl-N-methylimid oformamide,                                                              (15.152) N'-{5-bromo-6-[1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimidof ormamide,                                                                (15.153) N'-{5-bromo-6-[(1R)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methyli midoformamide,                                                           (15.154) N'-{5-bromo-6-[(1S)-1-(3,5-difluorophenyl)ethoxy]-2-methylpyridin-3-yl}-N-ethyl-N-methyli midoformamide,                                                           (15.155) N'-{5-bromo-6-[(cis-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methylimid oformamide,                                                              (15.156) N'-{5-bromo-6-[(trans-4-isopropylcyclohexyl)oxy]-2-methylpyridin-3-yl}-N-ethyl-N-methyli midoformamide,                                                           (15.157) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl)-1-methyl-1H-pyrazole-4-c arboxamide,                                                              (15.158) N-cyclopropyl-N-(2-cyclopropylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4 -carboxamide,                                                                (15.159) N-(2-tert-butylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-c arboxamide,                                                              (15.160) N-(5-chloro-2-ethylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazol e-4-carboxamide,                                                             (15.161) N-(5-chloro-2-isopropylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyr azole-4-carboxamide,                                                         (15.162) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-fluorobenzyl)-5-fluoro-1-methyl-1H-pyrazole -4-carboxamide,                                                              (15.163) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(5-fluoro-2-isopropylbenzyl)-1-methyl-1H-pyra zole-4-carboxamide,                                                          (15.164) N-cyclopropyl-N-(2-cyclopropyl-5-fluorobenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-p yrazole-4-carboxamide,                                                       (15.165) N-(2-cyclopentyl-5-fluorobenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-p yrazole-4-carboxamide,                                                       (15.166) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-fluoro-6-isopropylbenzyl)-1-methyl-1H-pyra zole-4-carboxamide,                                                          (15.167) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-5-methyl benzyl )-5-fluoro-1-methyl-1H-pyrazol e-4-carboxamide,                                                             (15.168) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropyl-5-methyl benzyl )-1-methyl-1H-pyr azole-4-carboxamide,                                                         (15.169) N-cyclopropyl-N-(2-cyclopropyl-5-methylbenzyl)-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyrazole-4-carboxamide,                                                      (15.170) N-(2-tert-butyl-5-methylbenzyl)-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-1H-pyr azole-4-carboxamide,                                                         (15.171) N-[5-chloro-2-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl- 1 H-pyrazole-4-carboxamide,                                                  (15.172) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl-N-[5-methyl-2-(trifluoromethyl)benzyl]- 1 H-pyrazole-4-carboxamide,                                                  (15.173) N-[2-chloro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1-methyl- 1 H-pyrazole-4-carboxamide,                                                  (15.174) N-[3-chloro-2-fluoro-6-(trifluoromethyl)benzyl]-N-cyclopropyl-3-(difluoromethyl)-5-fluoro-1- methyl-1 H-pyrazole-4-carboxamide,                                           (15.175) N-cyclopropyl-3-(difluoromethyl)-N-(2-ethyl-4,5-dimethylbenzyl)-5-fluoro-1-methyl-1H-pyr azole-4-carboxamide,                                                         (15.176) N-cyclopropyl-3-(difluoromethyl)-5-fluoro-N-(2-isopropylbenzyl )-1 -methyl-1 H-pyrazol-4-ca rbothioamide,                                                                (15.177) 3-(difluoromethyl)-N-(7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl)-1-methyl-1 H-pyr azole-4-carboxamide,                                                         (15.178) 3-(difluoromethyl)-N-[(3R)-7-fluoro-1 J,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1-methyl-1 H -pyrazole-4-carboxamide,                                                     (15.179) 3-(difluoromethyl)-N-[(3S)-7-fluoro-1,1,3-trimethyl-2,3-dihydro-1H-inden-4-yl]-1 -methyl-1 H -pyrazole-4-carboxamide,                                                     (15.180) N'-(2,5-dimethyl-4-phenoxyphenyl)-N-ethyl-N-methylimidoformamide,           (15.181) N'-{4-[(4,5-dichloro-1,3-thiazol-2-yl)oxy]-2,5-dimethylphenyl}-N-ethyl-N-methylimidoforma mide,                                                                        (15.182) N-(4-chloro-2,6-difluorophenyl)-4-(2-chloro-4-fluorophenyl)-1,3-dimethyl-1H-pyrazole-5-a mine. Depending on the circumstances, all the mixing components mentioned in (1) to (15) may form salts with suitable bases or acids, provided they are capable of doing so on the basis of their functional groups. Biological Pesticides as Mixing Components The compounds of Formula I can be combined with biological pesticides. Biological pesticides include especially bacteria, fungi, yeasts, plant extracts and products formed by microorganisms, including proteins and secondary metabolites. Biological pesticides include bacteria such as spore-forming bacteria, root-colonizing bacteria and bacteria which act as biological insecticides, fungicides or nematicides. Also included are bacteria and fungi which are added as ‘inoculant’ to plants or parts of plant or plant organs and which, by virtue of their particular properties, promote plant growth and plant health. Safeners as Mixing Components The compounds of Formula I can be combined with safeners, for example benoxacor, cloquintocet(-mexyl), cyometrinil, cyprosulfamide, dichlormid, fenchlorazole(-ethyl), fenclorim, flurazole, fluxofenim, furilazole, isoxadifen(-ethyl), mefenpyr(-diethyl), naphthalic                             anhydride,                             oxabetrinil, 2-methoxy-N-({4-[(methylcarbamoyl)amino]phenyl}sulfonyl)benzamide (CAS No.: 129531-12-0), 4-(dichloroacetyl)-1-oxa-4-azaspiro[4.5]decane (CAS No.: 71526-07-3), 2,2,5-trimethyl-3-(dichloroacetyl)-1,3-oxazolidine (CAS No.: 52836-31-4). Plants and Plant Parts All plants and plant parts can be treated in accordance with the present invention. Plants are understood herein to mean all plants and populations of plants, such as desirable and undesirable wild plants or crop plants (including naturally occurring crop plants), for example cereals (wheat, rice, triticale, barley, rye, oats), maize, soya bean, potato, sugar beet, sugar cane, tomatoes, peas and other vegetable species, cotton, tobacco, oilseed rape, and also fruit plants (with the fruits apples, peas, citrus fruits and grapes). Crop plants may be plants which can be obtained by conventional breeding and optimization methods or by biotechnological or genetic engineering methods or combinations of these methods, including transgenic plants and including plant cultivars which are protectable and non-protectable by plant breeders' rights. Parts of plants shall be understood to mean all parts and organs of the plants above and below ground, such as shoot, leaf, flower and root, examples given being leaves, needles, stalks, stems, flowers, fruit bodies, fruits and seeds, and also tubers, roots and rhizomes. Parts of plants also include harvested material and vegetative and generative propagation material, for example cuttings, tubers, rhizomes, slips and seeds. The inventive treatment of the plants and parts of plants with the compounds of Formula I is effected directly or by allowing them to act on the surroundings, habitat or storage space thereof by the customary treatment methods, for example by dipping, spraying, evaporating, fogging, scattering, painting on, injecting, and, in the case of propagation material, especially in the case of seeds, also by applying one or more coats. As already mentioned above, it is possible in accordance with the present invention to treat all plants and parts thereof. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars (genetically modified organisms) obtained by genetic engineering methods, if appropriate in combination with conventional methods, and parts thereof are treated. The term “parts” or “parts of plants” or “plant parts” has been explained above. Particular preference is given in accordance with the present invention to treating plants of the respective commercially customary cultivars or those that are in use. Plant cultivars are understood to mean plants having new properties (“traits”) and which have been obtained by conventional breeding, by mutagenesis or by recombinant DNA techniques. They may be cultivars, varieties, biotypes or genotypes. Transgenic Plants, Seed Treatment and Integration Events The preferred transgenic plants or plant cultivars (those obtained by genetic engineering) which are to be treated in accordance with the present invention include all plants which, through the genetic modification, received genetic material which imparts particular advantageous useful traits to these plants. Examples of such properties are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to levels of water or soil salinity, enhanced flowering performance, easier harvesting, accelerated ripening, higher yields, higher quality and / or higher nutritional value of the harvested products, better storage life and / or processability of the harvested products. Further and particularly emphasized examples of such properties are increased resistance of the plants against animal and microbial pests, such as against insects, arachnids, nematodes, mites, slugs and snails owing, for example, to toxins formed in the plants, in particular those formed in the plants by the genetic material from Bacillus thuringiensis (for example by the genes CrylA(a), CrylA(b), CrylA(c), CryllA, CrylllA, CrylllB2, Cry9c, Cry2Ab, Cry3Bb and CrylF and also combinations thereof), and also increased resistance of the plants against phytopathogenic fungi, bacteria and / or viruses caused, for example, by systemic acquired resistance (SAR), systemin, phytoalexins, elicitors and resistance genes and correspondingly expressed proteins and toxins, and also increased tolerance of the plants to certain active pesticidal ingredients, for example imidazolinones, sulphonylureas, glyphosate or glufosinate-P (for example the “PAT” gene). The genes which impart the desired traits in question may also be present in combinations with one another in the transgenic plants. Examples of transgenic plants include the important crop plants, such as cereals (wheat, rice, triticale, barley, rye, oats), maize, soya beans, potatoes, sugar beet, sugar cane, tomatoes, peas and other types of vegetable, cotton, tobacco, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), particular emphasis being given to maize, soya beans, wheat, rice, potatoes, cotton, sugar cane, tobacco and oilseed rape. Traits which are particularly emphasized are the increased resistance of the plants to insects, arachnids, nematodes and slugs and snails. Crop Protection—Types of Treatment The treatment of the plants and plant parts with the compounds of Formula I is effected directly or by action on their surroundings, habitat or storage space by the customary treatment methods, for example by dipping, spraying, atomizing, irrigating, evaporating, dusting, fogging, broadcasting, foaming, painting, spreading-on, injecting, watering (drenching), drip irrigating and, in the case of propagation material, especially in the case of seed, also by dry seed treatment, wet seed treatment, slurry treatment, incrustation, coating with one or more coats, etc. It is also possible to deploy the compounds of Formula I by the ultra-low volume method or to inject the use form or the compound of Formula I itself into the soil. A preferred direct treatment of the plants is foliar application, meaning that the compounds of Formula I are applied to the foliage, where treatment frequency and application rate should be adjusted according to the level of infestation with the pest in question. In the case of systemically active compounds, the compounds of Formula I also get into the plants via the root system. The plants are then treated by the action of the compounds of Formula I on the habitat of the plant. This can be accomplished, for example, by drenching, or by mixing into the soil or the nutrient solution, meaning that the locus of the plant (e.g., soil or hydroponic systems) is impregnated with a liquid form of the compounds of Formula I, or by soil application, meaning that the compounds of Formula I are introduced in solid form (e.g., in the form of granules) into the locus of the plants. In the case of paddy rice crops, this can also be accomplished by metering the compound of Formula I in a solid application form (for example as granules) into a flooded paddy field. Seed treatment The control of animal pests by the treatment of the seed of plants has long been known and is the subject of constant improvement. However, the treatment of seed entails a series of problems which cannot always be solved in a satisfactory manner. Thus, it is desirable to develop methods for protecting the seed and the germinating plant which dispense with, or at least reduce considerably, the additional application of pesticides during storage, after sowing or after emergence of the plants. It is additionally desirable to optimize the amount of active ingredient used so as to provide optimum protection for the seed and the germinating plant from attack by animal pests, but without damage to the plant itself by the active ingredient used. In particular, methods for the treatment of seed should also take account of the intrinsic insecticidal and / or nematicidal properties of pest-resistant or -tolerant transgenic plants in order to achieve optimal protection of the seed and the germinating plant with a minimum expenditure of crop protection products. The present invention therefore also relates, more particularly, to a method for protection of seed and germinating plants from attack by pests, by treating the seed with one of the compounds of Formula I. The inventive method for protecting seed and germinating plants against attack by pests further comprises a method in which the seed is treated simultaneously in one operation or sequentially with a compound of Formula I and a mixing component. It also comprises a method where the seed is treated at different time with a compound of Formula I and a mixing component. The present invention likewise relates to use of the compounds of Formula I for treatment of seed for protection of the seed and the resulting plant from animal pests. The present invention further relates to seed which have been treated with a compound of Formula I for protection from animal pests. The present invention also 36 relates to seed which have been treated simultaneously with a compound of Formula I and a mixing component. The present invention further relates to seed which have been treated at different time with a compound of Formula I and a mixing component. In the case of seed which has been treated at different time with a compound of Formula I and a mixing component, the individual substances may be present on the seed in different layers. In this case, the layers comprising a compound of Formula I and mixing components may optionally be separated by an intermediate layer. The present invention also relates to seed in which a compound of Formula I and a mixing component have been applied as part of a coating or as a further layer or further layers in addition to a coating. The present invention further relates to seed which, after the treatment with a compound of Formula I, is subjected to a film-coating process to prevent dust abrasion on the seed. One of the advantages that occurs when one of the compounds of Formula I acts systemically is that the treatment of the seed protects not only the seed itself but also the plants resulting therefrom, after emergence, from animal pests. In this way, the immediate treatment of the crop at the time of sowing or shortly thereafter can be dispensed with. A further advantage is that the treatment of the seed with a compound of Formula I can enhance germination and emergence of the treated seed. It is likewise considered to be advantageous that compounds of Formula I can especially also be used for transgenic seed. Compounds of Formula I can also be used in combination with signaling technology compositions, which results, for example, in better colonization by symbionts, for example rhizobia, mycorrhizae and / or endophytic bacteria or fungi, and / or in optimized nitrogen fixation. The compounds of Formula I are suitable for protection of seed of any plant variety which is used in agriculture, in the greenhouse, in forestry or in horticulture. More particularly, the seed includes seed of cereals (for example wheat, barley, rye, millet, and oats), corn, cotton, soya beans, rice, potatoes, sunflowers, coffee, tobacco, canola, oilseed rape, beets (for example sugar beets and fodder beets), peanuts, vegetables (for example tomatoes, cucumbers, beans, cruciferous vegetables, onions, and lettuce), fruit plants, lawns and ornamental plants. Of particular significance is the treatment of the seed of cereals (such as wheat, barley, rye, and oats), maize, soya, cotton, canola, oilseed rape, and rice. As already mentioned above, the treatment of transgenic seed with a compound of Formula I is also of particular significance. The seed includes the seed of plants which generally contain at least one heterologous gene which controls the expression of a polypeptide having insecticidal and / or nematicidal properties in particular. The heterologous genes in transgenic seed may originate from microorganisms such as Bacillus, Rhizobium, Pseudomonas, Serratia, Trichoderma, Clavibacter, Glomus, or Gliocladium. The composition of the present invention is particularly suitable for the treatment of transgenic seed containing at least one heterologous gene originating from Bacillus sp. The heterologous gene is more preferably derived from Bacillus thuringiensis. In the context of the present invention, the compound of Formula I is applied to the seed. The seed is preferably treated in a state in which it is sufficiently stable for no damage to occur in the course of treatment. In general, the seed can be treated at any time between harvest and sowing. It is customary to use seed which have been separated from the plant and freed from cobs, shells, stalks, coats, hairs or the flesh of the fruits. For example, it is possible to use seed which have been harvested, cleaned and dried down to a moisture content which allows storage. Alternatively, it is also possible to use seed which, after drying, have been treated with, for example, water and then dried again, for example priming. In general, in the treatment of the seed, it has to be ensured that the amount of the compound of Formula I and / or further additives applied to the seed is chosen such that the germination of the seed is not impaired and the plant which arises therefrom is not damaged. This has to be ensured particularly in the case of active ingredients which can exhibit phytotoxic effects at certain application rates. The compounds of Formula I are generally applied to the seed in a suitable formulation. Suitable formulations and processes for seed treatment are known to a person skilled in the art. The compounds of Formula I can be converted to the customary seed dressing formulations, such as solutions, emulsions, suspensions, powders, foams, slurries or other coating compositions for seed, and also ULV formulations. These formulations are produced in a known manner, by mixing the compounds of Formula I with customary additives, for example customary extenders and solvents or diluents, colorants, wetters, dispersants, emulsifiers, antifoams, preservatives, secondary thickeners, stickers, gibberellins and also water. Useful colorants which may be present in the seed dressing formulations usable in accordance with the present invention are all colorants which are customary for such purposes. It is possible to use either pigments, which are sparingly soluble in water, or dyes, which are soluble in water. Examples include the colorants known by the names 38 Rhodamine B, C.l. Pigment Red 112 and C.l. Solvent Red 1. Useful wetters which may be present in the seed dressing formulations usable in accordance with the present invention are all substances which promote wetting and are conventionally used for the formulation of active agrochemical ingredients. Preference is given to using alkyl naphthalenesulphonates, such as diisopropyl- or diisobutyl naphthalenesulphonates. Useful dispersants and / or emulsifiers which may be present in the seed dressing formulations usable in accordance with the present invention are all nonionic, anionic and cationic dispersants conventionally used for the formulation of active agrochemical ingredients. Preference is given to using nonionic or anionic dispersants or mixtures of nonionic or anionic dispersants. Suitable nonionic dispersants include in particular ethylene oxide / propylene oxide block polymers, alkylphenol polyglycol ethers and tristryrylphenol polyglycol ethers, and the phosphorylated or sulfated derivatives thereof. Suitable anionic dispersants are especially lignosulfonates, polyacrylic acid salts and arylsulfonate / formaldehyde condensates. Antifoams which may be present in the seed dressing formulations usable in accordance with the present invention are all foam-inhibiting substances conventionally used for formulation of active agrochemical ingredients. Silicone antifoams and magnesium stearate can be used with preference. Preservatives which may be present in the seed dressing formulations usable in accordance with the present invention are all substances usable for such purposes in agrochemical compositions. Examples include dichlorophen and benzyl alcohol hemiformal. Secondary thickeners which may be present in the seed dressing formulations usable in accordance with the present invention are all substances which can be used for such purposes in agrochemical compositions. Preferred examples include cellulose derivatives, acrylic acid derivatives, xanthan gum, modified clays and finely divided silica. Useful stickers which may be present in the seed dressing formulations usable in accordance with the present invention are all customary binders usable in seed dressing products. Preferred examples include polyvinylpyrrolidone, polyvinyl acetate, polyvinyl alcohol and tylose. Gibberellins which may be present in the seed dressing formulations usable in accordance with the present invention are preferably the gibberellins A1, A3 (=gibberellic acid), A4 and A7; particular preference is given to using gibberellic acid. The seed dressing formulations usable in accordance with the present invention can be used to treat a wide variety of different kinds of seed, either directly or after prior dilution with water. For instance, the concentrates or the preparations obtainable therefrom by dilution with water can be used to dress the seed of cereals (e.g., wheat, barley, rye, oats, and triticale), and also the seed of maize, rice, oilseed rape, peas, beans, cotton, sunflowers, soya beans and beets, or else a wide variety of different vegetable seed. The seed dressing formulations usable in accordance with the present invention, or the dilute use forms thereof, can also be used to dress seed of transgenic plants. For treatment of seed with the seed dressing formulations usable in accordance with the present invention, or the use forms prepared therefrom, all mixing units usable customarily for the seed dressing are useful. Specifically, the procedure in seed dressing is to place the seed into a mixer in batchwise or continuous operation, to add the particular desired amount of seed dressing formulations, either as such or after prior dilution with water, and to mix until the formulation is distributed homogeneously on the seed. If appropriate, this is followed by a drying operation. The application rate of the seed dressing formulations usable in accordance with the present invention can be varied within a relatively wide range. It is guided by the particular content of the compounds of Formula I in the formulations and by the seed. The application rates of the compound of Formula I are generally between 0.001 and 50 g per kilogram of seed, preferably between 0.01 and 15 g per kilogram of seed. Use in Animal Health In the animal health sector, i.e., in the field of veterinary medicine, the active ingredients according to the present invention act against animal parasites, especially ectoparasites or else, in a further embodiment, endoparasites. The term “endoparasites” includes especially helminths such as cestodes, nematodes or trematodes, and protozoa such as coccidia. Ectoparasites are typically and preferably arthropods, especially insects such as flies (biting and licking), parasitic fly larvae, lice, hair lice, bird lice, fleas and the like; or acarids such as ticks, for example hard ticks or soft ticks, or mites such as scab mites, harvest mites, bird mites and the like, and also aquatic ectoparasites such as copepods. In the field of veterinary medicine, the compounds of Formula I having favourable homeotherm toxicity are suitable for controlling parasites which occur in animal breeding and animal husbandry in livestock, breeding animals, zoo animals, laboratory animals, experimental animals and domestic animals. They are active against all parasites or parasites in specific stages of development. Agricultural livestock include, for example, mammals such as sheep, goats, horses, donkeys, camels, buffalo, rabbits, reindeer, fallow deer, and particularly cattle and pigs; poultry such as turkeys, ducks, geese, and particularly chickens; fish and crustaceans, for example in aquaculture, and also insects such as bees. Domestic animals include, for example, mammals, such as hamsters, guinea pigs, rats, mice, chinchillas, ferrets, and particularly dogs, cats, cage birds, reptiles, amphibians and aquarium fish. In a preferred embodiment, the compounds of Formula I are administered to mammals. In another preferred embodiment, the compounds of Formula I are administered to birds, namely caged birds and particularly poultry. Use of the compounds of Formula I for the control of animal parasites is intended to reduce or prevent illness, cases of deaths and reductions in performance (in the case of meat, milk, wool, hides, eggs, honey and the like), such that more economical and simpler animal keeping is enabled and better animal well-being is achievable. In relation to the animal health field, the term “control” or “controlling” means that the compounds of Formula I are effective in reducing the incidence of the particular parasite in an animal infected with such parasites to an innocuous degree. More specifically, “controlling” in the present context means that the compound of Formula I can kill the respective parasite, inhibit its growth, or inhibit its proliferation. In general, the inventive active ingredients can be employed directly when they are used for the treatment of animals. They are preferably employed (administered) in the form of pharmaceutical compositions which may comprise pharmaceutically acceptable excipients and / or auxiliaries known in the prior art. In the sector of animal health and in animal husbandry, the active ingredients are employed (administered) in a known manner, by enteral administration in the form of, for example, tablets, capsules, potions, drenches, granules, pastes, boluses, the feed-through process and suppositories; by parenteral administration, for example by injection (intramuscular, subcutaneous, intravenous, intraperitoneal inter alia), implants; by nasal administration; by dermal administration in the form, for example, of dipping or bathing, spraying, pouring on and spotting on, washing and powdering; and also with the aid of moulded articles containing the active ingredient, such as collars, earmarks, tailmarks, limb bands, halters, marking devices, etc. The active ingredients can be formulated as a shampoo or as suitable formulations applicable in aerosols or unpressurized sprays, for example pump sprays and atomizer sprays. In the case of employment for livestock, poultry, domestic pets, etc., the inventive active ingredients can be employed as formulations (for example powders, wettable 41 powders [“WP”], emulsions, emulsifiable concentrates [“EC”], free-flowing compositions, homogeneous solutions and suspension concentrates [“SC”]), which contain the active ingredients in an amount of 1% to 80% by weight, directly or after dilution (e.g., 100- to 10000-fold dilution), or they can be used as a chemical bath. In the case of use in the animal health sector, the inventive active ingredients, in order to broaden the spectrum of activity, can be used in combination with suitable synergists, repellents or other active ingredients, for example acaricides, insecticides, anthelmintics, anti-protozoal agents. Vector Control The compounds of Formula I can also be used in vector control. In the context of the present invention, a vector is an arthropod, especially an insect or arachnid, capable of transmitting pathogens, for example, viruses, helminths, single-cell organisms and bacteria, from a reservoir (plant, animal, human, etc.) to a host. The pathogens can be transmitted either mechanically (for example trachoma by non-stinging flies) to a host or after injection (for example malaria parasites by mosquitoes) into a host. Examples of vectors in the context of the present invention are insects, for example aphids, flies, leafhoppers or thrips, which can transmit plant viruses to plants. Other vectors capable of transmitting plant viruses are spider mites, lice, beetles and nematodes. Further examples of vectors in the context of the present invention are insects and arachnids such as mosquitoes, especially of the genera Aedes, Anopheles, for example Anopheles gambiae, Anopheles arabiensis, Anopheles funestus, Anopheles dirus (malaria) and Culex, lice, fleas, flies, mites and ticks, which can transmit pathogens to animals and / or humans. Vector control is also possible if the compounds of Formula I are resistance-breaking. Compounds of Formula I are suitable for use in the prevention of diseases and / or pathogens transmitted by vectors. Thus, a further aspect of the present invention is use of compounds of Formula I for vector control, for example in agriculture, in horticulture, in forestry, in gardens and in leisure facilities, and also in the protection of materials and stored products. Protection of Industrial Materials The compounds of Formula I are suitable for protecting industrial materials against attack or destruction by insects, for example from the orders Coleoptera, Hymenoptera, Isoptera, Lepidoptera, Psocoptera and Zygentoma. Industrial materials in the present context are understood to mean inanimate materials, such as preferably plastics, adhesives, sizes, papers and cards, leather, wood, processed wood products and coating compositions. The use of the present invention for protection of wood is particularly preferred. In a further embodiment, the compounds of Formula I are used together with at least one additional pesticide and / or at least one fungicide. In a further embodiment, the compounds of Formula I are in the form of a ready-to-use pesticide, meaning that they can be applied to the material in question without further modifications. Suitable additional pesticides or fungicides are in particular those mentioned above. It has also been found that, surprisingly, the compounds of Formula I can be used to protect objects which come into contact with saltwater or brackish water, especially hulls, screens, nets, buildings, moorings and signaling systems, against fouling. It is equally possible to use the compounds of Formula I, alone or in combinations with other active ingredients, as antifouling agents. Control of Animal Pests in the Hygiene Sector The compounds of Formula I are suitable for controlling animal pests in the hygiene sector. More particularly, the present invention can be used in the domestic sector, in the hygiene sector and in the protection of stored products, particularly for control of insects, arachnids and mites encountered in enclosed spaces, for example dwellings, factory halls, offices, vehicle cabins. For controlling animal pests, the compounds of Formula I are used alone or in combination with other active ingredients and / or auxiliaries. They are preferably used in domestic insecticide products. The compounds of Formula I are effective against sensitive and resistant species, and against all developmental stages. These pests include, for example, pests from the class Arachnida, from the orders Scorpiones, Araneae and Opiliones, from the classes Chilopoda and Diplopoda, from the class Insecta the order Blattodea, from the orders Coleoptera, Dermaptera, Diptera, Heteroptera, Hymenoptera, Isoptera, Lepidoptera, Phthiraptera, Psocoptera, Saltatoria or Orthoptera, Siphonaptera and Zygentoma and from the class Malacostraca the order Isopoda. Application is effected, for example, in aerosols, unpressurized spray products, for example pump and atomizer sprays, automatic fogging systems, foggers, foams, gels, evaporator products with evaporator tablets made of cellulose or plastic, liquid evaporators, gel and membrane evaporators, propeller-driven evaporators, energy-free or passive evaporation systems, moth papers, moth bags and moth gels, as granules or dusts, in baits for spreading or in bait stations. Figures FIG. 1 shows the single crystal diffraction patterns of Compound 1-12 in Table 1. Detailed Embodiments of the Invention The following examples are used to illustrate the present invention and should not be construed as limiting the present invention in any way. The scope of rights claimed by the present invention is described in the Claims. In view of the economy and diversity of the compounds, some compounds were preferably synthesized. Among the many synthesized compounds, selected ones are listed in Table 1 below. The specific compound structures and corresponding chemical data are as set forth in Tables 1-2. The compounds in Table 1 are only to better illustrate the present invention but do not limit the present invention. For a person skilled in the art, it should not be understood that the scope of the above-mentioned subject matters of the present invention is limited to the following compounds. Table 1 Compound structure 1-1 No. X Qi q2 Y Ri r2 r2 R. Rs Re 1-1 c2h5 0 CH 0 H SOCF3 H H H ch3 1-2 c2h5 0 CH 0 H SOCF3 H H H cf3 1-3 C2H5 0 CH 0 H SOCF3 H H H chf2 1-4 C2H5 0 CH 0 H SOCF3 H H H F 1-5 C2H5 0 CH 0 H SOCF3 H H H 1-6 C2H5 0 CH 0 H SCF3 H H H CHF2 1-7 C2H5 0 CH 0 H SO2CF3 H H H chf2 1-8 C2H5 0 C-Cl 0 H SOCF3 H H H chf2 1-9 c2h5 0 C-B r 0 H SOCF3 H H H chf2 1-10 c2h5 0 C-F 0 H SOCF3 H H H chf2 1-11 c2h5 N-CH3 CH 0 H cf3 H H H chf2 1-12 C2H5 N-CH3 N 0 H cf3 H H H chf2 1-13 C2Hs N-CF3 CH 0 H SOCF3 H H H chf2 1-14 c2h5 n-chf2 CH 0 H SOCF3 H H H chf2 1-15 C2H5 N-C2H5 CH 0 H SOCF3 H H H chf2 1-16 C2H5 n-ch2c f3 CH 0 H SOCF3 H H H chf2 1-17 c2h5 CH 0 H SOCF3 H H H chf2 1-18 c2h5 CH 0 H SOCF3 H H H chf2 1-19 C2H5 CH 0 H SOCF3 H H H chf2 1-20 C2Hs 0 CH N-CH3 H SOCF3 H H H chf2 1-21 C2H5 0 CH N-CN H SOCF3 H H H chf2 1-22 C2H5 0 CH 0 CH3 SOCF3 H H H chf2 1-23 C2H5 0 CH 0 cf3 SOCF3 H H H chf2 1-24 C2H5 0 CH 0 CHF2 socf3 H H H chf2 1-25 C2H5 0 CH 0 F SOCF3 H H H chf2 1-26 C2H5 0 CH 0 Cl SOCF3 H H H chf2 1-27 c2h5 0 CH 0 Br socf3 H H H chf2 1-28 c2h5 0 CH 0 no2 socf3 h H H chf2 1-29 c2h5 0 CH 0 CN socf3 H H H chf2 1-30 C2H5 0 CH 0 och3 S0CF3 H H H chf2 1-31 C2H5 0 CH 0 ocf3 S0CF3 H H H chf2 1-32 c2h5 0 CH 0 OCH2CF3 socf3 H H H chf2 1-33 c2h5 0 CH 0 SOCF3 socf3 H H H chf2 1-34 C2H5 0 CH 0 SCF3 S0CF3 H H H chf2 1-35 C2Hs 0 CH 0 so2cf3 SOCF3 H H H chf2 1-36 C2H5 0 CH 0 S0CF3 H H H chf2 1-37 C2H5 0 CH 0 S0CF3 H H H chf2 1-38 c2h5 0 CH 0 H och3 H H H chf2 1-39 C2H5 0 CH 0 H och2cf3 H H H chf2 1-40 C2H5 0 CH 0 H Cl H H H chf2 1-41 c2h5 0 CH 0 H Br H H H chf2 1-42 C2H5 0 CH 0 H H H H chf2 1-43 C2H5 0 CH 0 H H H H chf2 1-44 C2H5 0 CH 0 H H H H chf2 1-45 C2H5 0 CH 0 H b H H H chf2 1-46 C2H5 0 CH 0 H H H H chf2 1-47 c2h5 0 CH 0 H h H H chf2 1-48 c2h5 0 CH 0 H SOCF3 ch3 H H chf2 1-49 c2h5 0 CH 0 H socf3 cf3 H H chf2 1-50 c2h5 0 CH 0 H socf3 CN H H chf2 1-51 C2H5 0 CH 0 H socf3 F H H chf2 1-52 C2H5 0 CH 0 H socf3 Cl H H chf2 1-53 C2H5 0 CH 0 H socf3 OCH3 H H chf2 1-54 c2h5 0 CH 0 H SOCF3 och2cf3 H H chf2 1-55 c2h5 0 CH 0 H SOCF3 H H chf2 1-56 c2h5 0 CH 0 H SOCF3 H H chf2 1-57 c2h5 0 CH 0 H socf3 bb H H chf2 1-58 c2h5 0 CH 0 H SOCF3 H H chf2 1-59 c2h5 0 CH 0 H socf3 H CH3 H chf2 1-60 C2H5 0 CH 0 H SOCF3 H cf3 H chf2 1-61 C2H5 0 CH 0 H SOCF3 H CN H chf2 1-62 c2h5 0 CH 0 H socf3 H F H chf2 1-63 c2h5 0 CH 0 H socf3 h Cl H chf2 1-64 C2H5 0 CH 0 H S0CF3 H och3 H chf2 1-65 C2H5 0 CH 0 H S0CF3 H OCH2CF3 H chf2 1-66 C2H5 0 CH 0 H S0CF3 H H chf2 1-67 C2H5 0 CH 0 H S0CF3 H W H chf2 1-68 c2h5 0 CH 0 H SOCF3 H —\l H chf2 1-69 C2H5 0 CH 0 H SOCF3 H H chf2 1-70 c2h5 0 CH 0 H socf3 H H CH3 chf2 1-71 c2h5 0 CH 0 H socf3 h H cf3 chf2 1-72 C2H5 0 CH 0 H S0CF3 H H CN chf2 1-73 C2H5 0 CH 0 H S0CF3 H H F chf2 1-74 c2h5 0 CH 0 H socf3 H H Cl chf2 1-75 c2h5 0 CH 0 H socf3 h H OCH3 chf2 1-76 C2H5 0 CH 0 H S0CF3 H H och2cf3 chf2 1-77 c2h5 0 CH 0 H SOCF3 H H chf2 1-78 C2H5 0 CH 0 H SOCF3 H H chf2 1-79 C2H5 0 CH 0 H SOCFs H H —dl chf2 1-80 C2H5 0 CH 0 H SOCF3 H H chf2 1-81 c2h5 0 CH 0 H SOCF3 H H H H 1-82 C2H5 0 CH 0 H SOCF3 H H H CH2CF3 1-83 C2H5 0 CH 0 H SOCF3 H H H 1-84 c2h5 0 CH 0 H socf3 H H H ch2ch3 1-85 c2h5 0 CH 0 H SOCF3 H H H 1-86 C2H5 0 CH 0 H SOCF3 H H H 1-87 C2H5 0 CH 0 H SOCF3 H H H 1-88 C2H5 N-CH3 CH 0 OCF2O H H H chf2 1-89 c2h5 n-ch3 N 0 ocf2o H H H chf2 1-90 c2h5 n-ch3 N 0 H ocf3 H H H chf2 1-91 C2H5 0 CH 0 H 0 ■H?cf3 N \ H H H chf2 1-92 C2H5 0 CH 0 H 0 -H-cf3 NH H H H chf2 1-93 C2H5 0 N 0 H CF3 H H H chf2 1-94 C2H5 n-ch3 CH 0 H ocf3 H H H chf2 1-95 C2H5 N-CH3 N 0 H SCF3 H H H chf2 1-96 C2H5 N-CH3 N 0 H SOCF3 H H H chf2 1-97 C2H5 n-ch3 N 0 H so2cf3 H H H chf2 1-98 C2H5 n-ch3 CH 0 CF2OCF2 H H H chf2 1-99 C2H5 N-CH3 N 0 H cf3 H H H ch2cf3 1-10 0 C2H5 N-CH3 N 0 H cf3 H H H ch3 1-10 1 c2h5 n-ch3 N 0 H cf3 H H H CN 1-10 2 C2H5 N-CH3 N 0 H cf3 H H H 1-10 3 c2h5 N-CH3 N 0 H cf3 H H H CF3 1-10 4 C2H5 N-CH3 N 0 H cf3 H H H F F 1-10 5 c2h5 n-ch3 N 0 H cf3 H H H “ddl 1-10 6 C2H5 N-CH3 N 0 H cf3 H H H 1-10 7 c2h5 n-ch3 N 0 H cf3 H H H i— 1-10 8 c2h5 N-CH3 N 0 H cf3 H H H a 1-10 9 C2H5 N-CH3 N 0 H cf3 H H H HQ-CF; 1-11 0 c2h5 n-ch3 N 0 H cf3 H H H Cl 1-11 1 c2h5 n-ch3 N 0 H cf3 H Cl H chf2 1-11 2 C2H5 n-ch3 N 0 H cf3 H CH3 H chf2 1-11 3 c2h5 N-CHs N 0 H cf3 H cf3 H chf2 1-11 4 c2h5 n-ch3 N 0 H cf3 H H chf2 1-11 5 c2h5 N-CH3 N 0 H cf3 H OCH3 H chf2 1-11 6 c2h5 n-ch3 N 0 H cf3 H N(CH3)2 H chf2 1-11 7 C2Hs N-CH3 N 0 H cf3 H CN H chf2 1-11 8 ch3 N-CH3 N 0 H cf3 H H H chf2 1-11 9 NH(CH3 N-CH3 N 0 H cf3 H H H chf2 1-12 0 N(CH3)2 N-CH3 N 0 H cf3 H H H chf2 1-12 1 n-ch3 N 0 H cf3 H H H chf2 1-12 2 cf3 0 CH 0 H cf3 H H H chf2 1-12 3 CH2CF3 0 CH 0 H cf3 H H H chf2 1-12 4 0 CH 0 H cf3 H H H chf2 1-12 5 0 CH 0 H cf3 H H H chf2 1-12 6 0 CH 0 H cf3 H H H chf2 1-12 7 d 0 CH 0 H cf3 H H H chf2 1-12 8 c2h5 0 CH 0 H ocf3 H H H chf2 1-12 9 C2H5 N-CH3 N 0 H CF2CF3 H H H chf2 1-13 0 N-CH3 N 0 H cf3 H H H chf2 1-13 1 N-CH3 N 0 H cf3 H H H chf2 1-13 2 C2H5 N-CH3 N N-CH3 H cf3 H H H chf2 1-13 3 c2h5 N-CH3 N N-CN H cf3 H H H chf2 1-13 4 C2H5 N-CHs N N-CH3 H CF2CI H H H chf2 1-13 5 C2Hs N-CH3 N N-CN H CF2CI H H H chf2 1-13 6 c2h5 N-CH3 N N-CH3 H CF2CF3 H H H chf2 1-13 7 C2H5 N-CH3 N N-CN H CF2CF3 H H H chf2 1-13 8 c2h5 N-CH3 N N-CH3 H ocf3 H H H chf2 1-13 9 C2H5 N-CH3 N N-CH3 H 0CF2CI H H H chf2 1-14 0 c2h5 N-CH3 N N-CH3 H scf3 H H H chf2 1-14 1 C2H5 N-CH3 N N-CH3 H S0CF3 H H H chf2 1-14 2 c2h5 N-CH3 N N-CH3 H so2cf3 H H H chf2 1-14 3 c2h5 N-CH3 N N-CN H ocf3 H H H chf2 1-14 4 c2h5 N-CH3 N N-CN H scf3 H H H chf2 1-14 5 c2h5 N-CH3 N N-CN H socf3 H H H chf2 1-14 6 C2H5 N-CH3 N N-CN H SOCF2CI H H H chf2 1-14 7 c2h5 N-CH3 N N-CN H SO2CF3 H H H chf2 1-14 8 c2h5 N-CH3 N 0 H CF2CI H H H chf2 1-14 9 c2h5 0 CH 0 H CF2CI H H H chf2 1-15 0 C2H5 N-CH3 CH 0 H CF2CI H H H chf2 1-15 1 C2H5 N-CH3 N 0 H CFCI2 H H H CHF2 1-15 2 C2H5 n-ch3 N 0 H CCI3 H H H chf2 1-15 3 C2H5 N-CH3 N 0 H CHF2 H H H CHF2 1-15 4 C2H5 N-CH3 N NH H cf3 H H H CHF2 1-15 5 C2H5 N-CH3 N d H cf3 H H H CHF2 1-15 6 n-ch3 N 0 H cf3 H H H chf2 1-15 7 N(CH3)2 N-CH3 N 0 H ocf3 H H H CHF2 1-15 8 c2h5 S N 0 H cf3 H H H chf2 1-15 9 C2H5 0 CH 0 H CF3 H H H CHF2 1-16 0 c2h5 n-ch3 CH 0 H sf5 H H H CHF2 1-16 1 C2H5 n-ch3 C-Cl 0 H cf3 H H H chf2 1-16 2 c2h5 N-CH3 CH 0 H CN H H H chf2 1-16 3 C2H5 n-ch3 CH 0 H scf3 H H H chf2 1-16 4 C2H5 N-CH3 CH 0 H SOCF3 H H H chf2 1-16 5 C2H5 N-CH3 CH 0 H SO2CF3 H H H CHF2 1-16 6 C2H5 N-CH3 N 0 CF3 H H H H CHF2 1-16 7 c2h5 n-ch3 N 0 H H H H H chf2 1-16 8 C2H5 N-CH3 N 0 H F H H H CHF2 1-16 9 c2h5 N-CH3 N 0 H I H H H CHF2 1-17 0 C2H5 n-ch3 N 0 H Br H H H chf2 1-17 1 C2H5 N-CH3 N 0 H CN H H H CHF2 1-17 2 C2H5 N-CH3 N 0 H NO2 H H H CHF2 1-17 3 C2H5 N-CH3 N 0 H CH2F H H H CHF2 1-17 4 c2h5 n-ch3 N 0 H cf3 H F H CH2CF3 1-17 5 C2H5 N-CH3 N 0 H cf3 H I H CHF2 1-17 6 C2H5 N-CH3 N 0 Cl CF3 H H H CHF2 1-17 7 c2h5 N-CH3 N 0 cf3 H H H chf2 1-17 8 C2H5 n-ch3 N 0 CH3 cf3 H H H chf2 1-17 9 C2H5 N-CH3 N 0 H cf3 OCH3 H H CHF2 1-18 0 C2H5 N-CH3 N 0 H cf3 ch3 H H CHF2 1-18 1 C2H5 N-CH3 N 0 H cf3 H Br H CHF2 1-18 2 c2h5 n-ch3 N 0 H ch2cf3 H H H CHF2 1-18 3 C2H5 n-ch3 N 0 H Cl •^CF3 H H H chf2 1-18 4 C2H5 n-ch3 N 0 H F ^CF3 H H H chf2 1-18 5 c2h5 n-ch3 N 0 H H H H chf2 1-18 6 C2H5 N-CH3 N 0 H — H H H chf2 1-18 7 c2h5 n-ch3 N 0 H F H H H chf2 1-18 8 c2h5 N-CH3 N 0 H H H H chf2 1-18 9 C2H5 N-CH3 N 0 H OH ^CF, H H H CHF2 1-19 0 C2H5 N-CH3 N 0 H c i H H H chf2 1-19 1 c2h5 N-CH3 N 0 H CHO H H H chf2 1-19 2 C2H5 N-CH3 N 0 H H H H chf2 1-19 3 c2h5 n-ch3 N 0 H 0 H H H chf2 1-19 4 C2Hs n-ch3 N 0 H 0 FV H H H chf2 1-19 5 C2H5 N-CH3 N 0 H OCHF2 H H H chf2 1-19 6 c2h5 N-CH3 N 0 H OCH2CF3 H H H chf2 1-19 7 c2h5 n-ch3 N 0 H OCH2CHF2 H H H CHF2 1-19 8 C2H5 N-CH3 N 0 H fZ^^G^ F^ F F H H H CHF2 1-19 9 C2H5 n-ch3 N 0 H H H H chf2 1-20 0 c2h5 n-ch3 N 0 H 0. / cn. <<c H H H chf2 1-20 1 C2Hs N-CH3 N 0 H OSO2CF3 H H H chf2 1-20 2 C2H5 n-ch3 N 0 H OSO2CHF2 H H H chf2 1-20 3 C2H5 N-CH3 N 0 H s H H H chf2 1-20 4 c2h5 n-ch3 N 0 H sch3 H H H chf2 1-20 5 C2H5 N-CH3 N 0 H SCHF2 H H H chf2 1-20 6 c2h5 n-ch3 N 0 H SOCH3 H H H chf2 1-20 7 C2H5 N-CHs N 0 H SOCHF2 H H H chf2 1-20 8 c2h5 n-ch3 N 0 H ^ = 0 6' x H H H chf2 1-20 9 c2h5 n-ch3 N 0 H so2chf2 H H H chf2 1-21 0 C2H5 N-CH3 N 0 H 0 F' / 'N^ F H H H H chf2 1-21 1 C2H5 N-CH3 N 0 H o% Os / W— W-Z '0 6 y H H H CHF2 1-21 2 c2h5 n-ch3 N 0 H < 9 O Z-W / 0 / 0 ' H H H CHF2 1-21 3 c2h5 N-CH3 N 0 H — CO 0 H H H chf2 1-21 4 C2H5 N-CH3 N 0 H 0 fs'-CF3 NH H H H CHF2 1-21 5 c2h5 0 CH 0 H 0 pSrCF3 N — H H H CHF2 1-21 6 C2H5 N-CH3 N 0 H fJo H H H CHF2 1-21 7 c2h5 0 CH 0 H 0 ^s'-cf3 CF3 H H H chf2 1-21 8 c2h5 n-ch3 N 0 H 0 s' cf3 cf3 H H H chf2 1-21 9 c2h5 n-ch3 N 0 H p-Y H H H chf2 1-22 0 c2h5 0 CH 0 H 0T fYS"n'cn F F H H H chf2 1-22 1 C2Hs N-CH3 N 0 H T f>"n'cn F F H H H CHF2 1-22 2 C2H5 0 CH 0 H H H H CHF2 1-22 3 C2H5 N-CH3 N 0 H 4 H H H CHF2 1-22 4 C2Hs 0 CH 0 H q 0 ft n H H H CHF2 1-22 5 C2H5 N-CH3 N 0 H °4 z pp H H H CHF2 1-22 6 C2H5 0 CH 0 H oT '4^ H H H CHF2 1-22 7 C2H5 N-CH3 N 0 H p z H H H CHF2 1-22 8 c2h5 n-ch3 N 0 H —\l H H H chf2 1-22 9 C2H5 N-CH3 N 0 H F^x H H H chf2 1-23 0 C2H5 N-CH3 N 0 H F H H H chf2 1-23 1 C2H5 n-ch3 CH 0 H 0 । f,c H H H chf2 1-23 2 C2H5 N-CH3 N 0 H 0 J F3C H H H chf2 1-23 3 C2H5 N-CH3 N 0 H N..A Cl H H H chf2 1-23 4 c2h5 N-CH3 N 0 H b H H H chf2 1-23 5 c2h5 N-CH3 N 0 H cf3 H H H CHCI2 1-23 6 C2Hs N-CH3 CH 0 H 0CF3 H H H CHCI2 1-23 7 c2h5 N-CH3 CH 0 H 0CCI3 H H H chci2 1-23 8 c2h5 s CH 0 H cf3 H H H chf2 1-23 9 C2H5 0 N 0 H ocf3 H H H chf2 1-24 0 C2H5 N-CH3 N 0 H CN H H H chf2 1-24 1 C2H5 N-CH3 N 0 H CF3 H H H 1-24 2 c2h5 N-CH3 N 0 H cf3 H CH2F H chf2 1-24 3 c2h5 N-CH3 N 0 H cf3 H chf2 H chf2 1-24 4 c2h5 N-CH3 N 0 H cf3 H H chf2 1-24 5 C2H5 N-CH3 N 0 H cf3 H H CHF2 1-24 6 C2H5 N-CH3 N 0 H cf3 H H CHF2 1-24 7 c2h5 N-CH3 N 0 H cf3 H V^OH H chf2 1-24 8 C2H5 N-CH3 N 0 H CF3 H CHO H CHF2 1-24 9 C2H5 N-CH3 N 0 H cf3 H H CHF2 1-25 0 C2H5 N-CH3 N 0 H cf3 H \ 0 °1- H CHF2 1-25 1 c2h5 N-CH3 N 0 H cf3 H nh2 H chf2 1-25 2 C2Hs N-CH3 N 0 H cf3 H H 0 1 H CHF2 1-25 3 C2H5 N-CH3 N 0 H cf3 H %'Y / H CHF2 1-25 4 c2h5 N-CH3 N 0 H cf3 H SO2C2H5 H CHF2 1-25 5 c2h5 N-CH3 N 0 H cf3 H 1 H chf2 1-25 6 C2H5 n-ch3 N 0 H cf3 H H chf2 1-25 7 C2H5 N-CH3 N 0 H cf3 H p s H CHF2 1-25 8 C2H5 n-ch3 N 0 H cf3 H p y n N \ H chf2 1-25 9 c2h5 n-ch3 N 0 H cf3 H “33) H chf2 1-26 0 C2H5 N-CH3 N 0 H cf3 H ■333 f H CHF2 1-26 1 c2h5 n-ch3 N 0 H cf3 H H CHF2 1-26 2 C2H5 N-CH3 N 0 H cf3 H 33-°, H CHF2 1-26 3 c2h5 n-ch3 N 0 H cf3 H . / =N H chf2 1-26 4 C2H5 N-CH3 N 0 H cf3 H X / T=O 6 ) H CHF2 1-26 5 C2Hs 0 CH 0 H cf3 H H H 1-26 6 C2H5 N-CH3 N 0 H cf3 H H H 1-26 7 c2h5 n-ch3 N 0 H cf3 H H H ch2ch3 1-26 8 C2H5 N-CH3 N 0 H 0 H H H H chf2 1-26 9 C2H5 N-CH3 N H cf3 H H H chf2 1-27 0 C2H5 n-ch3 N n'""chf2 H cf3 H H H chf2 1-27 1 C2H5 N-CH3 N n^cf3 H CF3 H H H chf2 1-27 2 c2h5 n-ch3 N H cf3 H H H chf2 1-27 3 C2H5 N-CH3 N N—<] H cf3 H H H chf2 1-27 4 c2h5 N-CH3 N p 2 H cf3 H H H chf2 Table 2 1H NMR of Compounds No. 1H NMR 1-3 1H NMR (300 MHz, CDCh) 6 9.03 (s, 1H), 8.60 (d, J = 0.8 Hz, 1H), 8.40 - 8.28 (m, 1H), 7.98 - 7.86 (m, 2H), 7.59 (t, J = 59.1 Hz, 1H), 4.08 (q, J = 7.6 Hz, 2H), 1.48 (t, J = 7.4 Hz, 3H). 1-6 1H NMR (300 MHz, Chloroform-d) 6 9.02 (d, J= 0.9 Hz, 1H), 8.59 (d, J= 1.0 Hz, 1H), 8.19 (d, J= 1.6 Hz, 1H), 7.807.75 (m, 2H), 7.74-7.38 (m, 1H), 4.10 (q, J = 7.4 Hz, 2H), 1.47 (t, J = 7.5 Hz, 3H). 1-7 1H NMR (300 MHz, Chloroform-d) 5 9.03 (s, 1H), 8.60 (d, J= 1.0 Hz, 1H), 8.58 (d, J= 1.9 Hz, 1H), 8.18 (dd, J= 8.7, 1.9 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.60 (t, J = 59.1 Hz, 1H), 4.06 (q, J = 7.5 Hz, 2H), 1.49 (t, J = 7.5 Hz, 3H). 1-11 1H NMR (400 MHz, Chloroform-d) 5 8.96 (s, 1H), 8.52 (s, 1H), 8.08 (s, 1H), 7.74-7.44 (m, 3H), 3.89 (q, J= 7.5 Hz, 2H), 3.78 (s, 3H). 1.37 (t, J= TA Hz, 3H). 1-12 1H NMR (300 MHz, cdch) 6 8.97 (s, 1H), 8.77 (d, J = 1.3 Hz, 1H), 8.54 (s, 1H), 8.32 (d, J = 1.5 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.98 - 3.82 (m, 5H), 1.39 (t, J = 7.4 Hz, 3H). 1-41 1H NMR (400 MHz, Chloroform-d) 6 9.02 (s, 1H), 8.59 (s, 1H), 8.01 (s, 1H), 7.60-7.58 (m, 2H), 7.58 (t, 3 = 53.2 Hz, 1H), 4.09 (q, J= 7.4 Hz, 2H), 1.47 (t, 3= 7.4 Hz, 3H). 1-81 1H NMR (400 MHz, DMSO-d6) 6 8.79 (s, 1H), 8.76-8.63 (m, 1H), 8.48 (s, 1H), 8.25 (d, 3= 8.7 Hz, 1H), 8.05 (d, J = 8.7 Hz, 1H), 3.93 (q, 3 = 7.4 Hz, 2H), 1.26 (t, 3 = 7.4 Hz, 3H). 1-88 1H NMR (300 MHz, Chloroform-d) 5 8.95 (s, 1H), 8.50 (s, 1H), 7.58 (t, 3= 59.2 Hz, 1H), 7.42 (s, 1H), 7.13 (s, 1H), 3.86 (t, 3 = 7.4 Hz, 2H), 3.71 (s, 3H), 1.36 (t, 3 = 7.4 Hz, 3H). 1-90 1H NMR (300 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.49-8.42 (m, 1H), 8.00-7.92 (m, 1H), 7.60 (t, 3 = 59.2 Hz, 1H), 3.97 - 3.80 (m, 5H), 1.38 (t, 3 = 7.4 Hz, 3H). 1-91 1H NMR (300 MHz, cdch) 5 9.03 (s, 1H), 8.63 (d, J= 1.7 Hz, 1H), 8.60 (d, 3 = 0.8 Hz, 1H), 8.24 (dd, 3 = 8.7, 1.4 Hz, 1H), 7.89 (d, 3 = 8.8 Hz, 1H), 7.59 (t, 3 = 59.1 Hz, 1H), 4.09 (q, 3 = 7.5 Hz, 2H), 3.66 - 3.43 (m, 2H), 1.48 (t, 3 = 7.5 Hz, 3H), 1.34 (t, 3= 7.2 Hz, 3H). 1-92 1H NMR (300 MHz, cdch) 5 9.03 (s, 1H), 8.69 (d, 3= 1.6 Hz, 1H), 8.60 (s, 1H), 8.29 (dd, 3= 8.8, 1.7 Hz, 1H), 7.93 (d, 3 = 8.7 Hz, 1H), 7.60 (t, 3 = 59.1 Hz, 1H), 4.08 (q, 3= TA Hz, 2H), 3.79 (s, 1H), 1.48 (t, 3= 7.4 Hz, 3H). 1-93 1H NMR (300 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.81-8.78 (m, 1H), 8.61 (s, 1H), 8.45-8.42 (m, 1H), 7.60 (t, 3 = 59.1 Hz, 1H), 3.97 (q, 3 = 7.5 Hz, 2H), 1.49 (t, J = 7.5 Hz, 3H). 1-94 1H NMR (400 MHz, Chloroform-d) 5 8.96 (s, 1H), 8.51 (d, J= 1.0 Hz, 1H), 7.76-7.41 (m, 3H), 7.30-7.26 (m, 1H), 3.89 (q, J= TA Hz, 2H), 3.75 (s, 3H), 1.36 (t, 3= 7.4 Hz, 3H). 1-95 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.72 (d, 3= 1.9 Hz, 1H), 8.54 (s, 1H), 8.39 (d, 3= 1.9 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.95 - 3.86 (m, 5H), 1.40 (t, 3 = 7.4 Hz, 3H). 1-96 1H NMR (300 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.79 (d, 3 = 1.9 Hz, 1H), 8.61 -8.57 (m, 1H), 8.55 (d, 3= 0.8 Hz, 1H), 7.61 (t, J= 59.1 Hz, 1H), 3.95-3.86 (m, 5H), 1.41 (t, 3= 7.4 Hz, 3H). 1-97 1H NMR (300 MHz, Chloroform-d) 6 9.09 (d, 3= 2.0 Hz, 1H), 8.99 (s, 1H), 8.70 (d, 3 = 2.0 Hz, 1H), 8.58-8.54 (m, 1H), 7.62 (t, 3= 59.1 Hz, 1H), 3.94-3.85 (m, 5H), 1.42 (t, 3= 7.4 Hz, 3H). 1-99 1H NMR (300 MHz, cdch) 5 9.05 (s, 1H), 8.73-8.64 (m, 1H), 8.61 (s, 1H), 8.45-8.25 (m, 1H), 5.20 (q, 3 = 8.1 Hz, 2H), 4.37 (s, 3H), 3.63 (q, 3= 7.4 Hz, 2H), 1.34 (t, 3 = 7.4 Hz, 3H). 1-100 1H NMR (400 MHz, Chloroform-d) 6 8.77 - 8.74 (m, 1H), 8.70-8.67 (m, 1H), 8.44-8.40 (m, 1H), 8.31 -8.29 (m, 1H), 4.28 (s, 3H), 3.91 -3.84 (m, 5H), 1.37 (t, J = 7.4 Hz, 3H). 1-102 1H NMR (400 MHz, cdch) 6 9.02 (s, 1H), 8.70-8.68 (m, 1H), 8.67 (s, 1H), 8.36-8.27 (m, 1H), 5.82 (s, 2H), 4.41 (s, 3H), 3.67 (q, 3 = 7.5 Hz, 2H), 3.52 (s, 3H), 1.34 (t, 3 = 7.5 Hz, 3H). 1-104 1H NMR (300 MHz, cdch) 6 9.05 (s, 1H), 8.77-8.66 (m, 1H), 8.59 (s, 1H), 8.40-8.29 (m, 1H), 6.57-6.14 (m, 1H), 5.00 -4.89 (m, 2H), 4.41 (s, 3H), 3.63 (q, 3 = 7.4 Hz, 2H), 1.36 (t, 3 = 7.4 Hz, 3H). 1-111 1H NMR (400 MHz, cdch) 6 8.98 (s, 1H), 8.79 (d, 3 = 2.0 Hz, 1H), 8.33 (d, 3 = 2.0 Hz, 1H), 7.52 (t, 3 = 59.1 Hz, 1H), 3.96 (q, 3= 7.4 Hz, 2H), 3.93 (s, 3H), 1.41 (t, 3= 7.4 Hz, 3H). 1-112 1H NMR (300 MHz, Chloroform-d) 6 8.90 (s, 1H), 8.78 (dd, J = 1.8, 0.9 Hz, 1H), 8.35-8.30 (m, 1H), 7.52 (t, J = 59.5 Hz, 1H), 3.92-3.83 (m, 5H), 2.72 (s, 3H), 1.39 (t, J = 7.4 Hz, 3H). 1-113 1H NMR (300 MHz, cdch) 6 9.07 (s, 1H), 8.89-8.71 (m, 1H), 8.44-8.25 (m, 1H), 7.63 (t, 3= 58.6 Hz, 1H), 4.06 (q, J = TA Hz, 2H), 3.95 (s, 3H), 1.44 (t, 3 = 7.4 Hz, 3H). 1-114 1H NMR (300 MHz, Chloroform-d) 6 8.87 (s, 1H), 8.81-8.73 (m, 1H), 8.37-8.29 (m, 1H), 7.46 (t, 1H), 3.94-3.87 (m, 5H), 2.52-2.42 (m, 1H), 1.43-1.39 (m, 2H), 1.38-1.32 (m, 3H), 1.23-1.16 (m, 2H). 1-115 1H NMR (400 MHz, cdch) 6 8.82 (s, 1H), 8.76 (d, 3= 1.3 Hz, 1H), 8.30 (d, 3= 1.5 Hz, 1H), 7.37 (t, 3 = 59.9 Hz, 1H), 4.22 (s, 3H), 3.92 - 3.84 (m, 5H), 1.38 (t, J = 7.4 Hz, 3H). 1-117 1H NMR (300 MHz, Chloroform-d) 5 9.08 (s, 1H), 8.82-8.79 (m, 1H), 8.36-8.32 (m, 1H), 7.64 (t, 3= 58.5 Hz, 1H), 4.02 (q, 3= 7.4 Hz, 2H), 3.96 (s, 3H), 1.42 (t, 3= 7.4 Hz, 3H). 1-118 1H NMR (400 MHz, Chloroform-d) 6 9.04 (s, 1H), 8.79-8.76 (m, 1H), 8.54 (d, 3 = 1.0 Hz, 1H), 8.33-8.31 (m, 1H), 7.60 (t, 3 = 59.1 Hz, 1H), 3.89 (s, 3H), 3.68 (s, 3H). 1-119 1H NMR (400 MHz, DMSO-de) 6 9.11 -9.08 (m, 1H), 9.01 -8.97 (m, 1H), 8.89-8.85 (m, 1H), 8.70-8.68 (m, 1H), 8.51 (t, 3 = 57.4 Hz, 1H), 7.60 (q, 3 = 5.0 Hz, 1H), 3.85 (s, 3H), 2.67 (d, 3 = 4.9 Hz, 3H). 1-120 1H NMR (400 MHz, Chloroform-d) 6 8.86 (s, 1H), 8.77 (d,3= 1.9 Hz, 1H), 8.50 (s, 1H), 8.31 (d, 3= 1.9 Hz, 1H), 7.59 (t, J = 59.2 Hz, 1H), 3.77 (s, 3H), 2.79 (s, 6H). 1-128 1H NMR (400 MHz, Chloroform-d) 6 9.03 (s, 1H), 8.60 (s, 1H), 7.75-7.70 (m, 2H), 7.59 (t, 3= 59.2 Hz, 1H), 7.397.35 (m, 1H), 4.11 (q, 3 = 7.4 Hz, 2H), 1.48 (t, J = 7.5 Hz, 3H). 1-129 1H NMR (300 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.74-8.71 (m, 1H), 8.56-8.53 (m, 1H), 8.31 -8.28 (m, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.95 - 3.87 (m, 5H), 1.39 (t, J = 7.4 Hz, 3H). 1-130 1H NMR (400 MHz, Chloroform-d) 6 8.95 (s, 1H), 8.79-8.78 (m, 1H), 8.55-8.53 (m, 1H), 8.33-8.31 (m, 1H), 7.60 (t, 3 = 59.2 Hz, 1H), 4.62-4.53 (m, 1H), 3.87 (s, 3H), 1.38 (s, 3H), 1.37 (s, 3H). 1-131 1H NMR (300 MHz, Chloroform-d) 5 9.04 (s, 1H), 8.79-8.76 (m, 1H), 8.54 (d, 3 = 0.9 Hz, 1H), 8.32-8.29 (m, 1H), 7.60 (t, 3= 59.1 Hz, 1H), 3.89 (s, 3H), 3.82 (d, 3= 7.3 Hz, 2H), 1.20-1.09 (m, 1H), 0.66-0.57 (m, 2H), 0.41 -0.32 (m, 2H). 1-132 1H NMR (400 MHz, cdch) 6 8.88 (s, 1H), 8.82-8.69 (m, 1H), 8.51 (s, 1H), 8.35-8.24 (m, 1H), 7.59 (t, 3 = 59.2 Hz, 1H), 4.05-3.95 (m, 1H), 3.92 (s, 3H), 3.87-3.76 (m, 1H), 2.56 (s, 3H), 1.38 (t, 3= 7.4 Hz, 3H). 1-133 1H NMR (400 MHz, cdch) 6 9.03 (s, 1H), 8.86-8.79 (m, 1H), 8.60 (d, 3= 0.9 Hz, 1H), 8.35-8.27 (m, 1H), 7.64 (t, 3 = 59.1 Hz, 1H), 4.70-4.57 (m, 1H), 4.36 - 4.23 (m, 1H),4.08 (s, 3H), 1.54 (t,3=7.4 Hz, 3H). 1-153 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.65 (s, 1H), 8.54 (s, 1H), 8.24 (s, 1H), 7.60 (t, 3 = 59.2 Hz, 1H), 6.90 (t, 3= 56.1 Hz, 1H), 3.94-3.88 (m, 5H), 1.40 (t, 3 = 7.4 Hz, 3H). 1-154 1H NMR (300 MHz, Chloroform-d) 6 9.03 (s, 1H), 8.81 -8.70 (m, 1H), 8.52 (d, 3= 1.0 Hz, 1H), 8.31 (d, 3= 2.0 Hz, 1H), 7.60 (t, 3= 59.2 Hz, 1H), 3.99-3.77 (m, 5H), 1.39 (t, 3= 7.4 Hz, 3H). 1-155 1H NMR (400 MHz, cdch) 6 8.91 (s, 1H), 8.78-8.71 (m, 1H), 8.50 (s, 1H), 8.37-8.27 (m, 1H), 7.55 (t, 3= 59.2 Hz, 1H), 7.17-7.04 (m, 3H), 7.04-6.96 (m, 2H), 4.21 -4.07 (m, 2H), 3.97-3.82 (m, 2H), 3.72 (s, 3H), 1.44 (t, 3= 7.4 Hz, 3H). 1-156 1H NMR (300 MHz, Chloroform-d) 5 8.89 (s, 1H), 8.77 (d, 3= 1.8 Hz, 1H), 8.48 (s, 1H), 8.29 (d, 3= 1.8 Hz, 1H), 7.58 (t, 3= 59.2 Hz, 1H), 3.77 (s, 3H), 3.33-3.23 (m, 4H), 1.94-1.84 (m, 4H). 1-157 1H NMR (300 MHz, Chloroform-d) 6 8.86 (s, 1H), 8.53-8.42 (m, 2H), 7.95 (s, 1H), 7.59 (t, 3= 58.9 Hz, 1H), 3.74 (s, 3H), 2.78 (s, 6H). 1-158 1H NMR (300 MHz, Chloroform-d) 6 9.10 (s, 1H), 8.99-8.92 (m, 1H), 8.63-8.53 (m, 2H), 7.58 (t, J = 59.2 Hz, 1H), 4.21 (q, J = 7.5 Hz, 2H), 1.51 (t, J = 7.5 Hz, 3H). 1-159 1H NMR (400 MHz, cdcb) 6 9.03 (s, 1H), 8.60 (s, 1H), 8.16 (s, 1H), 7.85-7.75 (m, 2H), 7.59 (t, 4 = 59.1 Hz, 1H), 4.11 (q, 4 = 7.4 Hz, 2H), 1.48 (t, J = 7.5 Hz, 3H). 1-160 1H NMR (400 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.25 (d, 4=2.1 Hz, 1H), 7.83 (dd, 4 = 8.9, 2.1 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 7.51 (d, 4 = 8.9 Hz, 1H), 3.90 (q, 4 = 7.4 Hz, 2H), 3.79 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-161 1H NMR (400 MHz, Chloroform-d) 5 8.97 - 8.95 (m, 1H), 8.54-8.53 (m, 1H), 7.98-7.95 (m, 1H), 7.68 (t, 4= 59.2 Hz, 1H), 7.59 - 7.45 (m, 1H), 4.03 (s, 3H), 3.81 (q, 4 = 7.4 Hz, 2H), 1.37 (t, 4 = 7.4 Hz, 3H). 1-162 1H NMR (400 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.53 (d, 4= 0.9 Hz, 1H), 8.14 (dd, 4= 1.4, 0.7 Hz, 1H), 7.66 (dd, 4 = 8.4, 1.5 Hz, 1H), 7.60 (t, 4 = 59.1 Hz, 1H),7.55 (dd, 4= 8.5, 0.7 Hz, 1H)„ 3.86 (q, 4= 7.4 Hz, 2H), 3.78 (s, 3H), 1.38 (t, 4 = 7.4 Hz, 3H). 1-163 1H NMR (400 MHz, Chloroform-d) 6 8.98 - 8.96 (m, 1H), 8.52 (d, 4= 1.0 Hz, 1H), 8.15-8.12 (m, 1H), 7.67 (dd, 4 = 8.7, 1.6 Hz, 1H), 7.59 (t, 4 = 59.2 Hz, 1H), 7.51 (dd, 4 = 8.5, 0.7 Hz, 1H), 3.91 (q, 4 = 7.4 Hz, 2H), 3.77 (s, 3H), 1.38 (t, 4 = 7.4 Hz, 3H). 1-164 1H NMR (400 MHz, DMSO-ds) 6 9.17 - 9.14 (m, 1H), 9.03 (s, 1H), 8.56 (t, 4= 57.2 Hz, 1H), 8.33-8.30 (m, 1H), 8.06 (d, 4= 8.6 Hz, 1H), 7.91 -7.86 (m, 1H), 3.89 (q, 4= 7.3 Hz, 2H), 3.76 (s, 3H), 1.21 (t, 4= 7.4 Hz, 3H). 1-165 1H NMR (400 MHz, DMSO-de) 6 9.17 (d, 4= 1.0 Hz, 1H), 9.04 (s, 1H), 8.57 (t, 4 = 57.2 Hz, 1H), 8.54 (d, 4= 1.8 Hz, 1H), 8.17 (d, 4 = 8.7 Hz, 1H), 8.10-8.06 (m, 1H), 3.87 (q, 4= 7.3 Hz, 2H), 3.80 (s, 3H), 1.22 (t, 4= 7.4 Hz, 3H). 1-166 1H NMR (400 MHz, cdcb) 6 8.98 (s, 1H), 8.55 (d, 4 = 0.8 Hz, 1H), 8.20 (d, J = 8.3 Hz, 1H), 7.71 (d, 4 = 8.3 Hz, 1H), 7.53 (t, 4= 59.1 Hz, 1H), 3.94-3.77 (m, 5H), 1.38 (t, 4 = 7.4 Hz, 3H). 1-167 1H NMR (400 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.53 (s, 1H), 8.53-8.50 (m, 1H), 8.11 -8.04 (m, 1H), 7.59 (t, 4 = 59.2 Hz, 1H), 7.36 - 7.29 (m, 1H), 3.93 (q, 4 = 7.4 Hz, 2H), 3.86 (s, 3H), 1.38 (t, 4 = 7.4 Hz, 3H). 1-168 1H NMR (400 MHz, cdcb) 6 8.97 (s, 1H), 8.53 (d, 4 = 0.8 Hz, 1H), 8.40 (dd, 4= 2.5, 1.8 Hz, 1H), 7.78 (dd, 4 = 8.6, 2.6 Hz, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 3.90 (q, 4 = 7.4 Hz, 2H), 3.83 (s, 3H), 1.38 (t, J = 7.4 Hz, 3H). 1-169 1H NMR (400 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.67 (d, 4= 1.8 Hz, 1H), 8.54 (d, 4 = 0.9 Hz, 1H), 8.40 (d, 4= 1.8 Hz, 1H), 7.59 (t, 4 = 59.2 Hz, 1H), 3.89 (q, J = 7.4 Hz, 2H), 3.82 (s, 3H), 1.39 (t, J = 7.4 Hz, 3H). 1-170 1H NMR (300 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.61 -8.49 (m, 2H), 8.22 (d, 4= 2.1 Hz, 1H), 7.60 (t, 4= 59.2 Hz, 1H), 3.90 (q, 4 = 7.4 Hz, 2H), 3.83 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-171 1H NMR (300 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.79-8.73 (m, 1H), 8.55 (s, 1H), 8.39-8.33 (m, 1H), 7.61 (t, 4 = 59.1 Hz, 1H), 3.92-3.81 (m, 5H), 1.40 (t, 4 = 7.4 Hz, 3H). 1-172 1H NMR (300 MHz, cdcb) 6 9.41 (d, 4 = 2.3 Hz, 1H), 8.98 (s, 1H), 8.89 (d, 4 = 2.3 Hz, 1H), 8.56 (s, 1H), 7.61 (t, 4 = 59.1 Hz, 1H), 3.92-3.84 (m, 5H), 1.40 (t, 4 = 7.4 Hz, 3H). 1-173 1H NMR (400 MHz, cdcb) 6 8.98 (s, 1H), 8.57-8.51 (m, 2H), 8.15-8.11 (m, 1H), 7.60 (t, 4= 59.2 Hz, 1H), 5.57 (d, 4 = 48.3 Hz, 2H), 3.92 (q, 4 = 7.4 Hz, 2H), 3.86 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-175 1H NMR (400 MHz, dmso) 6 8.88 (s, 1H), 8.86-8.79 (m, 1H), 8.70-8.59 (m, 1H), 8.33 (t, 4= 57.1 Hz, 1H), 4.48 (s, 3H), 3.68 (q, 4= 7.4 Hz, 2H), 1.24 (t, 4= 7.4 Hz, 3H). 1-176 1H NMR (400 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.55 (s, 1H), 8.42 (s, 1H), 7.60 (t, J = 59.1 Hz, 1H), 3.90-3.83 (m, 5H), 1.40 (t, J = 7.3 Hz, 3H). 1-177 1H NMR (300 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.26 (s, 1H), 7.59 (t, 4 = 59.3 Hz, 1H), 3.92 (q, 4= 7.4 Hz, 2H), 3.78 (s, 3H), 2.55 - 2.43 (m, 1H), 1.39 (t, 4 = 7.4 Hz, 3H), 1.35 - 1.30 (m, 2H), 1.14-1.07 (m, 2H). 1-178 1H NMR (400 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.54 (s, 1H), 8.30 (s, 1H), 7.60 (t, 4= 59.2 Hz, 1H), 3.90 (q, 4= 7.4 Hz, 2H), 3.85 (s, 3H), 2.85 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-179 1H NMR (400 MHz, cdcb) 6 9.01 - 8.95 (m, 1H), 8.58 (d, 4= 0.6 Hz, 1H), 8.55 (d, 4 = 0.9 Hz, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 4.59 (s, 3H), 3.84 (q, 4= 7.5 Hz, 2H), 3.81 (s, 3H), 1.41 (t, 4= 7.5 Hz, 3H). 1-180 1H NMR (400 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.71 (s, 1H), 8.54 (d,4= 1.0 Hz, 1H), 7.60 (t,4=59.2 Hz, 1H), 3.96 (q, 4= 7.4 Hz, 2H), 3.87 (s, 3H), 2.82-2.79 (m, 3H), 1.42 (t, 4 = 7.4 Hz, 3H). 1-181 1H NMR (300 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.79 (s, 1H), 8.33 (s, 1H), 7.55 (t, 4 = 59.1 Hz, 1H), 4.01-3.89 (m, 5H), 1.41 (t, 4 = 7.5 Hz, 3H). 1-182 1H NMR (400 MHz, cdcb) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.45 (s, 1H), 8.07 (s, 1H), 7.60 (t,4=59.2 Hz, 1H), 3.92 (q, 4 = 7.1 Hz, 2H), 3.86 (s, 3H), 3.57 (q, 2H), 1.40 (t, 4= 7.3 Hz, 3H). 1-183 1H NMR (400 MHz, cdcb) 6 8.98 (s, 1H), 8.56 (d, 4= 1.8 Hz, 1H), 8.53 (s, 1H), 8.28 (s, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 5.36 (q, 4 = 6.7 Hz, 1H), 3.93 (q, 4 = 7.4 Hz, 2H), 3.86 (s, 3H), 1.40 (t, 4 = 7.4 Hz, 3H). 1-184 1H NMR (400 MHz, cdcb) 6 8.98 (s, 1H), 8.56 (s, 1H), 8.53 (d, 4 = 0.7 Hz, 1H), 8.22 (s, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 5.82 (dq, 4 = 43.8, 5.9 Hz, 1H), 3.91 (q, 2H), 3.87 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-185 1H NMR (300 MHz, cdcb) 5 8.97 (s, 1H), 8.66-8.39 (m, 2H), 8.11 (d, 4= 1.9 Hz, 1H), 7.59 (t, 4= 59.2 Hz, 1H), 6.89 (dd, 4= 17.6, 11.0 Hz, 1H), 5.85 (d, 4= 17.6 Hz, 1H), 5.36 (d, 4 = 11.0 Hz, 1H), 3.93 (q, 4= 7.4 Hz, 2H), 3.84 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-186 1H NMR (400 MHz, Chloroform-d) 5 8.97 (d, 4= 0.9 Hz, 1H), 8.63 (d, 4= 1.8 Hz, 1H), 8.53 (d, 4= 1.0 Hz, 1H), 8.18 (d, 4= 1.8 Hz, 1H), 7.59 (t, 4= 59.2 Hz, 1H), 3.90 (q, 4 = 7.5 Hz, 2H), 3.84 (s, 3H), 3.19 (s, 1H), 1.38 (t, 4 = 7.4 Hz, 3H). 1-187 1H NMR (400 MHz, cdcb) 6 8.97 (s, 1H), 8.53 (S, 1H), 8.42 (d, 4= 1.9 Hz, 1H), 8.10 (d, J= 1.9 Hz, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 5.47 (dd, 4 = 25.9, 3.3 Hz, 1H), 3.93 (q, 4 = 7.4 Hz, 2H), 3.82 (s, 3H), 1.38 (t, 3H). 1-188 1H NMR (400 MHz, cdcb) 5 8.97 (s, 1H), 8.53 (d, 4 = 0.9 Hz, 1H), 8.47 (d, 4 = 1.9 Hz, 1H), 8.08 - 8.05 (m, 1H), 7.60 (t, J = 59.2 Hz, 1H), 4.86 (d, 4 = 5.6 Hz, 2H), 3.90 (q, 4 = 7.4 Hz, 2H), 3.84 (s, 3H), 2.31 (t, 4 = 5.8 Hz, 1H), 1.37 (t, 4 = 7.4 Hz, 3H). 1-189 1H NMR (400 MHz, cdcb) 6 8.96 (s, 1H), 8.54 (d, 4 = 0.7 Hz, 1H), 8.40 (d, 4= 1.5 Hz, 1H), 8.07 (s, 1H), 7.61 (t, 4 = 59.2 Hz, 1H), 5.09 (q, 1H), 5.03 (s, 1H), 3.91 - 3.76 (m, 5H), 1.37 (t, 4 = 7.4 Hz, 3H). 1-190 1H NMR (400 MHz, DMSO-de) 6 9.16 - 9.14 (m, 1H), 9.02 (s, 1H), 8.58 (dd, 4= 1.8, 0.5 Hz, 1H), 8.55 (t, 4 = 57.2 Hz, 1H), 8.31 -8.29 (m, 1H), 3.86 (q, 4 = 7.4 Hz, 2H), 3.69 (s, 3H), 1.21 (t, 4= 7.4 Hz, 3H), 0.26 (s, 9H). 1-191 1H NMR (400 MHz, Chloroform-d) 5 10.23 (s, 1H), 9.02 (d, 4= 1.8 Hz, 1H), 8.99 (s, 1H), 8.57 (d, 4= 1.8 Hz, 1H), 8.55 (s, 1H), 7.61 (t, 4 = 59.1 Hz, 1H), 3.94-3.84 (m, 5H), 1.40 (t, 4= 7.4 Hz, 3H). 1-192 1H NMR (400 MHz, Chloroform-d) 5 9.14 (d, 4= 1.9 Hz, 1H), 8.98 (s, 1H), 8.65 (d, 4= 1.9 Hz, 1H), 8.55 (s, 1H), 7.60 (t, 4 = 59.2 Hz, 1H), 3.97-3.82 (m, 5H), 2.74 (s, 3H), 1.40 (t, 4 = 7.4 Hz, 3H). 1-193 1H NMR (400 MHz, cdsod) 6 9.02 (s, 1H), 8.74 (d, 4 = 0.9 Hz, 1H), 8.72 (d, 4= 1.8 Hz, 1H), 8.33 (d, 4= 1.8 Hz, 1H), 8.08 (t, J = 58.5 Hz, 1H), 3.87 - 3.74 (m, 5H), 1.32 (t, 4 = 7.4 Hz, 3H). 1-194 1H NMR (400 MHz, Chloroform-d) 6 9.19 (d, 4 = 1.8 Hz, 1H), 8.98 (s, 1H), 8.72 (d, 4= 1.9 Hz, 1H), 8.54 (d, 4= 0.9 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 4.00 (s, 3H), 3.92 (q, 4 = 7.5 Hz, 2H), 3.88 (s, 3H), 1.39 (t, 4 = 7.4 Hz, 3H). 1-195 1H NMR (300 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.54 (s, 1H), 8.42 (d, 4= 1.9 Hz, 1H), 7.90 (d, 4= 2.3 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 6.59 (t, 4 = 73.0 Hz, 1H), 3.92 (q, 4 = 7.4 Hz, 2H), 3.85 (s, 3H), 1.40 (t, 4 = 7.4 Hz, 3H). 1-196 1H NMR (400 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.53 (d, 4 = 0.9 Hz, 1H), 8.35 (d, 4 = 2.6 Hz, 1H), 7.64 (d, 4= 2.6 Hz, 1H), 7.59 (t, J= 59.2 Hz, 1H), 4.47 (q, J= 8.1 Hz, 2H), 3.92 (q, J = 7.4 Hz, 2H), 3.84 (s, 3H), 1.39 (t, 7 = 7.4 Hz, 3H). 1-197 1H NMR (300 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.32 (dd, 7= 2.6, 0.9 Hz, 1H), 7.83-7.36 (m, 2H), 6.39-5.91 (m, 1H), 4.36-4.25 (m, 2H), 3.93 (q, 7= 7.4 Hz, 2H), 3.83 (s, 3H), 1.38 (t, 7= 7.4 Hz, 3H). 1-198 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.53 (s, 1H), 8.34 (d, J= 2.6 Hz, 1H), 7.64 (d, J = 2.5 Hz, 1H), 7.59 (t, J = 59.2 Hz, 1H), 4.59 - 4.51 (m, 2H), 3.93 (q, J = 7.4 Hz, 2H), 3.84 (s, 3H), 1.39 (t, J = 7.5 Hz, 3H). 1-199 1H NMR (400 MHz, Chloroform-d) 6 8.97 (s, 1H), 8.52 (s, 1H), 8.33 (dd, J = 2.6, 0.6 Hz, 1H), 7.60 (d, J= 2.6 Hz, 1 H),7.59 (t, J = 59.2 Hz, 1H), 4.26-4.21 (m, 2H), 3.93 (q, J = TA Hz, 2H), 3.84-3.80 (m, 5H), 3.49 (s, 3H), 1.38 (t, 7 = 7.4 Hz, 3H). 1-200 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.54 (s, 1H), 8.48 (d, J= 2.4 Hz, 1H), 8.07 (d, J = 2.4 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.92 (q, 2H), 3.86 (s, 3H), 3.25 (s, 3H), 1.40 (t, J = 7.4 Hz, 3H). 1-201 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.54 (s, 1H), 8.49 (d, J = 2.5 Hz, 1H), 8.03 (d, J = 2.5 Hz, 1H), 7.60 (t, J = 59.1 Hz, 1H), 3.93-3.86 (m, 5H), 1.40 (t, J = 7.4 Hz, 3H). 1-202 1H NMR (400 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.54 (s, 1H), 8.49 (s, 1H), 8.03 (s, 1H), 7.60 (t, J = 59.2 Hz, 1H), 6.55 (t, J = 52.5 Hz, 1H), 3.93-3.85 (m, 5H), 1.39 (t, 7 = 7.4 Hz, 3H). 1-203 1H NMR (300 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.53 (s, 1H), 8.32 (dd, J= 2.4, 0.7 Hz,1H), 7.84 (dd, J = 2.4, 0.7 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.92 (q, J = 7.6 Hz, 2H), 3.87 (s, 3H), 2.72 (s, 3H), 1.38 (t, J = 7.4 Hz, 3H). 1-204 1H NMR (300 MHz, odds) 6 8.97 (s, 1H), 8.53 (s, 1H), 8.52-8.48 (m, 1H), 8.13-8.00 (m, 1H), 7.59 (t, 7 = 59.2 Hz, 1H), 3.92 (q, J = 7.4 Hz, 2H), 3.83 (s, 3H), 2.57 (s, 3H), 1.39 (t, J = 7.4 Hz, 3H). 1-205 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.67 (d, J= 1.8 Hz, 1H), 8.54 (s, 1H), 8.33 (d, J= 1.8 Hz, 1H), 7.60 (t, J= 59.1 Hz, 1H), 6.86 (t, J= 56.9 Hz, 1H), 3.92 (q, J= 7 A Hz, 2H), 3.87 (s, 3H), 1.40 (t, J= 7.4 Hz, 3H). 1-206 1H NMR (300 MHz, odds) 6 8.98 (s, 1H), 8.72-8.61 (m, 1H), 8.54 (s, 1H), 8.51 -8.44 (m, 1H), 7.60 (t, J = 59.1 Hz, 1H), 3.95-3.87 (m, 5H), 2.87 (S, 3H), 1.39 (t, 7= 7.1 Hz, 3H). 1-207 1H NMR (400 MHz, Chloroform-d) 5 8.99 (s, 1H), 8.75-8.71 (m, 1H), 8.55 (s, 1H), 8.52 (d, J= 1.8 Hz, 1H), 7.61 (t, J = 59.1 Hz, 1H), 6.22 (t, J = 55.2 Hz, 1H), 3.94-3.88 (m, 5H), 1.41 (t, J= TA Hz, 3H). 1-208 1H NMR (400 MHz, cdcb) 6 9.07 (d, J= 2.0 Hz, 1H), 8.99 (s, 1H), 8.63 (d, J = 2.0 Hz, 1H), 8.56 (s, 1H), 7.62 (t, J = 59.1 Hz, 1H), 3.96 - 3.88 (m, 5H), 3.20 (s, 3H), 1.42 (t, J = 7.4 Hz, 3H). 1-209 1H NMR (400 MHz, Chloroform-d) 5 9.04 (d, J= 2.0 Hz, 1H), 8.99 (s, 1H), 8.67 (s, 1H), 8.56 (s, 1H), 7.61 (t, 7= 59.2 Hz, 1H), 6.30 (t, J = 53.5 Hz, 1H), 3.97 - 3.82 (m, 5H), 1.41 (t, J = 7.3 Hz, 3H). 1-210 1H NMR (400 MHz, Chloroform-d) 6 8.98 (s, 1H), 8.61 (d, J = 2.3 Hz, 1H), 8.53 (d, 7 = 0.9 Hz, 1H), 8.45 (d, J= 2.3 Hz, 1H), 8.20 (s, 1H), 7.60 (t, J = 59.2 Hz, 1H), 6.09 (t, J = 54.3 Hz, 1H), 3.94 (q, 7 = TA Hz, 2H), 3.85 (s, 3H), 1.40 (t, 7 = TA Hz, 3H). 1-211 1H NMR (400 MHz, Chloroform-d) 5 8.97 (s, 1H), 8.54 (s, 1H), 8.50 (d, 7 = 1.8 Hz, 1H), 8.15-8.09 (m, 1H), 7.61 (t, 7 = 59.2 Hz, 1H), 3.94 - 3.85 (m, 5H), 3.47 (s, 6H), 1.39 (t, J = 7.3 Hz, 3H). 1-212 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.58 - 8.49 (m, 2H), 8.10 (d, 7 = 2.2 Hz, 1H), 7.60 (t, 7 = 59.2 Hz, 1H), 3.94 - 3.85 (m, 5H), 3.66 (q, 7 = 7.4 Hz, 4H), 1.52 (t, J = 7.4 Hz, 6H), 1.39 (t, J = 7.4 Hz, 3H). 1-213 1H NMR (400 MHz, Chloroform-d) 6 8.96 (s, 1H), 8.51 (s, 1H), 8.28 (d, 7= 2.2 Hz, 1H), 7.83 (d, J= 2.2 Hz, 1H), 7.66 (t, 7 = 59.3 Hz, 1H), 3.97 (q, J = 7 A Hz, 2H), 3.82 (s, 3H), 3.20 (s, 6H), 1.38 (t, J = 7.4 Hz, 3H). 1-214 1H NMR (400 MHz, odds) 6 9.18 (d, 7 = 2.0 Hz, 1H), 8.98 (s, 1H), 8.79 (d, 7 = 2.0 Hz, 1H), 8.55 (d, 7= 0.8 Hz, 1H), 7.62 (t, J = 59.1 Hz, 1H), 3.93-3.86 (m, 6H), 1.40 (t, 7 = 7.4 Hz, 3H). 1-215 1H NMR (300 MHz, cdcb) 6 9.03 (s, 1H), 8.65-8.57 (m, 2H), 8.23 (dd, J= 8.7, 1.6 Hz, 1H), 7.90 (d, J= 8.8 Hz, 1H), 7.59 (t, J = 59.1 Hz, 1H), 4.08 (q, J= 7.5 Hz, 2H), 3.20-3.07 (m, 3H), 1.48 (t, J= 7.5 Hz, 3H). 1-216 1H NMR (400 MHz, cdcb) 6 9.13 (d, 7 = 1.9 Hz, 1H), 8.97 (s, 1H), 8.74 (d, 7 = 1.8 Hz, 1H), 8.63-8.44 (m, 1H), 7.61 (t, J = 59.1 Hz, 1H), 3.92 - 3.84 (m, 5H), 3.60 - 3.43 (m, 2H), 1.42 - 1.32 (m, 6H). 1-217 1H NMR (300 MHz, cdcb) 6 9.03 (s, 1H), 8.69-8.63 (m, 1H), 8.61 (s, 1H), 8.31 -8.14 (m, 1H), 7.94 (d, J = 8.8 Hz, 1H), 7.60 (t, J= 59.1 Hz, 1H), 4.08 (q, J= 7.4 Hz, 2H), 4.00-3.84 (m, 2H), 1.49 (t, J= 7.4 Hz, 3H). 1-218 1H NMR (400 MHz, cdcb) 6 9.15 (d, J = 2.0 Hz, 1H), 8.98 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.55 (s, 1H), 7.62 (t, 7 = 59.1 Hz, 1H), 4.02-3.85 (m, 7H), 1.41 (t, 7 = 7.4 Hz, 3H). 1-219 1H NMR (400 MHz, cdcb) 6 9.14 (d, J = 2.0 Hz, 1H), 8.98 (s, 1H), 8.76 (d, J = 2.0 Hz, 1H), 8.55 (s, 1H), 7.61 (t, J = 59.2 Hz, 1H), 6.16-5.74 (m, 1H), 3.96-3.90 (m, 3H), 3.89-3.67 (m, 4H), 1.41 (t, 7= 7.4 Hz, 3H). 1-220 1H NMR (300 MHz, cdcb) 6 9.03 (s, 1H), 8.66 (d, 7= 1.7 Hz, 1H), 8.61 (s, 1H), 8.24 (dd, J = 8.8, 1.8 Hz, 1H), 8.07 (d, 7 = 8.8 Hz, 1H), 7.61 (t, 7 = 59.1 Hz, 1H), 4.03 (q, 7 = 7.4 Hz, 2H), 1.49 (t, J = 7 A Hz, 3H). 1-221 1H NMR (400 MHz, cdcb) 6 9.12 (d, 7 = 2.2 Hz, 1H), 8.99 (s, 1H), 8.75 (d, 7 = 2.1 Hz, 1H), 8.57 (d, 7= 0.7 Hz, 1H), 7.63 (t, J= 59.1 Hz, 1H), 3.94 (s, 3H), 3.87 (q, J= 7 A Hz, 2H), 1.42 (t, J= 7A Hz, 3H). 1-222 1H NMR (400 MHz, cdcb) 6 9.03 (s, 1H), 8.68-8.49 (m, 2H), 8.21 (d, J= 8.7 Hz, 1H), 7.97-7.82 (m, 1H), 7.59 (t, J = 59.1 Hz, 1H), 4.08 (q, J = 7.4 Hz, 2H), 3.04 - 2.94 (m, 1H), 1.48 (t, J = 7.5 Hz, 3H), 0.80 - 0.65 (m, 4H). 1-223 1H NMR (400 MHz, cdcb) 6 9.09 (d, J = 2.0 Hz, 1H), 8.97 (s, 1H), 8.70 (d, J = 2.0 Hz, 1H), 8.62 - 8.48 (m, 1H), 7.61 (t, 7= 59.1 Hz, 1H), 3.93-3.85 (m, 5H), 3.12-2.63 (m, 1H), 1.39 (t, 7 = TA Hz, 3H), 0.81 -0.64 (m, 4H). 1-224 1H NMR (300 MHz, cdcb) 6 9.03 (s, 1H), 8.60 (s, 2H), 8.18 (d, J = 8.7 Hz, 1H), 7.97 (d, J= 8.8 Hz, 1H), 7.60 (t, J = 59.1 Hz, 1H), 4.06 (q, J = 7.4 Hz, 2H), 2.30 (s, 3H), 1.48 (t, J = 7.4 Hz, 3H). 1-225 1H NMR (400 MHz, cdcb) 6 9.07 (d, J= 1.9 Hz, 1H), 8.98 (s, 1H), 8.71 (d, 7= 1.9 Hz, 1H), 8.55 (s, 1H), 7.62 (t, 7 = 59.2 Hz, 1H), 3.92 (s, 3H), 3.86 (d, J = 7.3 Hz, 2H), 2.31 (s, 3H), 1.41 (t, J = 7.4 Hz, 3H). 1-226 1H NMR (400 MHz, cdcb) 5 9.04 (s, 1H), 8.74-8.65 (m, 1H), 8.65-8.54 (m, 1H), 8.39-8.21 (m, 1H), 7.98-7.84 (m, 1H), 7.67 (t, J = 59.1 Hz, 1H), 7.51 -7.44(m, 2H), 7.41-7.34 (m, 2H), 7.32-7.26 (m, 1H), 4.75 (d, J= 14.5 Hz, 1H), 4.57 (d, J= 14.5 Hz, 1H), 4.09 (q, 7= 7.4 Hz, 2H), 1.49 (t, J= 7.4 Hz, 3H). 1-227 1H NMR (400 MHz, cdcb) 6 9.21 (d, J = 2.0 Hz, 1H), 8.99 (s, 1H), 8.79 (d, J = 2.0 Hz, 1H), 8.55 (d, J = 0.9 Hz, 1H), 7.68 (t, J = 59.2 Hz, 1H), 7.49-7.45 (m, 2H), 7.40-7.34 (m, 2H), 7.31 -7.27 (m, 1H), 4.76 (d, J= 14.5 Hz, 1H), 4.58 (dd, J = 14.6, 1.8 Hz, 1H), 3.92-3.85 (m, 5H), 1.41 (t, 7 = 7.4 Hz, 3H). 1-228 1H NMR (300 MHz, Chloroform-d) 5 8.97 (s, 1H), 8.52 (s, 1H), 8.38 (d, J= 1.9 Hz, 1H), 7.69 (d, J= 1.9 Hz, 1H), 7.49 (t, 7 = 59.2 Hz, 1H), 3.94 (q, J= 7.4 Hz, 2H), 3.83 (s, 3H), 2.15-2.04 (m, 1H), 1.38 (t, 7 = 7.4 Hz, 3H), 1.10-1.00 (m, 2H), 0.86-0.74 (m, 2H). 1-229 1H NMR (300 MHz, cdcb) 6 8.97 (s, 1H), 8.52 (s, 1H), 8.43 (d, 7 = 1.7 Hz, 1H), 7.90 (d, 7= 1.0 Hz, 1H), 7.59 (t, 7 = 59.2 Hz, 1H), 3.92 (q, 7 = 7.4 Hz, 2H), 3.84 (s, 3H), 3.00-2.84 (m, 1H), 2.04-1.89 (m, 1H), 1.76-1.66 (m, 1H), 1.38 (t, 7 = 7.4 Hz, 3H). 1-230 1H NMR (400 MHz, Chloroform-d) 5 8.99 (s, 1H), 8.83 (d, 7 = 2.3 Hz, 1H), 8.68 (s, 1H), 8.56 (s, 1H), 8.39 (d, 7 = 2.3 Hz, 1H), 7.61 (t, 7 = 59.2 Hz, 1H), 3.95 - 3.87 (m, 5H), 1.41 (t, 7 = 7.4 Hz, 3H). 1-231 1H NMR (400 MHz, Chloroform-d) 5 8.98 (s, 1H), 8.59 (dd, 7= 1.5, 0.6 Hz, 1H), 8.53 (d, 7= 0.9 Hz, 1H), 8.17 (dd, 7 = 8.5, 1.6 Hz, 1H), 7.60 (dd, 7 = 8.6, 0.6 Hz, 1 H),7.60 (t, 7 = 59.2 Hz, 1 H).,3.94 (q, 7 = 7.4 Hz, 2H), 3.81 (s, 3H), 1.39 (t. J = 7 A Hz, 3H). 1-232 1H NMR (400 MHz, Chloroform-d) 6 9.27 (d, 7 = 1.9 Hz, 1H), 8.99 (s, 1H), 8.79 (d, J= 1.9 Hz, 1H), 8.55 (d, J= 1.0 Hz, 1H), 7.60 (t, J = 59.2 Hz, 1H), 3.97 - 3.89 (m, 5H), 1.41 (t, J = 7.4 Hz, 3H). 1-233 1H NMR (400 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.82 (d, 7 = 2.3 Hz, 1H), 8.55 (s, 1H), 8.32 (d, 7 = 2.3 Hz, 1H), 7.98 (s, 1H), 7.72 (s, 1H), 7.60 (t, J = 59.2 Hz, 1H), , 3.92 (q, J = 7 A Hz, 2H), 3.88 (s, 3H), 1.40 (t, 7 = 7.4 Hz, 3H). 1-234 1H NMR (300 MHz, Chloroform-d) 5 8.99 (s, 1H), 8.82-8.71 (m, 1H), 8.55 (s, 1H), 8.30-8.22 (m, 1H), 7.80-7.60 (m, 3H), 7.55 - 7.48 (m, 2H), 7.45 - 7.39 (m, 1H), 3.97 (q, 7 = 7.4 Hz, 2H), 3.89 (s, 3H), 1.40 (t, J = 7A Hz, 3H). 1-235 1H NMR (300 MHz, Chloroform-d) 6 9.21 (d, 7= 0.9 Hz, 1H), 8.80-8.77 (m, 1H), 8.46-8.44 (m, 1H), 8.34-8.32 (m, 1H), 8.11 (s, 1H), 3.95 (q, 7 = 7.4 Hz, 2H), 3.90 (s, 3H), 1.42 (t, 7 = 7.4 Hz, 3H). 1-236 1H NMR (300 MHz, Chloroform-d) 5 9.20-9.17 (m, 1H), 8.44-8.40 (m, 1H), 8.10 (s, 1H), 7.69-7.65 (m, 1H), 7.46 (d, 7= 8.8 Hz, 1H), 7.33-7.27 (m, 1H), 3.93 (q, 7= 7.4 Hz, 2H), 3.77 (s, 3H), 1.39 (t, 7= 7.4 Hz, 3H). 1-237 1H NMR (300 MHz, Chloroform-d) 6 9.20 - 9.18 (m, 1H), 8.44-8.42 (m, 1H), 8.11-8.10 (m, 1H), 7.88-7.85 (m, 1H), 7.51-7.47 (m, 1H), 7.46-7.42 (m, 1H), 3.94 (q, 7= 7.4 Hz, 2H), 3.78 (s, 3H), 1.39 (t, 7 = 7.4 Hz, 3H). 1-238 1H NMR (300 MHz, Chloroform-d) 6 9.09 (s, 1H), 8.56 (d, 7= 1.0 Hz, 1H), 8.40-8.32 (m, 1H), 8.15-8.07 (m, 1H), 5 7.75-7.70 (m, 1H), 5 7.57 (t, 7= 59.1 Hz, 1H), 4.26 (q, 7= 7.5 Hz, 2H), 1.51 (t, 7= 7.5 Hz, 3H). 1-239 1H NMR (300 MHz, Chloroform-d) 6 9.00 (s, 1H), 8.61 (d, 7 = 0.9 Hz, 1H), 8.46 (dd, 7= 2.6, 0.7 Hz, 1H), 8.10-8.05 (m, 1H), 7.59 (t, 7 = 59.1 Hz, 1H), 3.99 (q, 7 = 7.5 Hz, 2H), 1.49 (t, 7 = 7.4 Hz, 3H). 1-240 1H NMR (300 MHz, cdch) 6 8.98 (s, 1H), 8.54 (s, 1H), 8.44 (d, 7= 1.9 Hz, 1H), 8.11 (s, 1H), 7.60 (t, 7 = 59.1 Hz, 1H), 3.99 - 3.87 (m, 4H), 3.85 (s, 3H), 1.40 (t, 7 = 7.4 Hz, 3H). 1-241 1H NMR (300 MHz, Chloroform-d) 6 9.04 (s, 1H), 8.76-8.70 (m, 1H), 8.54 (s, 1H), 8.36-8.32 (m, 1H), 4.77 (d, 7 = 6.9 Hz, 2H), 4.47 (s, 3H), 3.46 (q, 7 = 7.4 Hz, 2H), 1.56- 1.49 (m, 1H), 1.46 (t, 7 = 7.4 Hz, 3H), 0.63 - 0.57 (m, 2H), 0.57-0.52 (m, 2H). 1-242 1H NMR (300 MHz, DMSO-de) 5 9.23 (s, 1H), 8.93-8.88 (m, 1H), 8.72-8.67 (m, 1H), 8.51 (t, 7 = 57.0 Hz, 1H), 5.92 (d, 7 = 47.2 Hz, 2H), 3.88 (q, 7 = 7.3 Hz, 2H), 3.76 (s, 3H), 1.23 (t, 7 = 7.4 Hz, 3H). 1-243 1H NMR (300 MHz, DMSO-de) 6 9.28 (s, 1H), 8.93-8.89 (m, 1H), 8.72-8.69 (m, 1H), 8.56 (t, 7 = 56.7 Hz, 1H), 7.65 (t, J = 52.4 Hz, 1H), 3.89 (q, 7 = 7.4 Hz, 2H), 3.76 (s, 3H), 1.24 (t, 7 = 7.4 Hz, 3H). 1-244 1H NMR (400 MHz, Chloroform-d) 5 8.93 (s, 1H), 8.79 (s, 1H), 8.33 (s, 1H), 7.53 (d, 7= 59.1 Hz, 1H), 7.06 (dd, 7 = 18.0, 11.1 Hz, 1H), 6.89 (d, 7= 18.0 Hz, 1H), 5.86 (d, 7= 11.1 Hz, 1H), 3.98-3.90 (m, 5H), 1.41 (t, 7= 7.4 Hz, 3H). 1-245 1H NMR (300 MHz, cdch) 6 8.99 (s, 1H), 8.85-8.70 (m, 1H), 8.41 -8.26 (m, 1H), 7.56 (t, 7= 59.0 Hz, 1H), 3.983.91 (m, 5H), 3.61 (s, 1H), 1.41 (t, 7= 7.4 Hz, 3H). 1-246 1H NMR (300 MHz, Chloroform-d) 6 8.88 (s, 1H), 8.79 (s, 1H), 8.33 (s, 1H), 7.49 (t, 7 = 59.1 Hz, 1H), 6.97-6.86 (m, 1H), 6.83-6.76 (m, 1H), 3.97-3.91 (m, 2H), 3.88 (s, 3H), 1.72-1.63 (m, 1H), 1.40 (t, 7 = 7.8 Hz, 3H), 0.96-0.90 (m, 2H), 0.64-0.59 (m, 2H). 1-247 1H NMR (300 MHz, Chloroform-d) 6 8.94 (s, 1H), 8.79-8.76 (m, 1H), 8.34-8.30 (m, 1H), 7.56 (t, 7= 59.2 Hz, 1H), 5.19 (d, 7= 6.1 Hz, 2H), 3.89 (q, 7 = 7.4 Hz, 2H), 3.86 (s, 3H), 2.80 (t, 7 = 6.2 Hz, 1H), 1.38 (t, 7 = 7.4 Hz, 3H). 1-248 1H NMR (300 MHz, Chloroform-d) 6 10.46 - 10.42 (m, 1H), 9.07 (s, 1H), 8.81 -8.77 (m, 1H), 8.34-8.30 (m, 1H), 7.68 (t, J = 58.5 Hz, 1H), 4.04 (q, 7 = 7.5 Hz, 2H), 3.97 (s, 3H), 1.43 (t, J = 7.4 Hz, 3H). 1-249 1H NMR (300 MHz, Chloroform-d) 5 9.04 (s, 1H), 8.83-8.73 (m, 1H), 8.32 (s, 1H), 7.66 (t, 7= 58.7 Hz, 1H), 4.03 (q, 7 = 7.4 Hz, 2H), 3.98 (s, 3H), 2.86 (s, 3H), 1.42 (t, 7 = 7.4 Hz, 3H). 1-250 1H NMR (300 MHz, Chloroform-d) 5 9.06 (s, 1H), 8.79 (dd, 7= 1.4, 0.6 Hz, 1H), 8.38-8.28 (m, 1H), 7.67 (t, 7= 58.6 Hz, 1H), 4.10 (s, 3H), 4.07-4.02 (m, 2H), 3.99 (s, 3H), 1.44 (t, 7 = 7.4 Hz, 3H). 1-251 1H NMR (300 MHz, cdch) 6 8.91 -8.61 (m, 2H), 8.39-8.27 (m, 1H), 7.41 (t, 7 = 60.2 Hz, 1H), 4.78 (s, 2H), 3.873.79 (m, 5H), 1.37 (t, 7 = 7.4 Hz, 3H). 1-252 1H NMR (300 MHz, cdch) 6 8.87 (s, 1H), 8.83 - 8.73 (m, 1H), 8.37 - 8.29 (m, 1H), 7.77 - 7.35 (m, 2H), 3.87 - 3.79 (m, 5H), 1.54 (s, 9H), 1.37 (t, 7= 7.4 Hz, 3H). 1-253 1H NMR (300 MHz, cdch) 6 8.78 (s, 1H), 8.75-8.69 (m, 1H), 8.35-8.20 (m, 1H), 7.42 (t, 7= 59.8 Hz, 1H), 3.873.80 (m, 5H), 3.43 (s, 6H), 1.33 (t, 7= 7.4 Hz, 3H). 1-254 1H NMR (300 MHz, cdch) 6 9.09 (s, 1H), 8.86-8.74 (m, 1H), 8.39-8.28 (m, 1H), 7.68 (t, 7= 58.4 Hz, 1H), 4.06 (q, 7 = 7.4 Hz, 2H), 3.97 (s, 3H), 3.58 (q, 7 = 7.5 Hz, 2H), 1.47 - 1.40 (m, 6H). 1-255 1H NMR (300 MHz, Chloroform-d) 6 8.90 (s, 1H), 8.78 (dd, 7 = 2.0, 0.8 Hz, 1H), 8.33 (dd, 7= 2.0, 0.8 Hz, 1H), 7.64 (t, 7 = 59.5 Hz, 1H), 7.37-7.30 (m, 1H), 4.00 - 3.89 (m, 5H), 2.98-2.89 (m, 2H), 2.68-2.58 (m, 2H), 2.11 - 2.00 (m, 2H), 1.41 (t, 7= 7.4 Hz, 3H). 1-256 1H NMR (300 MHz, Chloroform-d) 6 8.95 (s, 1H), 8.83-8.78 (m, 1H), 8.51 (dd, 7 = 1.6, 0.8 Hz, 1H), 8.37-8.32 (m, 1H), 7.69 (t, 7= 59.4 Hz, 1H), 7.57 (t, 7 = 1.6 Hz, 1H), 7.11 (dd, 7= 1.9, 0.8 Hz, 1H), 3.99-3.90 (m, 5H), 1.42 (t, 7 = 7.4 Hz, 3H). 1-257 1H NMR (300 MHz, Chloroform-d) 5 8.97 (s, 1H), 8.82-8.76 (m, 1H), 8.60-8.52 (m, 1H), 8.35 (d, 7 = 2.0 Hz, 1H), 7.98-7.92 (m, 1H), 5 7.61 (t, 7= 59.3 Hz,1H), 5 7.49-7.45 (m, 1H), 4.00-3.92 (m, 5H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-258 1H NMR (300 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.82-8.77 (m, 1H), 8.34 (d, 7 = 2.2 Hz, 1H), 7.77 (t, 7 = 59.2 Hz, 1H), 7.49 (d, 7 = 2.2 Hz, 1H), 7.26 (s, 1H), 4.06 (s, 3H), 4.04 - 3.94 (m, 5H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-259 1H NMR (400 MHz, Chloroform-d) 5 8.99 (s, 1H), 8.83 - 8.78 (m, 1H), 8.48 (dd, J = 7.8, 1.9 Hz, 2H), 8.37 - 8.33 (m, 1H), 7.72 (t, 1H), 7.52 - 7.48 (m, 3H), 3.97 (q, 7 = 7.5 Hz, 2H), 3.93 (s, 3H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-260 1H NMR (300 MHz, Chloroform-d) 6 8.99 (s, 1H), 8.81 (d, 7 = 1.8 Hz, 1H), 8.54-8.46 (m, 2H), 8.35 (d, 7= 1.9 Hz, 1H), 7.63 (t, J = 59.5 Hz, 1H), 7.20 (t, 7 = 8.6 Hz, 2H), 4.00 - 3.90 (m, 5H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-261 1H NMR (300 MHz, Chloroform-d) 5 8.99 (s, 1H), 8.81 (s, 1H), 8.45 (d, 7= 8.4 Hz, 2H), 8.35 (d, 7= 1.9 Hz, 1H), 7.63 (t, 7 = 59.3 Hz, 1H), 7.48 (d, 7 = 8.4 Hz, 2H), 4.00 - 3.91 (m, 5H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-262 1H NMR (300 MHz, Chloroform-d) 6 9.00 (s, 1H), 8.81 (d, 7= 1.9 Hz, 1H), 8.56 (d, 7 = 2.0 Hz, 1H), 8.54 (d, 7= 2.2 Hz, 1H), 8.35 (d, 7= 2.0 Hz, 1H), 7.65 (t, 7= 59.3 Hz, 1H), 7.37 (s, 1H), 7.34 (s, 1H), 4.00-3.90 (m, 5H), 1.43 (t, 7 = 7.4 Hz, 3H). 1-263 1H NMR (300 MHz, Chloroform-d) 6 9.71 (s, 1H), 9.02 (s, 1H), 8.81 (dd, 7= 2.0, 0.8 Hz, 1H), 8.79-8.74 (m, 1H), 8.73 (d, 7 = 4.8 Hz, 1H), 8.35 (dd, 7 = 2.0, 0.8 Hz, 1H), 7.77 (t, 7 = 59.2 Hz, 1H), 7.49 - 7.44 (m, 1H), 4.01 - 3.90 (m, 5H), 1.43 (t, 7= 7.4 Hz, 3H). 1-264 1H NMR (300 MHz, cdch) 6 9.11 -8.97 (m, 1H), 8.82-8.73 (m, 1H), 8.36-8.26 (m, 1H), 7.69 (t, 7= 58.7 Hz, 1H), 4.47 - 4.28 (m, 1H), 4.20 - 4.08 (m, 1H), 4.02 - 3.94 (m, 2H), 3.91 (s, 3H), 2.02 - 1.97 (m, 3H), 1.41 (t, 7 = 7.4 Hz, 3H), 1.31 (t, 7 = 7.0 Hz, 3H). 1-265 1H NMR (300 MHz, Chloroform-d) 5 8.76 (d, 7= 1.0 Hz, 1H), 8.52-8.50 (m, 1H), 8.14-8.11 (m, 1H), 7.81 -7.76 (m, 1H), 7.74-7.70 (m, 1H), 5.09-4.95 (m, 1H), 4.11 (q, 7 = 7.4 Hz, 2H), 1.69 (s, 3H), 1.67 (s, 3H), 1.46 (t, 7= 7.4 Hz, 3H). 1-266 1H NMR (300 MHz, Chloroform-d) 5 8.75-8.71 (m, 1H), 8.69 (d, 7= 1.0 Hz, 1H), 8.43-8.41 (m, 1H), 8.30-8.27 (m, 1H), 5.07 - 4.97 (m, 1H), 3.88 (q, J = 7.4 Hz, 2H), 3.85 (s, 3H), 1.68 (s, 3H), 1.66 (s, 3H), 1.35 (t, J = 7.4 Hz, 3H). 1-267 1H NMR (400 MHz, cdch) 5 8.98 (s, 1H), 8.80-8.59 (m, 1H), 8.49 (s, 1H), 8.39-8.23 (m, 1H), 4.64 (q, J = 7.3 Hz, 2H), 4.40 (s, 3H), 3.67 (q, J = 7.4 Hz, 2H), 1.73 (t, 7 = 7.3 Hz, 3H), 1.34 (t, J = 7.4 Hz, 3H). 1-268 1H NMR (400 MHz, DMSO-de) 5 9.85 (s, 1H), 9.16 (d, 7 = 0.9 Hz, 1H), 9.04 (s, 1H), 8.57 (t, 7= 57.3 Hz, 1H), 8.40 (d, 7 = 2.2 Hz, 1H), 8.02 (d, J = 2.2 Hz, 1H), 3.91 (q, 7 = 7.4 Hz, 2H), 3.70 (s, 3H), 3.05 (s, 3H), 1.24 (t, 7 = 7.4 Hz, 3H). 1-269 1H NMR (300 MHz, cdch) 6 8.91 (s, 1H), 8.77-8.69 (m, 1H), 8.59-8.43 (m, 1H), 8.34-8.23 (m, 1H), 7.59 (t, J = 59.2 Hz, 1H), 4.10-3.98 (m, 1H), 3.88 (s, 3H), 3.81 -3.70 (m, 1H), 3.00-2.87 (m, 1H), 2.83-2.70 (m, 1H), 1.38 (t, 7 = 7.4 Hz, 3H), 0.97 (t, 7 = 7.2 Hz, 3H). 1-270 1H NMR (300 MHz, cdch) 6 8.93 (s, 1H), 8.82-8.68 (m, 1H), 8.62-8.49 (m, 1H), 8.37-8.18 (m, 1H), 7.60 (t, 7 = 59.1 Hz, 1H), 5.83-5.41 (m, 1H), 4.19 - 4.06 (m, 1H), 3.91 (s, 3H), 3.89-3.81 (m, 1H), 3.32-3.15 (m, 1H), 3.143.01 (m, 1H), 1.40 (t, 7 = 7.4 Hz, 3H). 1-271 1H NMR (300 MHz, cdch) 5 8.94 (s, 1H), 8.77 (d, J= 1.2 Hz, 1H), 8.53 (s, 1H), 8.31 (d, 7= 1.8 Hz, 1H), 7.59 (t, 7 = 59.1 Hz, 1H), 4.25-4.10 (m, 1H), 3.91 (s, 3H), 3.89-3.81 (m, 1H), 3.49-3.33 (m, 2H), 1.42 (t, 7 = 7.4 Hz, 3H). 1-272 1H NMR (300 MHz, cdch) 5 9.08 (s, 1H), 8.79-8.71 (m, 1H), 8.58-8.44 (m, 1H), 8.39-8.24 (m, 1H), 7.59 (t, 7 = 59.2 Hz, 1H), 4.16-4.03 (m, 1H), 3.93 (s, 3H), 3.88-3.79 (m, 1H), 3.74-3.62 (m, 2H), 2.11 -1.91 (m, 1H), 1.40 (t, 7 = 7.4 Hz, 3H). 1-273 1H NMR (300 MHz, cdch) 6 8.99 (s, 1H), 8.78-8.71 (m, 1H), 8.54-8.46 (m, 1H), 8.34-8.23 (m, 1H), 7.60 (t, J = 59.2 Hz, 1H), 4.05 - 3.95 (m, 1H), 3.88 (s, 3H), 3.82 - 3.73 (m, 1H), 2.33 - 2.22 (m, 1H), 1.37 (t, J = 7.4 Hz, 3H), 0.42 - 0.32 (m, 2H), 0.21 - 0.05 (m, 2H). 1-274 1H NMR (300 MHz, cdch) 6 9.16 (s, 1H), 8.84-8.74 (m, 1H), 8.48 (s, 1H), 8.42-8.32 (m, 1H), 7.60 (t, 7= 59.2 Hz, 1H), 7.00-6.94 (m, 2H), 6.84-6.76 (m, 1H), 6.39-6.31 (m, 2H), 4.49-4.36 (m, 1H), 4.12-4.01 (m, 1H), 3.18 (s, 3H), 1.48 (t, 7 = 7.4 Hz, 3H). Several methods for preparing the compounds of the present invention are illustrated in detail in the following solutions and examples. Raw materials can be purchased on the market or can be prepared by methods known in literature or as shown in the detailed description. A person skilled in the art should understand that other synthetic routes may also be used to synthesize the compounds of the present invention. Although the specific raw materials and conditions in the synthetic routes have been illustrated below, they may be easily replaced with other similar raw materials and conditions. Various isomers and the like of the compounds resulted from such modifications to or variants of the preparation methods of the present invention are all included in the scope of the present invention. In addition, the preparation methods as described below can be further modified according to the disclosure of the present invention using conventional chemical methods well known to a person skilled in the art. For example, the protection for appropriate groups during the reaction, etc. The examples of the methods provided below are used to enhance further understanding of the preparation method of the present invention. The specific substances, types and conditions used are determined to further illustrate the present invention rather than limit its reasonable scope. Reagents used in the synthesis of the compounds shown hereinafter either are commercially available or can be easily prepared by a person skilled in the art. Examples of representative compounds are as follows. The synthesis methods of other compounds are similar and will not be described in detail here. 1. Synthesis of Compound 1-3 (1) Compound 1-3-1 (5.2 g, 22.4 mmol) was dissolved in 30 mL of DMF, sequentially added with sodium chlorodifluoroacetate (6.82 g, 44.8 mmol) and cesium carbonate (14.6 g, 44.8 mmol), and reacted at 120°C for 8 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-3-2 (1.4 g, 22.2% yield, white solid). (2) Compound 1-3-2 (1.4 g, 4.9 mmol) was dissolved in 20 mL of methanol and added with triethylamine (1.0 g, 9.9 mmol). After the air in the system being replaced with CO gas, the system was added to with a catalytic amount of 1,T-bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex, and reacted at 70°C for 6 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-3-3 (0.9 g, 69.4% yield, yellow solid). 1-3-2 CO.MeOH F 1-3-3 (3) Compound 1-3-3 (0.9 g, 3.4 mmol) was dissolved in 20 mL of tetra hydrofuran, in ice bath added with sodium hydride (0.17 g, 6.9 mmol) and ethanethiol (0.32 g, 5.2 mmol), slowly warmed to room temperature, and reacted for 2 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and the residue was added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain the crude Compound 1-3-4 (0.58 g, 58.7% yield, yellow solid). (4) Compound 1-3-4 (0.58 g, 2.0 mmol) was dissolved in 10 mL of DCM, in ice bath added with m-chloroperbenzoic acid (0.69 g, 4.0 mmol), and reacted at room temperature for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, added with water, extracted with DCM for three times, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-3-5 (0.55 g, 85.3% yield, white solid). (5) Compound 1-3-5 (0.55 g, 1.7 mmol) was dissolved in 10 mL of tetrahydrofuran and 3 mL of water, added with lithium hydroxide (0.08 g, 3.5 mmol), and reacted at room temperature for 2 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain the crude Compound 1-3-6 (0.5 g, 95.1% yield, yellow solid). (6) Compound 1-3-6 (0.5 g, 1.6 mmol) was dissolved in 10 mL of DCM, in ice bath added with oxalyl chloride (0.25 g, 1.9 mmol) and a drop of DMF, and reacted at room temperature for 0.5 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried to obtain the crude product which was dissolved with tetrahydrofuran for later use. Compound 1-3-7 (0.41 g, 1.8 mmol) was dissolved in 10 mL of tetrahydrofuran, in ice bath added with the aforementioned tetrahydrofuran solution of the crude product, and reacted at room temperature for 2 h. The reaction solution was concentrated, extracted with ethyl acetate for three times, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain the crude Compound 1-3-8 (0.4 g, 47.7% yield, yellow solid). (7) Compound 1-3-8 (0.4 g, 0.78 mmol) was dissolved in 10 mL of xylene, added with p-toluenesulfonic acid (0.03 g, 0.016 mmol), slowly heated to 150°C, and reacted for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and the residue was added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-3 (0.075 g, 19.4% yield, yellow solid). 1-3-8 TsOH 1-3 2. Synthesis of Compound 1-6 (1) Compound 1-3-6 (0.3 g, 0.98 mmol) was dissolved in 10 mL of DCM, in ice bath added with oxalyl chloride (0.19 g, 1.47 mmol) and a drop of DMF, and reacted at room temperature for 0.5 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried to obtain the crude product which was dissolved with tetrahydrofuran for later use. Compound 1-6-1 (0.25 g, 1.18 mmol) was dissolved in 10 mL of tetrahydrofuran, added with triethylamine (0.4 g, 3.93 mmol), in ice bath added with the aforementioned tetrahydrofuran solution of the crude product, and reacted at room temperature for 2 h. The reaction solution was concentrated, extracted with ethyl acetate for three times, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain the crude Compound 1-6-2 (0.41 g, 84.0% yield, yellow solid). (2) Compound 1-6-2 (0.41 g, 0.82 mmol) was dissolved in 10 mL of xylene, added with p-toluenesulfonic acid (0.07 g, 0.41 mmol), slowly heated to 150°C, and reacted for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and the residue was added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-6 (0.16 g, 41.3% yield, yellow solid). 1-6 3. Synthesis of Compound 1-7 (1) Compound 1-3-6 (0.3 g, 0.98 mmol) was dissolved in 10 mL of DCM, in ice bath added with oxalyl chloride (0.15 g, 1.18 mmol) and a drop of DMF, and reacted at room temperature for 0.5 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried to obtain the crude product which was dissolved with tetrahydrofuran for later use. Compound 1-7-1 (0.28 g, 1.18 mmol) was dissolved in 10 mL of tetrahydrofuran, added with triethylamine (0.4 g, 3.93 mmol), in ice bath added with the aforementioned tetrahydrofuran solution of the crude product, and reacted at room temperature for 2 h. The reaction solution was concentrated, extracted with ethyl acetate for three times, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain the crude Compound 1-7-2 (0.4 g, 76.7% yield, yellow solid). (2) Compound 1-7-2 (0.4 g, 0.75 mmol) was dissolved in 10 mL of xylene, added with p-toluenesulfonic acid (0.06 g, 0.37 mmol), slowly heated to 150°C, and reacted for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and the residue was added with water, extracted three times with ethyl acetate, washed three times with saturated saline solution, dried over anhydrous sodium sulfate, then stirred and purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-7 (0.062 g, 15.9% yield, yellow solid). 4. Synthesis of Compound 1-88 (1) Compound 1-3-6 (0.2 g, 0.65 mmol) was dissolved in 20 mL of DCM, sequentially added with Compound 1-88-1 (0.15 g, 0.75 mmol), triethylamine (0.26 g, 2.62 mmol) and HATU (0.37 g, 0.98 mmol), and reacted at room temperature for 12 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was added with water, extracted with DCM for three times, washed three times with saturated saline solution, and dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain the crude Compound 1-88-2 (300 mg, 93.6% yield, yellow solid). (2) Compound 1-88-2 (300 mg, 0.61 mmol) was dissolved in 20 mL of anhydrous acetic acid, heated to 120°C and reacted for 8 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried, added with water, and extracted with ethyl acetate for three times. The organic phase was washed with saturated saline solution for three times, dried over anhydrous sodium sulfate, and then purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-88 (134 mg, 46.4% yield, white solid). 1-88-2                                                  1-88 5. Synthesis of Compound 1-90 (1) Compound 1-3-6 (0.13 g, 0.43 mmol) was dissolved in 20 mL of DCM, sequentially added with Compound 1-90-1 (0.1 g, 0.49 mmol), triethylamine (0.17 g, 1.7 mmol) and HATU (0.24 g, 0.64 mmol), and reacted at room temperature for 12 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was added with water, extracted with DCM for three times, washed three times with saturated saline solution, and dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain the crude Compound 1-90-2 (198 mg, 94.0% yield, yellow solid). (2) Compound 1-90-2 (198 mg, 0.4 mmol) was dissolved in 20 mL of anhydrous acetic acid, heated to 120°C and reacted for 8 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried, added with water, and extracted with ethyl acetate for three times. The organic phase was washed with saturated saline solution for three times, dried over anhydrous sodium sulfate, and then purified through a silica gel column. The fraction was spin-dried to obtain Compound 1-90 (48 mg, 25.2% yield, white solid). 6. Synthesis of Compound 1-92 Compound 1-6 (200 mg, 0.42 mmol) was dissolved in 10 mL of 2,2,3,3,4,4,5,5-octafluoro-1-pentanol, sequentially added with ammonium carbamate (58.5 mg, 0.75 mmol) and iodobenzene diacetate (241.5 mg, 0.75 mmol), and reacted at room temperature for 12 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and the residue was purified through column chromatography to obtain Compound 1-92 (139 mg, 65.6% yield, white solid). 7. Synthesis of Compound 1-91 Compound 1-92 (100 mg, 0.19 mmol) was dissolved in 10 mL of DMF, sequentially added with potassium carbonate (51.9 mg, 0.37 mmol) and ethyl bromide (41.4 mg, 0.38 mmol), and reacted at room temperature for 12 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was added with water and ethyl acetate and extracted three times. The organic phase was purified through column chromatography to obtain Compound 1-91 (39 mg, 37.1% yield, white solid). 8. Synthesis of Compound 1-100 (1) Compound 1-3-1 (7 g, 30.11 mmol) was dissolved in 50 mL of DMF, sequentially added with potassium carbonate (12.48 g, 90.34 mmol) and methyl iodide (12.82 g, 90.34 mmol), and stirred at 80°C for 1 h. The reaction was monitored until the starting raw materials had disappeared. The system was filtered with diatomaceous earth. The filtrate was added with water, extracted three times with ethyl acetate, washed three times with half-saturated saline solution, and washed once with saturated saline solution. The sample was dried over anhydrous sodium sulfate, mixed with silica gel and purified through column chromatography to obtain Compound 1-100-1 (2.14 g, 28.83% yield, white solid). 1-100-1 (2) A 250-mL carbonylation reactor was prepared, and Compound 1-100-1 (2.14 g, 8.68 mmol) was dissolved in 35 mL of methanol, added with triethylamine (2.64 g, 26.05 mmol), and added with a catalytic amount of 0.2 g of 1,1'-bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex. The system was evacuated, then introduced with CO, pressurized to > 0.2 MPa, and reacted at 70°C for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, mixed with silica gel and purified through normal phase column chromatography to obtain Compound 1-100-2 (1.8 g, 91.89% yield, white solid). 1-100-1 CO 1-100-2 (3) Ethanethiol (4.54 g, 73.13 mmol) was dissolved in 30 mL of DMSO, and in ice bath added with 60% sodium hydride (1.95 g, 48.75 mmol), and stirred at room temperature for 30 min. Compound 1-100-2 (1.10 g, 4.88 mmol) was dissolved in 10 mL of DMSO which was then added dropwise to the system at room temperature. After addition, the system was heated to 130°C and reacted for 30 min. The reaction was monitored until the starting raw materials had disappeared and the reaction was terminated. After the system was cooled down, the sample was poured into water and extracted with EA. The aqueous phase was extracted once again with EA. The organic phase was washed with saturated saline solution, dried and concentrated to obtain Compound 1-100-3 (450 mg, 38.90% yield, white solid). (4) Compound 1-100-3 (450 mg, 1.90 mmol) was dissolved in 10 mL of DMF, sequentially added with potassium carbonate (786.32 mg, 5.69 mmol) and methyl iodide (807.57 mg, 5.69 mmol), and stirred at room temperature for 1 h. The reaction was monitored until the starting raw materials had disappeared. The system was added with water, extracted three times with ethyl acetate, washed three times with half-saturated saline solution, and washed once with saturated saline solution. The sample was dried over anhydrous sodium sulfate, mixed with silica gel, and purified through column chromatography to obtain Compound 1-100-4 (418 mg, 87.70% yield, white solid). (5) Compound 1-100-4 (418 mg, 1.66 mmol) was dissolved in 20 mL of DCM, slowly added portionwise with 85% m-chloroperbenzoic acid (844.21 mg, 4.16 mmol), and reacted at room temperature for 2-3 h. The reaction was monitored until the starting raw materials had disappeared. The system was filtered. The mother liquor was added with 10 mL of H2O, slowly added dropwise with saturated sodium thiosulfate solution to quench the reaction, extracted and washed with DCM and water, and washed three times with DCM. The DCM phase was washed 6-8 times with saturated sodium bicarbonate solution until the m-chloroperbenzoic acid cannot be detected by in-process control in LCMS. The DCM phase was washed once with saturated saline solution. After being dried over anhydrous sodium sulfate, the DCM phase was spin-dried to obtain Compound 1-100-5 (470 mg, 99.74% yield, white solid). (6) Compound 1-100-5 (470 mg, 1.66 mmol) was dissolved in 30 mL of tetrahydrofuran, and lithium hydroxide (79.46 mg, 3.32 mmol) was dissolved in 10 mL of water. In ice bath, the aqueous solution of lithium hydroxide was added dropwise to the THF system and reacted at room temperature for 1-2 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated and extracted once with ethyl acetate. The aqueous phase was adjusted with dilute hydrochloric acid to pH <4. The acidified aqueous phase was extracted three times with EA. The EA phase was washed once with saturated saline solution, dried over anhydrous 66 sodium sulfate and then spin-dried to obtain Compound 1-100-6 (340 mg, 76.11% yield, yellow solid). 1-100-5 1-100-6 (7) Compound 1-100-6 (340 mg, 1.26 mmol) was dissolved in 10 mL of DCM, in ice bath added with 0.5 mL of oxalyl chloride, and reacted at room temperature for 1 h. After the completion of the reaction was detected by In-Process Control, the solvent was spin-dried to obtain the crude Compound 1-100-7 which was dissolved in 2 mL of DCM for later use. Compound 1-12-1 (277.57 mg, 1.45 mmol) was dissolved in 10 mL of DCM, added with triethylamine (511.09 mg, 5.05 mmol), and in ice bath added dropwise with the obtained DCM solution of Compound 1-100-7 mentioned above in batches. After addition, the system reacted at room temperature for 1 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was washed with saturated ammonium chloride solution. The aqueous phase was extracted three times with DCM. Next, the DCM phase was washed three times with water and once with saturated saline solution, and dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain 558 mg of Compound 1-100-8 (100% yield, yellow viscous solid). (8) Compound 1-100-8 (558 mg, 1.26 mmol) was dissolved in 30 mL of anhydrous acetic acid, heated to 120°C and reacted for 20 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried, mixed with silica gel powder, and purified through normal phase chromatography (PE:EA = 4:1). The fraction was spin-dried to obtain 47 mg of Compound 1-100 (8.78% yield). 9. Synthesis of Compound 1-111 (1) Compound 1-3-1 (2.31 g, 10 mmol) was dissolved in 50 mL of ACN, added with NCS (1.60 g, 12 mmol), and reacted at 70°C overnight. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried, added with ethyl acetate and water for extraction and to separate liquid phases, and washed three times with saturated saline solution. The organic phase was purified through column chromatography to obtain Compound 1-111-1 (2.29 g, 86.7% yield, white solid). Cl Cl 1-111-1 (2) Compound 1-111-1 (2.29 g, 8.6 mmol) was dissolved in 30 mL of DMF, sequentially added with sodium chlorodifluoroacetate (2.65 g, 17.2 mmol) and cesium carbonate (5.59 g, 17.2 mmol), reacted at 120°C, vigorously bubbled and refluxed. The reaction was monitored until the starting raw materials had disappeared. The system was filtered using diatomaceous earth. The filtrate was added with water, extracted three times with ethyl acetate, and washed three times with half-saturated saline solution and once with saturated saline solution. The organic phase was purified through column chromatography to obtain Compound 1-111-2 (1.56 g, 57.3% yield, white solid). (3) A250-mL carbonylation autoclave was prepared. Compound 1-111-2 (1.56 g, 4.97 mmol) was dissolved in 50 mL of methanol and added with triethylamine (1.5 g, 14.9 mmol) and 0.2 g of a catalytic amount of 1,1 '-bis(diphenylphosphino)ferrocene-palladium(ll)dichloride dichloromethane complex. The system was evacuated, then introduced with CO, pressurized to > 0.2 MPa, and reacted at 55°C for 8 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, mixed with silica gel, and purified through column chromatography to obtain Compound 1-111-3 (1.29 g, 88.4% yield, white solid). CO.MeOH (4) Compound 1-111-3 (1.29 g, 4.37 mmol) was dissolved in 40 ml_ of tetrahydrofuran, and in ice bath, added with 60% sodium hydride (0.35 g, 8.75 mmol). Ethanethiol (0.41 g, 6.5 mmol) was dissolved in 5 mL of THF, and in ice bath slowly added dropwise to the system. After addition, the reaction solution was stirred for 0.5 h in ice bath, and then slowly warmed to room temperature for 3-h reaction. The reaction was monitored until the starting materials had disappeared. The system was slowly added to with ice water and extracted with EA. The organic phase was washed once with saturated saline solution, and purified through column chromatography to obtain Compound 1-111-4 (1.11 g, 79.3% yield, white solid). (5) Compound 1-111-4 (1.11 g, 3.46 mmol) was dissolved in 20 mL of DCM, in ice bath slowly added with m-chloroperbenzoic acid (1.39 g, 6.92 mmol) in batches, and reacted at room temperature for 4 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was added dropwise with saturated sodium thiosulfate solution to quench the reaction, and then extracted and washed with DCM and water. The organic phase was washed once with saturated saline solution and purified through column chromatography to obtain Compound 1-111-5 (0.98 g, 80.3% yield, white solid). (6) Compound 1-111-5 (0.98 g, 2.78 mmol) was dissolved in 30 mL of tetrahydrofuran. Lithium hydroxide (0.19 g, 8.33 mmol) was dissolved in 100 mL of water. In ice bath, the aqueous solution of lithium hydroxide was added dropwise to the THF system and reacted at room temperature for 1 h. The reaction was monitored until the starting materials had disappeared. The reaction solution was concentrated, and extracted once with ethyl acetate. The aqueous phase was adjusted with dilute hydrochloric acid to pH < 4. The acidified aqueous phase was extracted three times with EA. The EA phase was washed once with saturated saline solution, dried over anhydrous sodium sulfate and spin-dried to obtain the crude Compound 1-111-6 (0.88 g, 93.6% yield, white solid). (7) Compound 1-111-6 (0.88 g, 2.6 mmol) was dissolved in 20 mL of DCM, sequentially added with Compound 1-12-1 (0.57 g, 3.1 mmol) and triethylamine (0.79 g, 7.8 mmol), and in ice bath added with HATU (1.5 g, 3.9 mmol) in batches. After addition, the system reacted at room temperature for 1 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was washed with saturated ammonium chloride solution. The aqueous phase was extracted three times with DCM, and the DCM phase was washed once with saturated saline solution and dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain the crude Compound 1-111-7 (1.12 g, 86.2% yield, yellow oily matter). (8) Compound 1-111-7 (0.56 g, 1.1 mmol) was dissolved in 50 mL of anhydrous acetic acid, and heated to 120°C to react for 20 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, mixed with silica gel, and purified through column chromatography to obtain Compound 1-111 (0.49 g, 90.7% yield, white solid). 10. Synthesis of Compound 1-120 (1) Compound 1-3-3 (1.00 g, 3.82 mmol) was dissolved in 10 mL of DMF, in ice bath added with cesium carbonate (2.49 g, 7.64 mmol) and Compound 1-120-1 (1.42 g, 11.47 mmol), and reacted for 30 min at room temperature. The completion of the reaction was detected by LCMS. The reaction solution was diluted with water and ethyl acetate. The organic phase was sequentially washed with saturated ammonium chloride solution and saturated saline solution, dried, and concentrated. The residue was purified through column chromatography (EA / PE = 1 / 3) to obtain Compound 1-120-2 (900 mg, 67.4% yield, white solid). 1-3-3 1-120-2 (2) Compound 1-120-2 (500.0 mg, 1.43 mmol) was dissolved in 15 mL of a solvent (dichloromethane:water = 2:1), in ice-water bath, sequentially added with 2 mL of concentrated hydrochloric acid and 10 mL of sodium hypochlorite solution, and reacted at room temperature for 30 min. The completion of the reaction was detected by LCMS. The reaction solution was diluted with water and dichloromethane. The organic phase was washed with saturated saline solution, dried and concentrated to obtain the crude Compound 1-120-3 (450 mg, 96.7% yield, pale yellow solid). HCI, NaClO (3) Compound 1-120-3 (450 mg, 1.38 mmol) was dissolved in 4 mL of tetrahydrofuran, in ice-water bath, added with dimethylamine (2.76 ml, 5.52 mmol, 2 M in THF), and reacted at room temperature for 30 min. The completion of the reaction was detected by LCMS. The reaction solution was diluted with water and dichloromethane. The organic 71 phase was washed with saturated saline solution, dried, and concentrated. The residue was purified through column chromatography (EA / PE = 1 / 2) to obtain Compound 1-120-4 (310 mg, 67.4% yield, pale yellow solid). 1-120-3 (4) Compound 1-120-4 (310 mg, 0.93 mmol) was dissolved in 4 mL of a solvent (tetrahydrofuran:water = 3:1), at 0°C added with lithium hydroxide (44.6 mg, 1.86 mmol), and reacted at 45°C for 6 h. The completion of the reaction was detected by LCMS. The reaction solution was added with water and the pH was adjusted to acidity. The aqueous phase was extracted with ethyl acetate. The organic phase was washed with saturated saline solution, dried and concentrated to obtain Compound 1-120-5 (270 mg, 91.2% yield, white solid). 1-120-4 LiOH 1-120-5 F (5) Compound 1-120-5 (200 mg, 0.60 mmol) was dissolved in 4 mL of dichloromethane, sequentially added with Compound 1-12-1 (172 mg, 0.90 mmol), triethylamine (242.4 mg, 2.40 mmol), and HATU (342.0 mg, 0.90 mmol), and reacted at room temperature for 2 h. The completion of the reaction was detected by LCMS. The reaction solution was diluted with water and dichloromethane. The organic phase was sequentially washed with saturated aqueous solution of ammonium chloride and saturated saline solution, dried, and concentrated. The residue was purified through column chromatography (EA / PE = 1 / 1) to obtain Compound 1-120-6 (200.0 mg, 67.8% yield, white solid). (6) Compound 1-120-6 (200.0 mg, 0.40 mmol) was dissolved in 4 mL of acetic acid and reacted at 120°C for 24 h. The completion of the reaction was detected by LCMS. The reaction solution was quenched with saturated aqueous solution of sodium bicarbonate. The aqueous phase was extracted with ethyl acetate. The organic phase was washed with saturated saline solution, dried and concentrated. The residue was purified through column chromatography (EA / PE = 1 / 1) to obtain Compound 1-120 (100.0 mg, 52.6% yield, white solid). AcOH 1-120 11. Synthesis of Compound 1-131 (1) Compound 1-3-3 (1.7 g, 6.5 mmol) was dissolved in 30 mL of DMF, and added with cesium carbonate (4.3 g, 13 mmol). Next, in ice bath, the reaction solution was added dropwise with Compound 1-131-1 (3.0 g, 19.5 mmol), stirred for 10 min, then warmed to room temperature and continued reaction under stirring for half an hour. The reaction was monitored until the starting raw materials had disappeared. The system was added to with water, extracted three times with ethyl acetate, washed three times with half-saturated saline solution, dried over anhydrous sodium sulfate, and then rotary-evaporated to remove the solvent and to obtain 2.4 g of Compound 1-131-2 (97.2% yield, white solid). (2) Compound 1-131-2 (2.4 g, 6.33 mmol) was dissolved in 30 mL of trifluoroacetic acid, heated to 70°C and reacted for 8-10 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, dissolved with ethyl acetate, added with water and thoroughly mixed. The pH of the system was adjusted to neutrality with saturated sodium bicarbonate solution. The system was extracted three times with ethyl acetate, washed three times with half-saturated saline solution, dried over anhydrous sodium sulfate, and then rotary-evaporated to remove the solvent and to obtain 1.5 g of Compound 1-131-3 (91.5% yield, white solid). TFA 1-131-3 (3) Compound 1-131-3 (1.5 g, 5.79 mmol) was dissolved in 30 mL of DMF, sequentially added with cesium carbonate (3.83 g, 11.57 mmol) and cyclopropylmethyl bromide (1.17 g, 8.68 mmol), and stirred at 60°C for 40 min. The reaction was monitored until the starting raw materials had disappeared. The system was added to with water and thoroughly mixed, extracted three times with ethyl acetate, washed three times with half-saturated saline solution, and dried over anhydrous sodium sulfate. Then the organic phase was concentrated, mixed with silica gel and purified through normal phase chromatography to obtain 1.5 g of Compound 1-131-4 (83.3% yield, white solid). 1-131-3 F 1-131-4 (4) Compound 1-131-4 (1 g, 3.19 mmol) was dissolved in 20 mL of DCM, in ice bath slowly added with 85% m-chloroperbenzoic acid (1.62 g, 7.98 mmol) in batches, and reacted at room temperature for 4 h. The reaction was monitored until the starting raw materials had disappeared. The system was filtered. The mother liquor was added with 20 mL of H2O, slowly added dropwise with saturated sodium thiosulfate solution to quench the reaction, extracted and washed with DCM and water, and extracted three times with DCM. The DCM phase was washed 6-8 times with saturated sodium bicarbonate solution until no m-chloroperbenzoic acid had been detected by LCMS. The DCM phase was washed once with saturated saline solution, dried over anhydrous sodium sulfate, and then spin-dried to obtain 1 g of Compound 1-131-5 (90.9% yield, white solid). m-CPBA (5) Compound 1-131-5 (1.00 g, 2.9 mmol) was dissolved in 30 mL of tetrahydrofuran. Lithium hydroxide (208 mg, 8.69 mmol) was dissolved in 10 mL of water. In ice bath, the aqueous solution of lithium hydroxide was added dropwise to the THF system and reacted at room temperature for 0.5-1 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was concentrated, and extracted once with ethyl acetate. The aqueous phase was adjusted with dilute hydrochloric acid to pH < 4. The acidified aqueous phase was extracted three times with EA. The EA phase was washed once with saturated saline solution, dried over anhydrous sodium sulfate and spin-dried to obtain 880 mg of Compound 1-131-6 (91.9% yield, white solid). 1-131-5 LiOH 1-131-6 (6) Compound 1-131-7 was prepared from the reaction of Compound 1-131-6 (300 mg, 0.95 mmol) with oxalyl chloride. Upon the completion of the reaction, the reaction solution was spin-dried to obtain the crude Compound 1-131-7 which was dissolved with DCM for later use. Compound 1-12-1 (199 mg, 1.04 mmol) and triethylamine (275 mg, 2.72 mmol) was dissolved in DCM, and in ice bath, added dropwise with the aforementioned DCM solution of Compound 1-131-7. After addition, the system reacted at room temperature for 20 min. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was washed with water. The aqueous phase was extracted three times with DCM, then washed once with saturated saline solution, and dried over anhydrous sodium sulfate. The organic phase was spin-dried to obtain 400 mg of Compound 1-131-8 (85.7% yield, yellow solid). (7) Compound 1-131-8 (400 mg, 0.79 mmol) was dissolved in 30 mL of anhydrous acetic acid, heated to 120°C and reacted for 16-20 h. The reaction was monitored until the starting raw materials had disappeared. The reaction solution was spin-dried, mixed with silica gel powder, and purified through normal phase chromatography. The fraction was spin-dried to obtain 40 mg of Compound 1-131 (10.4% yield). AcOH Evaluation of Biological Activity: Pesticidal activity assay: The technical material was diluted with acetone to prepare it into liquids with gradient concentrations. Spodoptera frugiperda, Spodoptera litura, Mythimna separata-. 3-4 leaves of the host plant (young corn leaves) that had not been treated with drugs and did not contain an insect-resistance gene were picked, cut into pieces of 3-4 cm long, then put into a small plastic box, inoculated with 10 test insects that had been starved for 2 h, and applied with the drug agent using a spray tower. The procedure was carried out in triplicate. The amount of acetone contained in the highest dose group was taken as the control. After drug application, the box was tightly covered with a lid and placed in a process chamber (at 25°C, humidity of 60%). Nilaparvata lugens-. test insects reared indoors with consistent physiological conditions were selected and put into a disposable clear plastic cup. Each cup was inoculated in with 40-50 test insects with same growth conditions, and put in with rice stalks which were wrapped with moisturized cotton balls to maintain humidity, and then sprayed with the drug agent using a spray tower. After spraying, the cup was covered with a lid. The procedure was carried out in triplicate. The amount of acetone contained in the highest dose group was taken as the control. After drug application, the box was tightly covered with a lid and placed in a process chamber (at 25°C, humidity of 60%). The number of dead insects was investigated after corresponding days and the mortality was calculated. The representative data are as shown in Tables 3^4. Mortality = (Number of dead insects / Number of test insects) * 100% Table 3 Representative results of pesticidal activity assay (2DAA) No. Spodoptera litura (3rd instar) / 100ppm 1-3 100 1-6 100 1-7 100 1-11 100 1-12 100 1-41 60 1-88 100 1-90 100 1-91 100 1-92 95 1-93 100 1-94 100 1-95 100 1-96 100 1-97 100 1-111 100 1-112 100 1-113 85 1-114 95 1-115 100 1-117 100 1-118 100 1-119 100 1-120 100 1-128 100 1-129 100 1-130 100 1-131 100 1-132 75 1-133 80 1-154 85 1-157 100 1-158 100 1-159 95 1-160 100 1-161 100 1-163 100 1-164 100 1-165 100 1-166 100 1-168 65 1-169 100 1-170 100 1-172 50 1-176 100 1-177 100 1-178 100 1-180 100 1-181 100 1-182 50 1-183 70 1-184 95 1-195 100 1-201 100 1-202 85 1-205 95 1-207 100 1-209 80 1-213 100 1-214 100 1-215 100 1-216 100 1-217 95 1-218 95 1-219 100 1-220 80 1-221 100 1-222 100 1-223 100 1-224 95 1-225 100 1-226 95 1-227 70 1-229 90 1-230 80 1-232 90 1-235 100 1-238 100 1-239 100 1-242 95 1-243 90 1-244 90 1-246 100 1-247 95 1-248 70 1-249 50 1-250 90 1-251 80 1-252 90 1-255 80 1-256 95 1-257 55 1-258 90 1-259 100 1-260 100 1-262 55 1-263 90 1-265 90 1-266 100 1-268 100 1-269 80 1-270 80 1-271 80 1-272 80 1-273 80 Control Compound A 0 Table 4 Representative results of pesticidal activity assay (2DAA) No. Spodoptera frugiperda (3rd instar) Mythimna separata (3rd instar) Spodoptera litura (3rd instar) Nilaparvata lugens (2^-3^ instar) 0.5ppm 2ppm 0.5ppm 2ppm 0.5ppm 2ppm 25ppm 50ppm 1-3 90 95 90 95 90 95 N 90 1-6 N 90 50 100 N 50 N 98 1-7 N 100 90 100 50 85 N 92 1-11 N 90 N 100 N 80 N N 1-12 90 100 100 100 100 100 N 100 1-41 N N N 70 N N N N 1-81 N 60 N 60 N N N 50 1-88 N 80 70 90 N N N 98 1-90 65 100 90 100 N 100 N 98 1-91 N 75 85 100 N 70 80 N 1-92 N 70 N N N N N N 1-93 N N N 50 N N N N 1-94 N 80 N 100 N 100 60 N 1-95 78 95 90 100 60 90 90 N 1-96 75 90 90 90 N 90 73 N 1-97 85 90 90 100 N 90 N N 1-100 N N N 60 N N N N 1-111 60 70 100 100 N 90 N N 1-112 N 80 N N N 70 98 100 1-114 N 50 N N N N N N 1-115 N 100 80 100 N 90 90 N 1-118 N 50 N N N 70 N N 1-120 N N N 70 N 70 N N 1-128 N 65 N N 60 90 N N 1-129 75 85 90 95 80 90 93 N 1-130 N N N 60 N N N N 1-131 N 90 100 100 70 90 90 N 1-157 N 50 N 90 N 50 N N 1-158 N 60 N 100 N N N N 1-159 N N N 60 N 50 N N 1-160 80 90 90 100 N N 80 N 1-161 N 80 50 85 60 90 N N 1-163 N 100 N 80 N N 90 N 1-164 N 80 N N N N 85 N 1-165 N 80 N 70 N N 80 N 1-166 N N N 70 N N N N 1-169 N 85 N 100 N 50 N N 1-170 N 75 N 70 80 90 N N 1-176 70 90 70 100 N N 80 N 1-177 N N N 90 N N N N 1-178 N N 90 100 N N 80 N 1-179 N N N 60 N N N N 1-181 N 70 50 70 N N N N 1-184 N 60 N 70 N N 90 N 1-200 N N N N N N 80 N 1-201 60 100 N 70 N N 65 N 1-209 N 80 N N N N N N 1-214 N 90 N N N N N N 1-216 N 100 N 60 N N N N 1-217 N 80 N 60 N N N N 1-219 N 60 N N N N N N 1-224 50 100 N N N N N N 1-225 N 90 N N N N N N 1-226 N 50 N N N N N N 1-239 N 80 N N N N N N 1-242 N 90 N N N 70 98 100 1-260 N 60 N N N N N N Control Compound A 0 0 0 0 0 0 6 N Note: N represents no data; Control compound A: Furthermore, it has been found after extensive experimentations that, many of the compounds of the present invention and compositions thereof have good controlling activity against agricultural pests such as Lepidoptera, Homoptera, Acarina, Diptera, Coleoptera and Thripidae and the like, as well as sanitary pests such as Blattidae, Muscidae and the like, not only possessing the characteristics of broad spectrum, high efficiency and strong systemic property, but also capable of controlling resistant insect pests, which have certain commercial values. In particular, Compounds 1-3, 1-12, 1-90, 1-95, 1-96, 1-97, 1-129, etc., demonstrate outstanding efficacy against the following pests at a liquid concentration of 1-100 ppm: Spodoptera exigua, Plutella xylostella, Athetis lepigone, Hyphantria cunea, Brachmia macroscopa, Phthorimaea absoluta, Mamestra brassicae, Chilo suppressalis, Cnaphalocrocis medinalis, Conogethes punctiferalis, Ostrinia furnacalis, Scirpophaga incertulas, Diaphania indica, Lamoria zelleri, Argyroploce schistaceana, Plodia interpunctella, Galleria mellonella, Helicoverpa armigera, Agrotis ipsilon, Pieris rapae, Laodelphax striatella, Sogatella furcifera, Diaphorina citri, Bemisia tabaci, Myzus persicae, Lipaphis erysimi, Acyrthosiphon pisum, Aphis gossypii, Megoura crassicauda, Rhopalosiphum padi, Aphis craccivora, Brevicoryne brassicae, Aphis citricola, Aphis glycines, Amrasca biguttula, Halyomorpha halys, Phyllotreta striolata, Colaphellus bowringi, Psylliodes punctifrons, Aulacophora femoralis, Aulacophora lewisii, Tenebrio molitor, Tribolium castaneum, Sitophilus oryzae, Rhyzopertha dominica, Monochamus alternatus, Cerodonta denticornis, Liriomyza sativae, Japanagromyza tristella, Bradysia odoriphaga, Armigeres subalbatus, Locusta migratoria manilensis, Atractomorpha sinensis, Acheta domesticus, Megalurothrips usitatus, Blattella germanica, Eupolyphaga sinensis, Lygus lucorum, Riptortus pedestris, Drosophila repleta, Drosophila melanogaster, Gryllotalpa orientalis, Holotrichia parallela, Holotrichia oblita Faldermann, Protaetia brevitarsis, Pleonomus canaliculatus, Camponotus japonicus, Myrmica jessensis, Periplaneta americana, Blaptica dubia, achieving mortality rates no less than 80%.

Claims

1. A substituted heterocyclic compound as shown in Formula I, or a salt or N-oxide thereof:wherein, Q represents Q-1Qi represents S, NR33 or O;Q2 represents N, CH, or C-halogen;Ri, R2, R3, R4, and Rseach independently represent hydrogen, halogen, alkyl, alkenyl,alkynyl, cyano, nitro, cycloalkyl, aryl, heterocyclyl, cycloalkenyl, SF5, -OR51,-O-alkylene-ORsi, -SR51, -O-alkylene-SRsi, -SOR51, -(SO2)R5i, -O(SO2)R5i,0 t^R.NR510t?,-R51NCNO, R51Sc Okh ,RsiA R51 0-N(R5i)2, -0(C0)R5i, -O(CS)OR5i,-O(CS)SR5i, -N(R5i)(COR5i), -N(R5i)(COOR5i), -N(R5i)(SO2R5i),   -N(SO2R5i)2,-(C0)0R5i, -0(C0)0R5-i, -(C0)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O- or-CH2OCH2-; the alkyl, alkenyl, or alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro,cycloalkyl, aryl, heterocyclyl, trialkylsilyl, -OR51, -SR51, -SOR51, -(SO2)Rsi, -N(Rsi)2, -0(C0)R5i, -0(C0)0R5i, -(C0)R5i, and -(CO)N(R5i)2;X represents alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, -N(R5i)2, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl; or -N(R5i)2 together forms heterocyclyl that is unsubstituted or substituted with a nitrogen atom at 1-position;Y represents 0 or N-Y1;Yi, Re, and R33 each independently represent hydrogen, alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl, cyano, -N(Rei)2, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl;R51 independently represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, cycloalkyl, cycloalkylalkyl, aryl, heterocyclyl, arylalkyl, or heterocyclylalkyl;the aforementioned cycloalkyl, heterocyclyl, aryl, or cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, haloalkenyl, haloalkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R;R independently represents hydrogen, alkyl, alkenyl, alkynyl; alkyl, alkenyl, or alkynyl that are substituted by at least one group selected from halogen, hydroxy, alkoxy, cyano, and alkoxycarbonyl; cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycyloalkenylalkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, alkyl, haloalkyl, alkoxycarbonyl, alkylsulfanyl, alkylsulfonyl, alkoxy, and haloalkoxy.

2. The substituted heterocyclic compound or its salt or N-oxide according to claim 1, wherein,Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, cyano, nitro, C3-C8 cycloalkyl, aryl, heterocyclyl, C3-C8 cycloalkenyl, SF5, -OR51, -O-(C1-C8 alkylene)-OR5i, -SR51, -0-(C1-C8 alkylene)-SR5i,O-SOR51, -(SO2)R5i, -O(SO2)R5i, nrsiO fs-R51NCNNk , R51 ^'R51 0-N(R5i)2, -O(CO)R5i, -O(CS)OR5i, -O(CS)SR5i, -N(R5i)(COR5i),-N(R5i)(COOR5i), -N(R5i)(SO2R5i), -N(SO2R5i)2, -(CO)OR5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-or -CH2OCH2-; the C1-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C8 cycloalkyl, aryl, heterocyclyl, tri C1-C8 alkylsilyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(Rsi)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, and -(CO)N(R5i)2;X represents C1-C8 alkyl, halo C1-C8 alkyl, C2-C8 alkenyl, halo C2-C8 alkenyl, C2-C8 alkynyl, halo C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, -N(R5i)2, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl; or -N(R5i)2unsubstituted or substituted by at least one group selected from oxo, C1-C8 alkyl, and C1-C8 alkoxycarbonyl;Yi, Re, and R33 each independently represent hydrogen, C1-C8 alkyl, halo C1-C8 alkyl, C2-C8 alkenyl, halo C2-C8 alkenyl, C2-C8 alkynyl, halo C2-C8 alkynyl, cyano, -N(Rei)2, C1-C8 alkoxy C1-C8 alkyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl;R51 independently represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, halo C1-C8 alkyl, halo C2-C8 alkenyl, halo C2-C8 alkynyl, C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, aryl, heterocyclyl, aryl C1-C8 alkyl, or heterocyclyl C1-C8 alkyl;the aforementioned C3-C8 cycloalkyl, heterocyclyl, aryl, or C3-C8 cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl, C3-C8 cycloalkyl, halo C1-C8 alkyl, halo C2-C8 alkenyl, halo C2-C8 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R;R each independently represents hydrogen, C1-C8 alkyl, C2-C8 alkenyl, C2-C8 alkynyl; C1-C8 alkyl, C2-C8 alkenyl, or C2-C8 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C8 alkoxy, cyano, and C1-C8 alkoxycarbonyl; C3-C8 cycloalkyl, C3-C8 cycloalkyl C1-C8 alkyl, C3-C8 cycloalkenyl, C3-C8 cycloalkenyl C1-C8 alkyl, phenyl, or phenyl that is substituted by at least one group selected from halogen, cyano, nitro, C1-C8 alkyl, halo C1-C8 alkyl, C1-C8 alkoxycarbonyl, C1-C8 alkylsulfanyl, C1-C8 alkylsulfonyl, C1-C8 alkoxy, and halo C1-C8 alkoxy.

3. The substituted heterocyclic compound or its salt or N-oxide according to claim 1 or 2, wherein,Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, C3-C6 cycloalkenyl, SF5, -OR51, -O-(C1-C6 alkylene)-ORsi, -SR51, -O-(C1-C6 alkylene)-SR5i,0-^-S-R5.-SOR51, -(SO2)R51, -O(SO2)R51, nr^0fS-R51NCNN^. - R51 ^'R51 0R51^°vp^R51, -N(R5i)2, -O(CO)R5i, -O(CS)OR5i, -O(CS)SR5i, -N(R5i)(COR5i), -N(R5i)(COOR5i), -N(R5i)(SO2R5i), -N(SO2R5i)2, -(CO)OR5i, -O(CO)OR5i, -(CO)R5i, or -(CO)N(R5i)2, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-or -CH2OCH2-; the C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl are optionally substituted by at least one group selected from halogen, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, tri C1-C6 alkylsilyl, -OR51, -SR51, -SOR51, -(SO2)R5i, -N(Rsi)2, -O(CO)R5i, -O(CO)OR5i, -(CO)R5i, and -(CO)N(R5i)2;X represents C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, -N(R5i)2, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl; or -N(R5i)2unsubstituted or substituted by at least one group selected from oxo, C1-C6 alkyl, and C1-C6 alkoxycarbonyl;Y1, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkenyl, halo C2-C6 alkenyl, C2-C6 alkynyl, halo C2-C6 alkynyl, cyano, -N(R5i)2, C1-C6 alkoxy C1-C6 alkyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl;R51 independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, aryl, heterocyclyl, aryl C1-C6 alkyl, or heterocyclyl C1-C6 alkyl;the aforementioned C3-C6 cycloalkyl, heterocyclyl, aryl, or C3-C6 cycloalkenyl are optionally substituted by at least one group selected from oxo, halogen, cyano, nitro, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, halo C1-C6 alkyl, halo C2-C6 alkenyl, halo C2-C6 alkynyl, -OR, -SR, -(CO)R, -(CO)OR, -(CO)N(R)2, -(CS)N(R)2, -(SO)R, and -(SO2)R;R each independently represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl; C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl that are substituted by at least one group selected from halogen, hydroxy, C1-C6 alkoxy, cyano, and C1-C6 alkoxycarbonyl; C3-C6 cycloalkyl, C3-C6 cycloalkyl C1-C6 alkyl, C3-C6 cycloalkenyl, C3-C6 cycloalkenyl C1-C6 alkyl, phenyl, or phenyl that is substituted by at least one groupselected from halogen, cyano, nitro, C1-C6 alkyl, halo C1-C6 alkyl, C1-C6 alkoxycarbonyl, C1-C6 alkylsulfanyl, C1-C6 alkylsulfonyl, C1-C6 alkoxy, and halo C1-C6 alkoxy;preferably, the compound is selected from any one in Table 1.

4. The substituted heterocyclic compound or its salt or N-oxide according to claim 1, wherein,Qi represents S, NR33 or O;Q2 represents N, CH, or C-halogen;Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, C3-C6 cycloalkenyl,O       R2 fs-R51 °-s / 1 0 -f S-R51   ? NSF5, -OR51, -SR51, -SOR51, -(SO2)R51, -O(SO2)R51, NR^ , CN ,          Rsi,*     / ,'R51o , -N(R51)2, -N(R5i)(COOR5i), -N(R5i)(SO2R5i), -(CO)OR5i, or -(CO)R5i, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51;X represents C1-C6 alkyl, C3-C6 cycloalkyl C1-C6 alkyl, or -N(R5i)2;Y represents O or N-Y1;Y1, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, cyano, or C3-C6 cycloalkyl;R51 independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl;the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR;R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen;preferably, Qi represents NR33 or O;Q2 represents N, CH, or C-halogen;Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl,C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51,0-(S02)Rsi, NR51 , -N(R5i)2, or -(CO)Rsi, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51;X represents C1-C6 alkyl, C3-C6 cycloalkyl C1-C6 alkyl, or -N(R5i)2;Y represents O or N-Y1;Y1, Re, and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, cyano, or C3-C6 cycloalkyl;R51 independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl;the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR;R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen;preferably, X represents ethyl;Y represents O;Qi represents NR33 or O;Q2 represents N, CH, or C-halogen;Ri, R2, R3, R4, and R5 each independently represent hydrogen, halogen, C1-C6 alkyl, C2-C6 alkenyl, cyano, nitro, C3-C6 cycloalkyl, aryl, heterocyclyl, -OR51, -SR51, -SOR51, -(SO2)Rsi, -N(R5i)2, or -(C0)R5i, or Ri and R2 together form unsubstituted or halogen-substituted -OCH2O-; the C1-C6 alkyl or C2-C6 alkenyl are optionally substituted by at least one group selected from halogen, C3-C6 cycloalkyl, and -OR51;Re and R33 each independently represent hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C2-C6 alkynyl, or C3-C6 cycloalkyl;R51 independently represents hydrogen, C1-C6 alkyl, halo C1-C6 alkyl, C3-C6 cycloalkyl, or aryl C1-C6 alkyl;the aforementioned C3-C6 cycloalkyl, heterocyclyl, or aryl are optionally substituted by at least one group selected from halogen, C1-C6 alkyl, halo C1-C6 alkyl, and -OR;R independently represents C1-C6 alkyl that is substituted by at least one group selected from halogen.

5. The substituted heterocyclic compound or its salt or N-oxide according to any one of claims 1 to 4, wherein,Qi represents NR33 or O; Q2 represents N, CH, or C-halogen; and when Qi represents O, Q2 represents CH or C-halogen.

6. A method for preparing the substituted heterocyclic compound or its salt or N-oxide according to any one of claims 1 to 5, wherein it comprises the following steps:(1) when Q represents Q-1, the compound represented by Formula 1-1 is prepared from the compound represented by Formula 11-1, and the reaction equation is as follows:1-1wherein, Hal represents halogen; the definitions of Ri, R2, R3, R4, Rs, Re, Qi, Q2, X, and Y are as defined according to any one of claims 1 to 5;preferably, the reaction (1) is carried out in the presence of an acid; more preferably, the reaction (1) is carried out in the presence of a solvent; further preferably, the acid is selected from at least one of inorganic acids and organic acids, and / or the solvent is selected from at least one of aromatic hydrocarbons, DMF, DMA, THF, acetonitrile, dichloroethane, DMSO, dioxane, dichloromethane, and ethyl acetate.

7. The preparation method according to claim 6, wherein,(2) the compound represented by Formula 11-1 is prepared by reaction between the compound represented by Formula 111-1 and the compound represented by Formula IV-1, and the reaction equation is as follows:wherein, M represents OH or halogen;preferably, the reaction (2) is carried out in the presence of a solvent; more preferably, a condensing agent and / or a base is added during the reactions; further preferably, the base is selected from at least one of inorganic bases and organic bases, the condensing agent is selected from at least one of Py-BOP, Py-AOP, EDCI, HOBT, DCC, HBTU, and HATU, and / or the solvent is selected from at least one of aromatic hydrocarbons, DMF, DMA, THF, acetonitrile, dichloroethane, DMSO, dioxane, dichloromethane, and ethyl acetate.

8. A pesticidal composition, wherein it comprises a pesticidally effective amount of at least one of the substituted heterocyclic compound or its salt or N-oxide according to any one of claims 1 to 5; preferably, also comprises a formulation auxiliary; more preferably, further comprises an additional active ingredient.

9. A method for controlling a pest, wherein it comprises exposing the pest or its environment to a biologically effective amount of the substituted heterocyclic compound or its salt or N-oxide according to any one of claims 1 to 5 or the composition according to claim 8.

10. Use of the substituted heterocyclic compound or its salt or N-oxide according to any one of claims 1 to 5 or the composition according to claim 8 in pest control.

11. An intermediate, as shown in Formula 11-1, 111-1, or IV-1 according to claim 6 or 7.

Images